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ABSTRACT 
MOLECULAR CHARACTERIZATION OF HUMAN PAPILLOMAVIRUS  
IN HEAD AND NECK TUMORS 
Sujita Khanal 
July 15, 2016 
Head and neck cancers (HNCs) are common causes of cancer-related deaths 
worldwide. An increasing incidence of subsets of HNCs is due to human papillomavirus 
(HPV). Other subsets are associated with tobacco and alcohol use. Determination of 
differential biomarkers and molecular mechanisms distinguishing HPV-associated and 
unassociated HNCs should improve diagnostic and therapeutic strategies. This study was 
designed to identify potential biomarkers for HPV detection, and to evaluate viral and host 
genetic and epigenetic mechanisms involved in HPV-associated HNCs. 
Overexpression of a cellular protein, p16
INK4a
, which is widely used as a surrogate 
marker for HPV-positive HNC, is non-specific because some HPV-negative cancers can 
overexpress p16
INK4a
. I found “mitosoid cells” and “HPV E7 serology”, respectively, as 
histologic and serum biomarkers, which would improve diagnosis of HPV-positive head and 
neck (HN) tumors. Mitosoid cells were not only observed in HPV-positive benign epithelial 
hyperplasias but also abundantly present in subsets of pre-malignant tumors (high-grade oral 
epithelial dysplasia, hgOED). P16
INK4a
 could be used as an HPV-surrogate marker only in 
Group 1 hgOED (containing diffuse mitosoid cells), but not in Group 2 (with focal mitosoid 
cells) and Group 3 (lacking these cells). My study revealed that E7 seropositivity 
complements p16
INK4a 
overexpression in HNCs and a decrease in E7 serology potentially 
predicts patients’ response to treatment. To evaluate genetic and epigenetic changes in HPV-
induced malignancy, I assessed viral DNA- integration and -methylation, and viral-induced 
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methylation of host tumor suppressor genes (TSGs). Since viral DNA integration predicts 
malignancy, my data showing integrated HPV in Group 1 and malignant tumors, suggest 
greater malignant transforming potential of Group 1 than the other groups. Although viral 
methylation is another regulatory mechanism for malignancy, the HPV epigenome was mostly 
unmethylated in both premalignant and malignant HN tumors. Screening 38 host TSGs 
identified EREG as a candidate gene, which may be epigenetically regulated, specifically in 
HPV-positive HNC. 
Overall, the present study found that mitosoid cells and E7 serology in combination 
with p16
INK4a
 overexpression are significant markers for HPV-associated head and neck 
malignancy. HPV DNA integration and host EREG gene methylation, but not viral DNA 
methylation, may play roles in HPV-associated head and neck carcinogenesis.  
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CHAPTER I 
INTRODUCTION ON HUMAN PAPILLOMAVIRUS AND HEAD AND NECK TUMORS 
Human papillomavirus (HPV) 
Papillomaviruses are small, non-enveloped, icosahedral DNA viruses that have a 
diameter of 50–60 nm. Papillomaviruses (PVs) are species-specific, and can infect different 
mammals, birds, and reptiles. Human papillomavirus (HPV) are PVs that infect human 
epithelial cells (i.e. they are epitheliotropic in nature) (1). HPV is the most common sexually-
transmitted infection worldwide including the United States (2,3). HPVs are tissue-specific and 
normally infect either cutaneous or mucosal tissue, although some are both cutaneous and 
mucosotropic (1).  In 1974, the German virologist Harald zur Hausen found that the skin wart 
virus, HPV, contributes to the development of cervical cancers (4,5). Almost 10 years later, 
his group isolated HPV type 16 DNA from a cervical squamous cell carcinoma (6). He was 
awarded the Nobel Prize in Physiology or Medicine 2008 for this discovery. Presently, HPV is 
known to cause virtually all cervical cancers. Recent studies have shown that HPV-associated 
cancers are not just limited to the anogenital region. Instead, HPV is a highly prevalent human 
pathogen and causes ~5% of all solid-organ cancers worldwide (7). During the past few 
years, there has been considerable interest in the involvement of HPV in upper aerodigestive 
sites and its etiologic role in causing head and neck tumors. 
HPV genome 
Papillomaviruses contain a circular, double-stranded DNA genome of approximately 8 
kb. HPV genome contains a number of open reading frames (ORFs) classified as either early 
or late depending on the timing of their expression after infection. The genome also includes a 
long control region (LCR) or upstream regulatory region (URR), which lacks ORFs but 
contains cis-responsive elements that govern viral replication and gene expression.
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Figure 1 shows a genomic map of HPV type 16. The six early ORFs [E1, E2, E4 and E5 
(in green) and E6 and E7 (in red)] are expressed from promoter either p97 or p670 (in the 
case of HPV16) at different stages of epithelial cell differentiation. The late ORFs [L1 and L2 
(in yellow)] are also expressed from p670. All the viral genes are encoded on plus (+) strand 
of the double-stranded circular DNA genome. 
 
Figure 1: HPV type 16 genomic map showing early genes (E1, E2, E4, E5, E6, and E7), late 
genes (L1 and L2) and long control region (LCR) (Copyright permission obtained from John 
Wiley and Sons). 
The late genes encode for the structural proteins L1 (major capsid protein) and L2 
(minor capsid protein), which are only expressed in productive infections. During this 
productive infection, HPV genomes are packaged within the capsids for viral assembly and 
release from keratinocytes. The early genes E1, E2, E4-E7 are expressed prior to initiation of 
viral replication, but not the late genes. Among all genes, L1 and E1 genes are highly 
conserved among all papillomaviruses (8). 
E1, in combination with E2, has a regulatory function. E1 encodes a protein with 
ATPase and helicase activities and is essential for viral replication (9). E2 gene encodes a 
DNA-binding protein that binds to target sequences around the viral origin and recruits the E1 
helicase which in turn is involved in replicating the viral genome by recruiting host replication 
proteins (10). In addition to its role in viral DNA replication, the E2 protein functions as a 
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transcriptional repressor for the expression of E6 and E7 oncoproteins. The gene for the E4 
protein overlaps the E2 ORF (10). E4 proteins are expressed relatively late during infection 
before the expression of L2 and L1 and help in the maturation of viral particles (11,12). While 
a definite oncogenic role of E5 is not clear, it is thought to augment oncogenic activities of E6 
and E7 proteins, and allow the continuous proliferation of the host cell delaying differentiation 
(12,13). 
E6 and E7 are the main oncoproteins of high-risk HPVs. The E6 and E7 proteins bind 
and promote the degradation of the host p53 and retinoblastoma (pRb) tumor suppressor 
proteins, respectively (14) (Figure 2). Since most HPV-positive cancer cells harbor wild-type 
TP53 and Rb tumor suppressor genes, these cells have intact but dormant tumor suppressor 
pathways due to the continuous expression of E6 and E7 genes (15). E6 binds the tumor 
suppressor protein p53 and promotes ubiquitin-mediated proteasomal degradation of p53. 
Hence, HPV-infected cells do not undergo apoptosis or cell cycle arrest even if DNA is 
damaged. E6 also activates the expression of hTERT, the catalytic subunit of telomerase and 
increases telomerase activity, contributing to cell immortalization (16,17). E7 is another major 
oncoprotein. E7 binds with pRb protein and its family proteins, p107 and p130, and disrupts 
their ability to form complexes with E2F transcription factors, resulting in increased expression 
of E2F-responsive genes, many of which are required for cell cycle progression. In addition, 
the E7 protein accelerates degradation of hypophosphorylated pRb family members. 
Inactivation of pRb by E7 can be monitored by overexpression of p16
INK4a
 (Figure 3), which is 
often used as a surrogate marker of HPV infection (18). 
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Figure 2: The combined effects of HPV E6 and E7 oncoproteins in malignant transformation. 
E7 and E6 inactivate tumor suppressor proteins pRb and p53, respectively. E6 also increases 
telomerase activity (Copyright permission obtained from Elsevier)   
The long control region (LCR), also called upstream regulatory region (URR) 
regulates the transcription of viral genes, particularly oncogenes E6 and E7. The LCR 
contains viral promoters, enhancers, the replication origin and binding sites for several viral 
and cellular transcription factors, which are important for viral replication and gene expression 
(10).  
The expression of HPV E6 and E7 proteins is inhibited by the viral E2 protein through 
its interaction with the early promoter p97 located in the LCR. This promoter harbors four 
specific E2-binding sites (E2BSs) sharing the consensus sequence 5′-ACCG(N)4CGGT-3′ 
(19) (Figure 3). The three sites proximal to the TATA box, importantly E2BS2, E2BS3, and 
E2BS4, have been shown to be involved in E2-mediated repression of the promoter activity 
(20). Binding of E2 protein to E2BS inhibits the docking of transcription activators, such as 
specificity protein 1 (Sp1) and TATA-binding protein (TBP), from their binding sites, leading to 
a repression of E6 and E7 expression from the early promoter (21) (Figure 3). The integration 
of viral DNA in high-risk forms of HPV has been described as a key step in carcinogenesis 
since it generally results in the disruption of the E2 ORF (22). Additionally, DNA methylation 
on LCR region is shown to inhibit binding of the transcriptional repressor (E2), resulting in the 
overexpression of viral oncoproteins, leading to malignant transformation (23,24). 
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Figure 3: HPV long control region (URR) showing E2 and other transcription factor binding 
sites. Binding of E2 to E2BS causes repression of E6 and E7 expression. 
Classification of HPV types 
Papillomaviruses (PVs) belong to the family Papillomaviridae. Each PV has 
traditionally been referred as “type”. An HPV type is defined as an HPV isolate where the 
nucleotide sequence of the highly conserved viral L1 gene is at least 10% different from any 
known HPV type  (25,26). More than 150 PV types are capable of infecting humans and thus 
are referred to collectively as human papillomaviruses (HPVs).  
Isolates of the same HPV type are referred to as “variants” or “subtypes” when the 
nucleotide sequences of the L1 gene differ by less than 10%. An HPV variant contains a 
unique combination of single nucleotide polymorphisms (SNPs) mainly in E6 and/or LCR 
gene (27). Names of HPV variants are derived from the geographical origin of the human 
populations in which they are most prevalent. For example, HPV type 16 variants have been 
classified into 4 major lineages: European-Asian, African 1, African 2, and Asian 
American/North American (28,29).  
HPV types fall into 5 genera (namely- Alpha, Beta, Gamma, Mu, and Nu) based on 
sequence comparisons of L1 genes (members of the same genus share >60% nucleotide 
sequence identity between L1 genes). Many types of HPV, especially those of the Beta and 
Gamma genera, cause asymptomatic infections without the apparent disease. The most 
clinically significant group is the Alpha genus which includes HPV types that infect cutaneous 
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or mucosal sites. Cutaneous types include HPV2 and HPV57, which cause common warts 
and HPV3 and 10, which cause flat warts. Mucosal HPV types are sub-divided into low-risk 
types and high-risk types depending on the strength of their association with carcinogenesis, 
Table 1 (4,30). High-risk HPV mucosal types (such as HPV16 and 18) are highly associated 
with the development of precancerous and cancerous lesions while low-risk types (such as 
HPV6 and 11) cause benign conditions such as genital warts and respiratory papillomatosis 
(30). HPV is so common that nearly all sexually active people will have it at some point in 
their lives  (2). However, only persistent infections with specific subsets of high-risk HPVs are 
responsible for the development of cancer (31). Among the high-risk HPV types, HPV16 and 
18 are frequently found to be associated with malignancy. Between these two HPV types, 
HPV16 is the most prevalent carcinogenic HPV (32). 
Table 1: High-risk and low-risk HPV types, based on their oncogenic potential 
High-risk HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 
Putative high-risk HPV 23, 53, 66, 67, 68, 73,82 
Low-risk HPV 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, CP6108 
 
Strategies for HPV detection, their strengths, and limitations 
An ideal test for HPV would be highly sensitive, specific, cost-effective, and simple in 
the application so that it could be easily employed in routine diagnostic pathology practice. 
But none of the currently used HPV testing strategies completely satisfy all of these criteria. 
Depending on the technique used, the results of HPV detection can vary widely. 
Polymerase chain reaction (PCR)-based method of detecting a well-conserved HPV L1 
gene is very sensitive and can detect a large number of HPV types. However, this method is 
relatively more expensive and is not readily available in the routine pathology laboratory, and 
turnaround time is also longer. Also, because of the very high sensitivity, this method requires 
proper handling and processing of samples to avoid  a false positive result due to cross-
contamination (33). Another method of detecting HPV DNA is in situ hybridization (ISH). 
Although ISH is more specific, it is less sensitive than PCR and requires technical expertise to 
interpret results (33,34).  Also, ISH method cannot detect all HPV types using commercially 
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available HPV probe cocktails.  Both PCR and ISH- based HPV DNA detection method are 
unable to detect transcriptionally active HPV (i.e. E6/E7 expression). 
As HPV-driven tumor growth is caused by E6 and E7 expression, PCR detection of 
E6/E7 mRNA is the best method to detect transcriptionally active HPV (34). However, this is 
technically challenging to be used in clinical laboratory and can’t be performed effectively on 
formalin-fixed, paraffin-embedded (FFPE) tissues (35). A recently developed technique, RNA 
in situ hybridization is effective in FFPE tissues and is highly sensitive and specific for 
detecting E6/E7 mRNA (36-42). As this technique is technically cumbersome and is not yet 
commercially available (34), other techniques are often used in clinical practice.  For example, 
immunohistochemical detection of p16
INK4a
 expression in tumor tissue sections is commonly 
used in the clinic as surrogates for HPV status (43). This is based on the premise that HPV 
infection leads to the production of the E7 oncoprotein, which inactivates pRb tumor 
suppressor protein and releases p16
INK4a
 gene from transcriptional inhibition thereby causing 
overexpression of p16
INK4a
 in HPV-associated cancers, Figure 4 (34,44,45). 
Immunohistochemistry (IHC) for p16
INK4a 
is inexpensive, highly sensitive and can be 
performed in virtually any histology laboratory with very quick turnaround (34,46). 
Overexpression of p16
INK4a
 is often used as a surrogate marker of HPV infection in 
oropharyngeal cancers, while its use in oral cavity cancers is not well established, even 
though both are subgroups of HNC (46,47). Current studies show that other non-viral 
mechanism can also increase p16
INK4a
 expression, making it a non-specific marker for HPV 
infection, Figure 5 (18,46,48). This warrants the need for reliable and appropriate biomarkers 
to precisely diagnose HPV status in head and neck tumors or to determine HPV-associated 
cancer progression. 
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Figure 4: Presence of high-risk (HR)-HPV causes overexpression of p16
INK4a
; as such 
p16
INK4a
 immunohistochemistry is used as a surrogate marker of HPV infection.  The 
functional inactivation of pRb by HPV oncoprotein E7 results in the release of the 
transcriptional factor E2F from the pRb–E2F protein complex and lead to the release of the 
p16
INK4A
 gene from its transcriptional inhibition. 
 
 
Figure 5: p16
INK4a
 is not always a surrogate marker of HPV infection. p16
 INK4a
 is also 
overexpressed via non-viral mechanisms 
HPV-associated clinical lesions in head and neck region 
In the head and neck region, the majority of HPV-associated clinical manifestations 
occurs in squamous epithelium and includes benign lesions, premalignant dysplasia, and 
carcinomas.  
 
1. Benign Lesions of the head and neck 
There are many different types of benign oral tumors. In this study, I focused on two types 
of benign lesions of the oral cavity - Multiple Epithelial Hyperplasia (MEH) and squamous 
papilloma. 
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a. Multiple epithelial hyperplasias: MEH is an HPV-associated benign proliferation of oral 
squamous epithelium. It is also known as Heck’s disease or focal epithelial hyperplasia 
(FEH) (49). It commonly occurs in Native Americans in the US but is rare among 
Caucasians. It usually presents in children/adolescents or HIV-infected adults and is 
typically associated with HPV type 13 or 32. It occurs as multiple slightly elevated and 
minimally keratinized papules located mainly on labial and buccal mucosa. A prominent 
feature of MEH is the mitosoid cell; an enlarged cell with a fragmented nucleus 
resembling atypical mitotic figure (50,51). These cells are consistently observed in MEH. 
Although asymptomatic and self-limited in its course, the distinction of MEH from another 
benign oral lesion (for example, squamous papilloma) is important since these lesions 
may have overlapping clinical and histologic features.  
b. Squamous papilloma: Squamous papillomas are common benign epithelial lesions of 
the head and neck region. It has been suggested that many of these lesions have a viral 
origin but the etiology is still controversial. Several reports have demonstrated the 
presence of HPV in squamous papillomas (52,53). However, the presence of HPV in 
these types of lesions varies from one study to another (53-56). Of note, squamous 
papilloma may show some clinical and histologic overlap with MEH.  
 
2. Premalignant lesions of the head and neck 
Dysplasia is defined as an abnormality in maturation of epithelial cells. In other words, 
squamous dysplasia is the precancerous state referring to metaplastic alterations of the 
surface epithelium prior to the invasion of the subepithelial tissues. These changes include 
abnormal cellular organization, increased mitotic activity, and nuclear enlargement with 
pleomorphism. Although terminology varies, atypia limited to the lower one-third of the 
epithelium is generally referred to as mild dysplasia, atypia limited to the lower two-thirds as 
moderate dysplasia, and atypia involving the full thickness of the epithelium as severe 
dysplasia/carcinoma in situ. With progression, the carcinoma in situ breaks through the 
basement membrane and invades the subepithelial connective tissue (57). 
In this study, I focused on high-grade oral epithelial dysplasia (i.e. severe 
dysplasia/carcinoma in situ). These are pre-cancerous lesions which often develop into oral 
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squamous cell carcinoma (SCC), a subset of head and neck SCC (58). Studies of HPV-
associated cervical carcinogenesis have looked at clearly defined stages, including 
asymptomatic infection, cervical intraepithelial neoplasia (CIN) stages I to III, and cancer (59), 
whereas HNC studies conducted to date have mainly focused on primary cancers. As such, 
there are few studies evaluating the presence of HPV in the pre-cancerous lesions.   
3. Head and neck squamous cell carcinoma 
The majority of the cancers in the head and neck region develop from thin, flat cells 
called squamous cells. Cancer that starts in the layer of squamous cells is called squamous 
cell carcinoma. Head and neck squamous cell carcinoma (HNSCC) or head and neck cancer 
(HNC) is the sixth most common cancer and eighth leading cause of cancer-related deaths 
worldwide and it represents about 3% of all cancers in the United States (60,61). It develops 
in the mucosa of the upper aerodigestive sites including oral cavity, oropharynx, hypopharynx 
or larynx (62). Because of anatomic locations associated with the ability to look, talk, eat and 
breathe, these cancers can highly affect the quality of life. There are two major risk factors for 
the development of HNC: exogenous carcinogens (namely tobacco and alcohol exposure) 
and infection with HPV. Cancer-related death ranges widely from 20-60% in patients 
presenting with locally advanced forms of HNC. While many tobacco-related cancers are on 
the decline owing to decreases in smoking among Americans, the number of HPV-related 
HNC cases appears to be increasing (62).  
HPV-associated and unassociated HNCs display differences in clinical outcome: 
patients with HPV-positive HNC respond better to chemo/radiotherapy and have higher 
overall survival rates (63,64). Because of this, many clinicians advocate for a reduction in 
treatment intensity for patients with HPV-induced cancers to minimize post-treatment 
morbidity (65). However, a reduction in treatment intensity risks the possibility of under-
treatment, tumor progression, and metastasis in patients who are HPV negative and may 
have responded to current high-intensity treatments (66). So, a detailed understanding of 
HPV status of HNC patients is warranted to determine appropriate therapies. 
The molecular profiles of HPV-positive HNC are distinct from those of HPV-negative 
cancers. In HPV-positive cancers, HPV oncoproteins E6 and E7 promote the degradation of 
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p53 and pRb tumor suppressors, respectively, and p16
INK4a
 protein is upregulated. 
Overexpression of p16
INK4a
 protein is the result of the effect of the viral E7 protein in 
suppressing the function of pRb. In contrast, in HPV-negative HNC, TP53 is frequently 
mutated and p16
INK4a
 is under-expressed. HPV-negative HNCs are reported to accumulate a 
large number of cellular mutations compared to HPV-positive HNCs (67,68). These molecular 
differences are suggested to be the reasons behind better prognosis of HPV-positive HNC. 
However, the specific mechanisms responsible for improved prognosis/survival in HPV-
positive patients have not been fully elucidated. For these reasons, the knowledge of 
differential mechanisms distinguishing HPV-positive and -negative HNC is very important; 
which may underlie the molecular basis of improved prognosis for HPV-induced cancer as 
well as provide opportunities for new therapeutic development. 
 
 
Figure 6: Pictorial representation of the anatomy of the head and neck cancer showing 
different subgroups (Copyright permission obtained from Terese Winslow LLC, U.S. Govt).  
 
There are different subgroups of HNCs based on anatomic locations (69) (Figure 6). 
HNCs driven by tobacco and alcohol use can occur anywhere throughout the upper 
aerodigestive tract while cancers driven by HPV appear to be mostly localized to the 
oropharynx (34). 
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Oropharyngeal squamous cell carcinoma (OPSCC or OPC): The incidence of OPC 
is increasing as smoking-related cancers decrease (43). This increase is due to HPV, which 
has emerged as the primary etiologic factor in OPC, surpassing tobacco and alcohol as risk 
factors in this type of HNC (70). Cohort studies from the 1990s suggested that approximately 
50% of oropharyngeal cancers were attributable to HPV, while more recent studies suggest 
that HPV accounts for 70 to 80 % of cases in North America and Europe (71). 
An oropharyngeal subsite of the head and neck region most affected by HPV includes 
the soft palate, base of tongue, tonsils, throat walls and oropharynx (72). More specifically, 
HPV infection is most commonly associated with the palatine and lingual tonsils (62). 
Oral cavity squamous cell carcinoma (OCSCC): The possible role of HPV in the 
etiology of OCSCC is currently not well-defined. The role of HPV in carcinogenesis of the oral 
cavity is further obscured by discordant findings between p16
INK4a
 IHC and HPV testing in 
these tumors. While HPV is detected in relatively few OCSCC tumors, the majority of these 
tumors exhibit overexpression of p16
INK4a
 (58,73). Reports show that the majority of p16
INK4a
 -
positive OCSCC were negative for HPV (74-76), suggesting that p16
INK4a
 is not always an 
absolute marker to detect HPV. In OCSCC, non-viral mechanisms appear to stimulate 
p16
INK4a
 overexpression, making it relatively non-specific and therefore an increasingly 
unreliable surrogate marker for HPV detection in OCSCC (74-76).  
Other HNC types are nasopharyngeal, laryngeal and hypopharyngeal carcinoma 
where tobacco and alcohol are the main risk factors/ primary etiologic agents. These types of 
cancers in head and neck region are found to be less likely to be associated with HPV (77).  
Biology of HPV infection   
HPV infections are most frequently seen in the epithelia of the uterine cervix and 
head and neck region. The biology of HPV infection in cervical cancers has been well- 
documented but there is less information available for HNCs.  
In cervical cancer, HPV virions attach to the basement membrane and preferentially 
infect basal cells in cervical transformation zone, located in the boundary between the 
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squamous epithelium of ectocervix and the columnar epithelium of endocervix (called 
squamocolumnar junction) (4). Viruses are known to use the host cell machinery for 
replication. As the HPV-infected keratinocytes differentiate and move toward the epithelial 
surface, different viral genes are expressed, allowing high viral genome amplification and the 
expression of the late region genes that encode the viral capsid proteins necessary to 
complete viral life cycle (78). As the cells reach the surface, the HPV episomes are packaged 
within the capsids for final viral assembly and release (called lytic infection) (79). Abnormal 
cell growth in the lower 1/3 of the cervical epithelium is classified as HPV infection or cervical 
intraepithelial neoplasia 1 (CIN1) and 2/3 of the way from the basal layer as CIN2. These 
CIN1 and CIN2 lesions typically disappear within a few months by the immune system (80). 
However, the persistent infection causes abnormal cell growth to penetrate the entire 
thickness of cervical epithelium causing CIN3 or carcinoma in situ. When abnormal cells 
invade the basal membrane and spread into the tissues beneath, the condition becomes 
cervical cancer (81).  
The biology underlying HPV infections in the head and neck region is largely 
unknown, particularly in areas other than the oropharynx. Oropharyngeal tissues do not 
contain squamocolumnar junctions. However, the palatine and lingual tonsils are lined with 
stratified squamous epithelium and contain numerous tonsillar crypts that extend through the 
full thickness of the tonsil (82,83). These crypts are lined with specialized reticular epithelium 
that has a porous basal cell layer and disrupted basement membranes. It has been proposed 
that the structural porosity of the tonsillar reticulated crypt epithelium allows HPV access to 
the basement membrane and infection of basal cells without the associated trauma observed 
in cervical cancer (57).  
Since tumorigenesis in oropharynx often occurs deep within the crypts, it is difficult to 
identify premalignant precursors on the tissue surface (47). Unlike oropharyngeal cancers 
(OPC), oral squamous cell carcinoma (OSCC) often develops from a clinically apparent 
leukoplakia (84) that shows microscopic evidence of oral epithelial dysplasia. Therefore, oral 
cavity pre-malignant lesions may provide an in vivo model to study the development of head 
and necks involving an HPV etiology. 
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Molecular events associated with HPV malignancy 
Studies in cervical cancer, the most widely characterized HPV-associated 
malignancy, indicate that HPV-driven malignant conversion is associated with specific 
molecular events. HPV-associated carcinogenesis requires continuous overexpression of the 
two main viral oncoproteins E6 and E7, which interact with many cellular proteins leading to 
the induction and maintenance of a transformed phenotype in infected cells (15). E6 and E7 
expression are regulated by the viral E2 protein through the early promoter (termed p97 for 
HPV16) located in the LCR of the viral genome. Overexpression of E6 and E7 is caused 
either by disruption of E2 gene via HPV genome integration or by inhibition of E2 protein 
binding to the LCR via methylation of viral DNA. Therefore, the integration and methylation of 
viral DNA are considered as two main regulatory mechanisms for malignant transformation, 
mainly in the cervical region (85). Additionally, DNA hypermethylation of host genes was 
frequently detected in advanced forms of cervical cancer (86-90). In contrast, molecular 
events culminating in malignant transformation of the HPV-infected head and neck cells are 
largely unknown. 
HPV DNA integration 
HPV DNA may exist in the episomal (extra-chromosomal) form and/or become 
integrated into the host genome (Figure 7A). HPV DNA integration into the host genome has 
been considered to be an important molecular event during HPV-induced cervical 
carcinogenesis (91,92), (Figure 7B). In most invasive cervical cancers, high-risk HPV 
genomes are integrated into the host genome mainly via mechanisms that disrupt the E2 
reading frame (93-95).
 
Lack of E2 results in up-regulation of the viral oncogenes E6 and E7, 
thereby promoting tumorigenesis (Figure 7). In addition to invasive cervical cancers, 
integration of HPV DNA was also found in premalignant cervical intraepithelial neoplasia 
(CIN2/3). In contrast, in benign and low-grade cervical lesions the predominant form of HPV 
DNA is episomal (96,97). Accordingly, different patterns of HPV DNA integration are currently 
used to monitor cancer progression in cervical cancer patients (98,99).  
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While viral integration is thought to play an important role in cervical carcinogenesis 
(92), the relevance of viral DNA integration is controversial in head and neck tumors (100). 
Some studies suggest that viral DNA integration in the head and neck sites plays an 
important role in carcinogenesis (83,101-105), while other studies suggest that episomal HPV 
alone contributes to the development of most HNCs, in contrast to what is observed in 
cervical cancers (100,106-108). Therefore, more research needs to be done to better 
understand the role of HPV DNA integration in head and neck malignancy.  
HPV DNA methylation 
Methylation of DNA is facilitated by a family of DNA methyltransferases (DNMTs) that 
catalyze the addition of methyl group to cytosine located in CpG dinucleotides. Like the 
human genome, the HPV genome is subject to epigenetic regulation through alterations in 
DNA methylation. There are 15 CpG sites in the LCR of HPV16 genome (Figure 8).  
Methylation of these 15 CpG sites (mainly 5 sites) inhibits the binding of E2 protein to E2BS, 
in turn, leads to an overexpression of E6 and E7 from the early promoter, Figure 8. 
Methylation of the five CpGs located in the E2BS3 and E2BS4 and Sp1-binding site (Sp1BS) 
has been suggested as biomarkers for cervical cancer progression (23,24). Such 
hypermethylation has been reported in cervical cancers or high-grade cervical dysplasia 
compared with low-grade CIN (23,109,110). But it is unknown whether or not viral methylation 
in HNC has a similar association with malignancy, although recent studies have suggested 
that there may be some similarities between cervical cancers and HNCs with respect to viral 
methylation (111). In contrast, a large study reported hypomethylation of the LCR of the viral 
genome in oropharyngeal cancers (112). Therefore, more research remains to be done to 
clarify a role of viral methylation in HPV-associated HNCs.  
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Figure 7: (A) Episomal and integrated forms of HPV DNA. Integration of HPV DNA is 
associated with loss or disruption of E2, and subsequent upregulation of E6 and E7 oncogene 
expression. (B) HPV-DNA integration- mediated progression to cervical cancer.  
HPV infects basal cells in the cervix. Low-grade cervical intraepithelial lesions (CIN) support 
productive viral replication. The progression to high-grade CIN and invasive cancer is 
associated with the integration of the HPV genome into the host chromosomes (red nuclei) 
from episomal HPV (dark blue nuclei). (Copyright permission obtained from Nature Publishing 
Group) 
A. 
B. 
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Figure 8: Upstream regulatory region of HPV16. Methylated E2BS inhibits the binding of E2 
transcriptional repressor and in turn, increases E6 and E7 transcription. Fifteen CpG sites are 
shown along with their respective nucleotide positions using an Asian-American variant of 
HPV16 (Genbank accession number: AF402678.1) as a reference sequence.  
Host genomic epigenetic changes 
DNA methylation is one of the most intensely studied epigenetic modifications in 
humans. In normal cells, DNA methylation plays a role in maintaining genome stability and in 
regulating the expression of genes involved in signal transduction cascade pathways, cell 
cycle regulation, angiogenesis, apoptosis, and DNA repair (113). Methylation of DNA typically 
occurs on cytosines located in CpG dinucleotides, which are usually concentrated in large 
clusters called CpG islands. The methylation of cytosine residues is mediated by a class of 
enzymes called DNA methyltransferases (DNMTs) that catalyze the transfer of the methyl 
group from S-adenosyl-methionine to the carbon 5 position of cytosine (Figure 9A). DNA 
methylation often leads to gene silencing after chromatin structure remodeling (114). Methyl-
CpG-binding proteins (MBD) associates with methylated CpG that, in turn, recruits histone 
deacetylases (HDAC). As a consequence, chromatin becomes compacted and gene 
expression is inhibited (113), (Figure 9C).  
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Figure 9: Mechanism of gene silencing mediated by DNA methylation. A) Cytosine 
methylation catalyzed by DNMT in the presence of S-adenosyl-methionine (SAM). B) 
Unmethylated CpGs within the promoter region allows gene expression while methylated 
CpGs causes silencing of genes. C) DNA methylation occurs through the recruitment of 
methyl-CpG-binding proteins (MBD) and histone deacetylases (HDAC) resulting in compacted 
chromatin and gene inhibition (Copyright permission obtained from Elsevier) 
Aberrant methylation of gene promoters, particularly of tumor suppressors can lead to 
their transcriptional repression, thereby resulting in the pro-carcinogenic environment 
(115,116).
 
Recent studies have identified epigenetic alteration, most importantly aberrant 
DNA methylation, as a possible cause of progression of various cancers (116-118). In 
addition, recent evidence revealed that HPV16 induces DNA methylation in infected cells by 
up-regulating DNMTs (DNMT1 and DNMT3a) (119,120). Different studies related to 
epigenetic alterations have been largely investigated in cervical cancers, where 
hypermethylation of viral and host genes was frequently detected in advanced cancers (86-
90). In addition to cervical cancers, aberrant promoter hypermethylation also has been 
identified in the progression of HNCs (121,122). However, the differences in epigenetic 
anomalies between HPV-positive and HPV-negative HNCs are not well-defined (123-125). A 
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better understanding of these abnormalities will help to know the epigenetic mechanism 
regulated by the presence of HPV in HNCs.  
Dissertation Overview 
Overall Goal 
The information summarized above suggests that understanding molecular events 
involved in HPV-associated head and neck cancer progression will have diagnostic and 
prognostic significance. Therefore, it is crucial to study HPV-associated potential biomarkers 
and molecular events that occur early in head and neck cancer progression in order to 
enhance detection. The ability to document an HPV etiology for HNCs can affect therapeutic 
decision-making, factor into a patient’s long-term prognosis, and identify new therapeutic 
targets. 
Hypothesis and Research Aims  
The overall aim of my dissertation is to identify potential biomarkers and ascertain 
underlying molecular mechanisms associated with HPV-positive head and neck malignancy. I 
hypothesized that head and neck tumors display distinct HPV-associated biomarkers and 
oncogenic mechanisms for malignancy, which differ from that of HPV-negative head and neck 
tumors.  
My dissertation includes three major areas of investigation outlined in chapters 2, 3, 
and 4. In chapter 2, I analyzed tumors of the head and neck for the presence of HPV and 
found that HPV-positive tumors were molecularly and histologically distinct. In chapter 2 and 
3, I identified potential clinical biomarkers for the detection of HPV-associated head and neck 
malignancies. Finally, in chapter 4, I focused on the role of HPV DNA integration, HPV 
methylation and host gene methylation in tumors of the head and neck to identify genetic and 
epigenetic mechanisms involved in HPV-mediated malignancy.
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CHAPTER II 
HISTOLOGIC VARIATION IN HEAD AND NECK TUMORS WHEN ASSOCIATED WITH 
HUMAN PAPILLOMAVIRUS 
Chapter Overview 
Recently, HPV has been found to be increasingly implicated as a causative agent in 
different types of tumors in the head and neck region. In this chapter, I determined the 
involvement of HPV in pathologically distinct tumor specimens of the head and neck and 
identified potential histological biomarkers which could be used to detect HPV infection.  
This chapter is divided into three sub-headings, based on the study conducted on 
different head and neck tumor specimens: 
1. Benign oral lesions (126)  
2. Premalignant oral lesions (127) 
3. Carcinoma of head and neck 
1. Benign oral lesions 
Introduction 
Multifocal epithelial hyperplasia (MEH) or Heck’s disease is a benign oral condition 
that occurs in Native American children/adolescents or HIV-infected adults in the United 
States but is rare among Caucasians and HPV-negative adults. It is typically associated with 
low-risk HPV infections typically involving HPV type 13 or 32 (49). Histologically, MEH lesions
 
[A study of benign oral lesions was published in 2015 (126) and copyright permission was obtained from 
Elsevier to reuse in this dissertation. A manuscript regarding premalignant lesions is currently under revision for 
publication in Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology; an abstract published in 2016 (127)] 
 21 
 
are characterized by mild hyperkeratosis and thickening of the epithelium with elongated rete 
ridges. A prominent feature is the presence of a mitosoid cell, an enlarged cell with 
atypical/fragmented nucleus resembling a mitotic figure (50,51). Mitosoid cells are atypical 
mitotic figures, which are usually seen in well-differentiated upper epithelial layers of 
hyperplastic oral mucosa (128). 
Recently, we have identified oral lesions that mimic MEH microscopically but occur in 
adult Caucasian patients who are not known to be HIV positive. Oral squamous papillomas 
are another HPV-associated benign lesion which shows clinical & histological overlap with 
MEH but do not occur in the clinical setting expected for Heck’s disease (i.e. children/ 
adolescents) (52). It is important to distinguish different forms of MEH from one another and 
from squamous papilloma. HPV genotyping could potentially contribute to differentiating 
between these different lesions. Herein, I performed HPV genotyping of oral lesions 
microscopically consistent with MEH and compared these results with those derived for 
squamous papilloma. 
Experimental Procedures 
Patient’s biopsy sample collection: This study was approved by the Institutional Review 
Board (IRB) at the University of Louisville. MEH (N=22, 17 patients) and squamous papilloma 
(N=9, 9 patients) samples were selected based on well-defined histologic criteria. 
Histologically, MEH should have thickening of the epithelium (acanthosis) with elongated rete 
ridges and mitosoid cell(s) within the well-differentiated upper epithelial layer called spinous 
cell layer (Figure 10). The histologic inclusion criteria for squamous papilloma were: 
keratinized stratified epithelium with finger-like surface projection and without the presence of 
any mitosoid cell(s).  
Genomic DNA extraction and HPV detection: Formalin-fixed, paraffin-embedded (FFPE) 
specimens were deparaffinized using xylene, followed by an ethanol wash. DNA was 
extracted using DNAeasy Blood & Tissue kit (Qiagen, USA) as per manufacturer’s 
instructions. HPV DNA detection was performed by PCR amplification using conventional 
degenerate MY09/11 and GP5+/GP6+ consensus primers to a well-conserved HPV L1 gene. 
Both primers can detect a wide range of HPV types. The reaction conditions were as follows: 
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50-100ng of template DNA, HiFi PCR buffer, 50mM MgSO4, 10mM dNTPs, 20µM of each 
primer and 1U of HiFi Taq polymerase (Invitrogen) in a total volume of 20μl reaction mixture. 
PCR reaction consisted of an initial 94°C incubation for 2 min, followed by 44 cycles of 
denaturation at 94°C (45 sec), annealing step at 56°C (for MY product) or 48°C (for GP 
product) for 45 sec, and 68°C (45 sec) and a final elongation step of 1 min at 68°C in a MJ 
Research Peltier Thermal Cycler PTC-200. The PCR amplified products were analyzed by 
electrophoresis on a 3% agarose gel stained with ethidium bromide and observed under 
ultraviolet light. PCR products on gels were purified using QIAquick Gel Extraction Kit 
(Qiagen, USA) and sent for DNA sequencing to the DNA Core Facility at the University of 
Louisville. Sequences obtained were analyzed using NCBI BLASTn database and 
MegAlign®. DNASTAR software (Version 12.0, Madison, WI), and type of HPV was identified. 
The quality of the extracted DNA was checked by amplification of internal control (β-globin).  
For a patient who showed two types of HPV in his/her lesions, HPV-type specific PCR was 
employed (which detects the presence of the E7 region of specific HPV type) to test the co-
infection of HPV6 and 32 in lesions. 
Statistical Analysis: Distributions of the discrete lesion and subject characteristics were 
summarized by frequency and percentage. Fisher’s exact tests were applied to examine 
differences between the MEH cases and squamous papilloma. These studies also assessed 
the types of HPV associated with the MEH lesions in this patient cohort. Means, standard 
deviation, and p-values from Student’s t-tests were reported. All data analyses were 
conducted by SAS /STAT
®
 Software (Version 9.4.,SAS Institute Inc., Cary, NC, USA). 
Results 
Clinical and histologic features of MEH and squamous papilloma lesions  
MEH lesions presented as a well-circumscribed, white plaque or nodule with a finely 
stippled/papillary surface. There was significant differences between MEH and squamous 
papilloma cases in distributions of the number (p=0.006) and site (p<0.0001) of lesions (Table 
2). According to my data, MEH lesions occurred more frequently at multiple anatomic sites 
than squamous papillomas (66.7% vs. 0.0%). The MEH cases were less likely to appear in 
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the soft palate/oropharynx than squamous papillomas (0.0% vs. 55.6%) and were more likely 
to appear in both keratinized oral sites and the labial/buccal mucosa than squamous 
papillomas. Of the MEH lesions that were HPV positive 13/19 (68.4%) occurred on the 
labial/buccal mucosa.  
MEH lesions presented with characteristic histologic features: acanthosis with 
elongation of the rete ridges (Figure 10a) and occasionally altered nuclei typical of mitosoid 
cells in the spinous cell layer (Figure 10b). Squamous papilloma cases, on the other hand, 
showed multiple fingerlike surface projections covered by hyperkeratotic stratified squamous 
epithelium supported by fibrovascular connective tissues. While typical mitotic cells are often 
seen in these lesions they are confined to the basal and parabasal cell layers (Figure 11b). 
HPV status of MEH lesions and squamous papillomas  
Figure 12 shows images of agarose gels of 9 representative samples. When the 
amplicons of MY and GP primers were sequenced, 8 cases were HPV6, and 11 cases were 
HPV32, while one sample was HPV40. Other samples, which did not produce any bands and 
of an inappropriate size for both MY and GP amplicons, were classified as negative for HPV 
DNA. Altogether, 19/22 MEH samples and 1/9 squamous papilloma cases were HPV positive. 
The presence of HPV differed significantly between MEH and squamous papilloma 
specimens (p=0.0002, Table 2). The MEH lesions were more likely to have HPV than the 
squamous papillomas (86.4% vs. 11.1%), especially those involving HPV type 6 (36.4% vs. 
0%) and type 32 (45.4% vs. 11.1%).  
HPV status in MEH lesions 
Analysis of MEH lesions revealed that the number of oral lesions was significantly 
different depending on the HPV type detected (p=0.002). HPV32 lesions occurred 
significantly more often as multiple lesions than HPV6, HPV40, and HPV negative lesions 
(Table 3). Marginal differences in race, HIV status, and duration of the lesion were observed 
across HPV types in MEH cases. A higher proportion of African Americans were observed 
with HPV32 lesions than HPV6, HPV40, and HPV-negative lesions. Subjects who were 
reported as HIV positive had HPV32 but none of the other HPV types. In addition, HPV32 was 
most frequently associated with lesions occurring for a longer duration. 
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I examined more than one lesion, biopsied from different sites, per patient from four 
MEH subjects. All lesions were biopsied from different sites on the same day except in the 
case of patient #15. Three MEH patients were positive only for HPV32 in all of their lesions. In 
contrast, one patient (ID #15) with 3 lesions had HPV6 in two lesions and HPV32 in the other, 
as detected by MY/GP primer-based PCR. In one instance (case #35) sequencing based on 
HPV-type specific primers (HPV6 E7 and HPV32 E7) revealed co-infection with HPV6 and 32. 
  
 
Figure 10: Photomicrographs of MEH lesion showing (A) acanthosis and elongation of 
anastomosis of the rete ridges, H&E 100X; and (B) a mitosoid cell (arrow) in the spinous cell 
layer, H&E 200X magnification 
 
 
Figure 11: Photomicrographs of squamous papilloma showing (A) the characteristic 
hyperkeratosis and finger-like projections, H&E 100X, and (B) normal mitoses in the basal 
and parabasal cell layers, H&E 400X magnification 
A
. 
B
. 
A
. 
B
. 
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Table 2: Clinical variables of MEH cases and squamous papillomas 
  
  
Variable* 
Squamous papillomas 
(9 Subjects, 9 Lesions) 
MEH Lesions 
(17 Subjects, 22 Lesions) 
p-value 
n % n % 
 
Gender 
    
  
  Female 3 33.3 5 29.4 1.00 
  Male 6 66.7 12 70.6   
Race 
    
  
  African American 1 11.1 3 17.6 1.00 
  Caucasian 8 88.9 12 70.6   
  Unknown* 0 0.0 2 11.8   
Age (Mean ± SD) 46.9 ± 23.9 52.4 ± 16.9 0.50  
  <40 years 3 33.3 5 29.4 1.00 
  40-59 years 4 44.4 7 41.2   
  ≥60 years 2 22.2 5 29.4   
HIV 
    
  
  Negative 9 100.0 13 76.5 0.28
‡
 
  Positive 0 0.0 3 17.6   
  Unknown* 0 0.0 1 5.9   
HPV 
    
  
  Absent 8 88.9 3 13.6 0.0002
†
 
  6 0 0.0 8 36.4   
  32 1 11.1 10 45.5   
  40 0 0.0 1 4.5   
Number of Lesions 
    
  
  Single 7 100.0 7 33.3 0.006
‡
 
  Multiple 0 0.0 14 66.7   
  Unknown* 2 22.2 1 4.5   
Site of Lesion 
    
  
  Soft palate 5 55.6 0 0.0  <0.0001 
  Keratinized oral sites 0 0.0 4 18.2   
  Labial/buccal mucosa 0 0.0 14 63.3   
  Tongue/floor of mouth 4 44.4 4 18.2   
Duration of Lesion 
    
  
  ≤6 months 2 22.2 6 27.3 0.47
‡
 
  >6 months 0 0.0 6 27.3   
  Unknown* 7 77.8 10 45.5   
Size of Lesion 
    
  
  ≤3 mm 6 66.7 10 45.5 0.76
‡
 
  4-6 mm 2 22.2 6 27.3   
  >6 mm 1 11.1 5 22.7   
  Unknown* 0 0.0 1 4.5   
*unknown: clinical information that could not be retrieved from biopsy requisition sheets 
†
Negative (absent) vs. positive (HPV6, 32, and 40) 
‡ 
The unknown value was omitted for analysis. 
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Figure 12: HPV DNA detection in benign oral samples by PCR using MY and GP primers 
showing amplified products of 450bp and 150bp, respectively. Amplified β-globin represents 
the loading control to check the quality of extracted DNA.  
 
MEH lesions in HIV-positive subjects 
In the MEH group, 3 subjects (17.6%) had HIV compared to 0 subjects in the 
squamous papillomas group, although no significant difference was observed between HIV-
status and the groups, Table 2. HIV status was marginally associated with HPV genotyping 
(p=0.07, (Table 3). All 3 HIV-positive MEH patients (total of 5 lesions) were HPV32 positive 
(Table 3). Therefore, HPV6 was not detected in known HIV positive patients. Interestingly, I 
found that one MEH case in an HIV positive patient was on the skin side of the commissure. 
To our knowledge, HPV32 has never been reported in the skin. Since clinical pictures of 
specimens were not available to rule out the possibility that skin infection might be an 
extension from the oral mucosal side, I cannot substantiate my result as the first report of 
HPV32 on the skin surface.  
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Table 3: Clinical variables of MEH lesions based on HPV status 
Variable 
HPV-
negative 
MEH  
HPV-
positive 
MEH 
HPV-positive MEH cases 
p-value* HPV6 HPV32 HPV40 
n % n % n % n  % n % 
Gender                       
  Female 2 66.7 6 31.6 2 25.0 4 40.0 0 0.0 0.62 
  Male 1 33.3 13 68.4 6 75.0 6 60.0 1 100.0   
Race                       
  African American 0 0.0 5 26.3 0 0.0 4 40.0 1 100.0 0.08 
  Caucasian 3 100.0 12 63.2 6 75.0 6 60.0 0 0.0   
  Unknown 0 0.0 2 10.5 2 25.0 0 0.0 0 0.0   
Age                       
  <40 years 0 0.0 8 42.1 5 62.5 3 30.0 0 0.0 0.13 
  40-59 years 1 33.3 7 36.8 3 37.5 4 40.0 0 0.0   
  ≥60 years 2 66.7 4 66.7 0 0.0 3 30.0 1 100.0   
HIV                       
  Negative 3 100.0 13 68.4 7 87.5 5 50.0 1 100.0 0.07 
  Positive 0 0.0 5 26.3 0 0.0 5 50.0 0 0.0   
  Unknown 0 0.0 1 5.3 1 12.5 0 0.0 0 0.0   
Number of Lesions                       
  Single 2 66.7 5 26.3 4 50.0 0 0.0 1 100.0 0.002 
  Multiple 0 0.0 14 73.7 4 50.0 10 100.0 0 0.0   
  Unknown 1 33.3 0 0.0 0 0.0 0 0.0 0 0.0   
Site of Lesion                       
  Skin 0 0.0 1 5.3 0 0.0 1 10.0 0 0.0 0.36 
  Keratinized oral sites 2 66.7 2 10.5 1 12.5 1 10.0 0 0.0   
  Labial/buccal mucosa 0 0.0 13 68.4 6 75.0 6 60.0 1 100.0   
  Tongue/floor of mouth 1 33.3 3 15.8 1 12.5 2 20.0 0 0.0   
Duration of Lesion                       
  ≤6 months 1 33.3 5 26.3 4 50.0 0 0.0 1 100.0 0.07 
  >6 months 1 33.3 5 26.3 1 12.5 4 40.0 0 0.0   
  Unknown 1 33.3 9 90.0 3 37.5 6 60.0 0 0.0   
Size of Lesion                       
  ≤3 mm 1 33.3 9 47.4 3 37.5 6 60.0 0 0.0 0.20 
  4-6 mm 0 0.0 6 31.6 4 50.0 2 20.0 0 0.0   
  >6 mm 2 66.7 3 15.8 1 12.5 1 10.0 1 100.0   
  Unknown 0 0.0 1 5.3 0 0.0 1 10.0 0 0.0   
*analyses between HPV types and variables  
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Discussion 
I studied two types of benign oral lesions (MEH, multifocal epithelial hyperplasia, and 
squamous papilloma) and found a significant difference in HPV infection in these lesions. The 
most important finding from my study is the demographic presentation of MEH lesions. 
Although seen throughout the world, MEH is predominantly seen in Native Americans 
children/adolescents or HIV-infected adults and is typically associated with HPV types 13 and 
32. However, my study demonstrated a novel presentation of MEH with HPV6, 32 and a 
unique type HPV40 in middle-aged to older (31-82 years of age), HIV-negative Caucasian 
adults. Of note, the most widely and frequently published HPV in MEH, i.e.  type 13, (49) was 
not detected in any samples in this study. Future HPV detection protocols should include 
HPV32 as it may be currently overlooked. Another benign lesion i.e. squamous oral 
papilloma, which showed histologic overlap with MEH, was found to be mostly HPV negative.  
Interestingly, different HPV types were noted in a patient with recurrent lesions. This 
patient had an initial HPV6-positive lesion, followed 15 months later by a lesion with HPV6 
and another lesion co-infected with both HPV6 and HPV32. This indicates that more than one 
HPV type may be present in MEH lesions in the same patient. 
Although MEH is asymptomatic and can regress spontaneously without surgical 
intervention, diagnosis of MEH is important to ensure differential diagnosis from other benign 
lesions since these lesions may have overlapping clinical and histologic features. Here I have 
shown that HPV genotyping complements histologic characterization of benign oral lesions 
that are suspected of harboring HPV. 
2. Premalignant oral lesions  
Introduction 
In the head and neck, high-risk HPV infection is most often seen in oropharyngeal 
cancer (OPC), a subset of head and neck cancer that is increasing in incidence worldwide 
(62). While HPV is strongly associated with OPC, the relationship of HPV to oral squamous 
cell carcinoma (OSCC), another subgroup of HNC (58), and its premalignant precursor, high-
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grade oral epithelial dysplasia (hgOED), is still not clearly defined. While some reports have 
indicated that HPV is not commonly found in OSCC (73,129); others indicated ~25% 
prevalence of HPV16/18 in oral dysplasia (130). More recently, a subset of hgOED was 
shown to be strongly positive for high-risk HPV (131,132). In these studies, the authors 
indicated that diffuse atypical mitotic-like structures (herein referred to as “mitosoid” cells) and 
apoptotic cells are unique histologic features warranting the designation “high-risk HPV-
associated oral dysplasia”(132) or “HPV-associated Oral Intraepithelial Neoplasia (HPV-
OIN)”(131).  
In our laboratory, we have also noted hgOED cases that show the widespread 
mitosoid and apoptotic cells recently described (Group 1 for this study) but in compiling such 
cases we have also noted that hgOED may also show focal mitosoid and apoptotic cells 
(Group 2 for this study) while other cases completely lack these features (Group 3). Herein, I 
explore the association of high-risk HPV in these potential subsets of hgOED with the addition 
of HPV genotyping. I hypothesize that a high prevalence of high-risk HPV and strong p16
INK4a
 
expression will be seen in Group 1 cases with intermediate and lower associations for these 
variables in Group 2 lesions and Group 3 respectively.  
Experimental Procedures 
Biopsy sample selection: This study was approved by the IRB at the University of Louisville. 
Reports of biopsies accessioned into the University of Louisville Oral Pathology Laboratory 
were searched for keywords and/or phrases that could be associated with HPV infection (i.e. 
virus, viral, HPV, mitosoid, Bowen, koilocy-, apopto-, multinucleated keratinocyte). All 
retrieved cases whose diagnosis reported premalignant changes (i.e. dysplasia or carcinoma 
in situ) were then evaluated microscopically for the Group 1 histologic inclusion criteria as 
previously reported (near full thickness mitosoid and apoptotic cells) (131). Group 2 included 
cases which had focal mitosoid cells above the basal layer and occasional apoptotic cells (i.e. 
in at least one or more high power fields but not diffusely through the specimen), suggesting a 
possible early or isolated infection of those cells with high-risk HPV. Group 3 cases (N=10) 
lacked these features altogether in the histologic sections studied. 
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Genomic DNA extraction and HPV detection: The microscopic and clinical information for 
all cases were blinded before performing HPV genotyping. Genomic DNA extraction and HPV 
genotyping were performed as described in previously. Type-specific E7 HPV primers were 
used to confirm the presence of HPV6, 16, 33 and 45. 
Immunohistochemistry (IHC) for p16
INK4a
: Immunohistochemistry for p16
INK4a
 expression in 
FFPE specimens was performed by the Special Procedures Laboratory (University of 
Louisville) using an antibody to p16
INK4a
 (CINtec Histology Kit, Roche laboratories). The Leica 
Bond Polymer Refine Detection (DS9800) system and the Leica BOND III automated IHC 
stainer were used for histological staining. Staining for p16
INK4a
 was rated according to criteria 
used by McCord et al (132): grade 2 (strong and diffuse nuclear and cytoplasmic staining of at 
least the half depth of the epithelial thickness); grade 1 (patchy staining with unstained 
epithelial cells interspersed among positive cells); and grade 0 (negative, no staining or 
staining of scattered single cells). This system was modified such that if patchy staining was 
observed but it included >70% of the dysplastic areas, then it was categorized as grade 2. 
Also, grade 1 and grade 2 cases were classified as positive for p16
INK4a
 expression, rather 
than grade 1 cases being “equivocal,” and grade 0 cases were categorized as negative. 
Statistical analysis: Fisher’s exact tests were conducted to evaluate differences between (1) 
all groups, (2) Group 1 vs. Group 3 lesions, (3) Group 2 vs. Group 3 lesions, and (4) Group 1 
vs. Group 2 lesions. As pair-wise intergroup comparisons would produce prohibitively small 
sample sizes, statistical significance was reported for differences across all 3 groups.  As 
Group 2 and Group 3 were more similar histologically than Group 1, their results were pooled 
together for some comparisons and are designated as Group 2/Group 3, where applicable. 
For continuous characteristics, means, standard deviations, and p-values from one-way 
ANOVA or Student’s t-tests comparing groups are reported. To determine if high-risk HPV 
presence correlated with p16
INK4a
 status (negative vs. positive), stratified exact conditional 
logistic regression was conducted. Predictor test variables [histologic features alone (Group 1, 
Group 1 and 2) and in combination with positive p16
INK4a
 expression] of high-risk HPV 
presence were evaluated for sensitivity, specificity, positive predictive value (PPV) and 
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negative predictive value (NPV).  Statistical analyses were conducted in SAS Version 9.4 
(SAS Institute Inc., Cary, NC, USA). 
Results 
Clinical characteristics of hgOED lesions 
The typical clinical appearance for each group consisted of a white or red/white patch 
or plaque with a variably rough/papillary surface texture which most commonly affected the 
lateral tongue or floor of the mouth (Figure 13). Table 4 depicts comparisons among all three 
groups and between Group 1 and Group 2/Group 3. While the lateral tongue and floor of the 
mouth were most commonly affected in all groups, this location was nearly exclusively 
involved in Group 2/ Group 3 (95.8%) whereas Group 1 lesions affected other sites in 37.5% 
of cases (p=0.01). Group 1 lesions were significantly smaller than the Group 2/Group 3 
lesions with the latter tending to be >6mm (p=0.03); although, there were many cases for 
which size data was not available. Patients in Group 1 were typically younger than Group 
2/Group 3 patients by 8 years on average (p=0.03).  
Histologic features of hgOED lesions 
Group 1 hgOED presented with characteristic histologic features as described 
previously (131,132): abundant mitosoid and apoptotic cells throughout the full thickness of 
epithelium (Figure  14). Group 2, on the other hand, showed only focal apoptotic and 
mitosoid cells (Figure 15). Group 3 showed typical dysplastic features but lacked the 
combination of mitosoid and apoptotic cells (Figure 16). 
 
Figure 13: Clinical photograph showing a similar white patch/plaque on the floor of mouth for 
each group. A) Group 1. B) Group 2. C) Group 3 lesions.  
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Figure 14: Group 1 hgOED H&E- stained section showing diffuse apoptotic cells (red arrows) 
and mitosoid cells (black arrows) at A) 200x and B) 400x magnification.  
 
 
Figure 15: Group 2 hgOED H&E- stained section showing A) a focal apoptotic cell (red 
arrow) and mitosoid cells (black arrows) at 200x, and B) at 400x magnification. 
 
 
 
 
 
 
 
Figure 16: Group 3 hgOED H&E- stained section showing dysplastic epithelial features which lack 
mitosoid or apoptotic cells at 200x magnification. 
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HPV status in hgOED lesions 
Statistical significant differences among all groups were observed for HPV presence 
(p=0.02), Table 4. High-risk HPV was found significantly more often in Group 1 (81.3%) 
versus Group 2 (57.1%) and Group 3 (20.0%), (overall p=0.01).  HPV16 was seen in all 
except one HPV-positive case (being HPV33) in Group 1, comprised 7 of 9 (77.7%) of the 
HPV-positive cases in Group 2 (HPV6 and HPV45 seen in the other 2 cases respectively) and 
was the only HPV type seen in the Group 3 (2 cases). When Group 2 and Group 3 were 
combined, Group 1 was significantly more associated with high-risk HPV (p=0.02) and the 
odd ratio of HPV presence were 5.12 (95% CI 0.99, 33.9) times greater for Group 1 lesions 
than combined Group 2/Group 3 lesions. 
Immunohistochemical (IHC) staining for p16
INK4a
 expression 
IHC results for p16
INK4a
 expression between groups are reported in Table 5.  Strong 
and diffuse p16
INK4a
 staining (grade 2) was more common in Group 1 cases (75%) than in 
Group 2 (14.3%) or Group 3 (11.1%), (overall p= 0.0008). Similarly, p16
INK4a
 positive cases 
(grade 1 and 2, as depicted in Figure 17) were significantly higher in Group 1 (93.8%) than in 
Group 2 (42.9%) or Group 3 (33.3%) (overall p=0.001). The odd ratio of p16
INK4a
 positive 
status was 23.3 times greater for Group 1 than Group 2/Group 3 (Table 4). 
 
 
Figure 17: p16
INK4a immunohistochemistry. (A) Grade 2 (strong and diffuse) staining from 
Group 1. (B) Grade 1 (patchy) staining from the Group 3 group, at 200x magnification. 
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Association of p16
INK4a
 status with HPV presence 
Stratified logistic regression analysis (Table 5) showed a significant association 
between p16 expression and high-risk HPV status (p=0.04). Expression of p16 combined with 
high-risk HPV positivity was seen frequently in Group 1 (13/16, 81.3%) compared to Group 2 
(5/13, 38.5%) and Group 3 (1/9, 11.1%). All high-risk HPV-positive Group 1 and Group 3 
samples expressed p16 whereas only 5 of 8 (62.5%) high-risk HPV-positive samples in Group 
2 expressed p16
INK4a
. In Group 2/Group 3 samples, there was a variable association of the 
presence of high-risk HPV and p16
INK4a
 expression. 
Prediction of high-risk HPV presence in hgOED 
Analyses of the use of histologic features either alone or combined with p16 p16
INK4a
 
expression to predict HPV presence in hgOED are shown in Table 6. Histologic features of 
Group 1 and 2 combined (i.e. mitosoid and apoptotic cell(s) diffusely or focally present) were 
91.3% sensitive (95% CI: 72.0%, 99.0%) and 47.1% specific (95% CI: 23.0%, 72.2%) for 
detecting high-risk HPV with a positive predictive value of 70.0% and negative predictive 
value of 80.0%. Analysis of Group 1 histologic features alone to predict for the presence of 
high-risk HPV was more specific at 82.4% (95% CI: 56.7%, 96.2%) but showed a large 
decrease in sensitivity to 56.5% (95% CI: 34.5%, 76.8%).  
The combination of p16
INK4a
 expression and the histologic features of Group 1 lesions 
were 100% sensitive (95% CI: 75.3%, 100.0%) in predicting the presence of high-risk HPV 
with a positive predictive value of 86.7% (95% CI: 59.6%, 98.4%), though specificity was only 
33% (95% CI: 0.84%, 90.6%), Table 6. When Group 1 and 2 were combined then the 
addition of p16
INK4a
 expression was 81.8% sensitive (95% CI: 59.7%, 94.8%) and 62.5% 
specific (95% CI: 24.5%, 91.5%) in predicting the presence of high-risk HPV.  
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Table 4: Clinical variables of hgOED 
  
Group 1 
(N=16) 
Group 2 
(N=14) 
Group 3 
(N=10) 
p-value 
Odds Ratio 
Group1 vs. 
Group2/Group 3 
(95% CI)  Variable N % N % N % Overall 
Group1 vs. 
Group2/Group 3 
Gender          
 Male 13 81.3 11 78.6 9 90.0 0.88 1.00 0.87 (0.12, 
6.93)  Female 3 18.8 3 21.4 1 10.0   
Race 
       
  
 Black 3 18.8 2 14.3 0 0.0 0.72 0.60 2.63 (0.24, 
36.4)  Caucasian 8 50.0 7 50.0 7 70.0   
 Unknown
ǁ
 5 31.3 5 35.7 3 30.0    
Age (median ± 
IQR) 
51.1 ± 10.3 59.0 ± 12.3 59.3 ± 8.5 0.09
†
 0.03
†
  
 <40 yrs 1 6.3 1 7.1 0 0.0   0.38 (0.10, 
1.30)*  40-55 yrs 10 62.5 4 28.6 3 30.0   
 >55 yrs 5 31.3 9 64.3 7 70.0    
Smoking 
       
  
 Current 7 43.8 5 35.7 4 40.0 0.65 0.21 2.85 (0.46, 
21.4)
 ‡
 
  Non 3 18.8 6 42.9 5 50.0 
   Previous 3 18.8 2 14.3 1 10.0 
 
  
Unknown
ǁ
 3 18.8 1 7.1 0 0.0 
 Alcohol 
       
  
 Current 4 25.0 3 21.4 2 20.0 0.50 0.78 0.80 (0.09, 
6.76)
 ‡
  Non 5 31.3 1 7.1 4 40.0  
 Previous 1 6.3 1 7.1 0 0.0  
 Unknown
ǁ
 6 37.5 9 64.3 4 40.0  
HPV 
       
  
 Negative 3 18.8 5 35.7 8 80.0 0.02 0.03 N/A 
 Type 6 0 0.0 1 7.1 0 0.0    
 Type 16 12 75.0 7 50.0 2 20.0    
 Type 33 1 6.3 0 0.0 0 0.0    
 Type 45 0 0.0 1 7.1 0 0.0    
HPV risk 
       
  
 Low-risk HPV 0 0.0 1 7.1 0 0.0 0.01 0.02 5.12 (0.99, 
33.9)
 §
 
 High-risk HPV 13 81.3 8 57.1 2 20.0   
 Negative 3 18.8 5 35.7 8 80.0    
p16
INK4a
 grading 
       
  
  grade 2 12 75.0 2 14.3 1 11.1 0.0008 0.0001 7.06 (2.31, 
31.2)*   grade 1 3 18.8 4 28.6 2 22.2 
 
 
  grade 0 1 6.3 8 57.1 6 66.7 
 
  
p16
INK4a
 status 
       
  
 Positive 15 93.8 6 42.9 3 33.3 0.001 0.001 23.3 (2.50, 
1,050)  Negative 1 6.3 8 57.1 6 66.7   
Site 
       
  
 Tongue/ Floor of 
mouth 
10 62.5 13 92.9 10 100.0 0.13 0.01 N/A 
 Buccal/ labial 
mucosa 
3 18.8 0 0.0 0 0.0    
 
Soft palate 1 6.3 1 7.1 0 0.0 
 
  
 Hard palate/ 
gingiva 
2 12.5 0 0.0 0 0.0    
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Size 
       
  
 >6mm 4 25.0 10 71.4 5 50.0 0.09 0.03 0.24 (0.03, 
1.14)
 
*
,
  4-6mm 5 31.3 1 7.1 0 0.0   
 <4mm 1 6.3 0 0.0 1 10.0   
 Unknown
ǁ
 6 37.5 3 21.4 4 40.0    
Duration 
       
  
  >2 months 4 25.0 5 35.7 4 40.0 0.56 0.36 0.15 (0.00, 
2.83)
 
   ≤2 months 3 18.8 0 0.0 1 10.0 
 
 
  Unknown
ǁ
 9 56.3 9 64.3 5 50.0 
 
  
Abbreviations: IQR, interquartile range; N/A, not applicable; CI, confidence interval 
*Odds ratio computed assuming variable is ordinal 
†
 Wilcoxon rank-sum test p-value 
‡
Current vs. Non; 
§
Positive vs. Negative; 
ǁ 
Unknown level omitted for analysis  
 
 
 
 
 
Table 5: Association between p16
INK4a
 (p16) and high-risk HPV (HR-HPV) in hgOED  
 
Group 1 (N=16) Group 2 (N=13*) Group 3 (N=9) 
p-
value
†
 
P16 | HR-HPV Positive Negative Positive Negative Positive Negative 
p16 positive 
13 
(81.25%) 
2   
(12.5%) 
5 
(38.46%) 
1   
(7.69%) 
1 
(11.1%) 
2  
(22.2%) 
0.04 
p16 negative 
0     
(0.0%) 
1   
(6.25%) 
3  
(23.07%) 
4      
(30.77 %) 
0   
(0.0%) 
6 
(66.67%) 
* 
One low-risk HPV-positive sample omitted for analysis 
†
Stratified exact conditional logistic regression score test mid-p.  
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Table 6: Prediction of the presence of high-risk HPV (HR-HPV) in hgOED 
Predictor variables for 
HR-HPV presence 
Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
PPV  % 
(95% CI) 
NPV % 
(95% CI) 
Histologic features alone     
Group 1* 
56.5 
(34.5, 76.8) 
82.4 
(56.7, 96.2) 
81.3 
(54.4, 96.0) 
58.3 
(36.7, 77.9) 
Group 1 and 2
†
 
91.3 
(72.0, 99.0) 
47.1 
(23.0, 72.2) 
70.0 
(50.6, 85.3) 
80.0 
(44.4, 97.5) 
Histologic features with p16 expression    
Group 1* 100.0            
(75.3, 100.0) 
33.3              
(0.84, 90.6) 
86.7 
(59.6, 98.4) 
100 
(2.5, 100.0) 
Group 1 and 2
†
 
81.8 
(59.7, 94.8) 
62.5 
(24.5, 91.5) 
81.0 
(58.1, 94.6) 
55.6 
(21.2, 86.3) 
PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval 
*Comparison of Group 1 with Group 2/Group 3 
†
Comparison of Group 1/Group 2 with Group 3 
Discussion 
The present study analyzed histologically distinct high-grade oral epithelial dysplastic 
(hgOED) lesions based on the distribution of mitosoid/apoptotic cells: Group 1 hgOED with 
diffuse mitosoid cells, Group 2 with focal mitosoid cells and Group 3 hgOED lacking these 
histologic features. This study is the first study to perform HPV genotyping in histologically 
distinct hgOED lesions and show significant differences in both the presence of high-risk HPV 
and p16
INK4a
 expression between these lesions. In previous studies (131,132), researchers 
employed in situ hybridization (ISH) technique using cocktails of low-risk and high-risk HPV 
probes, which could not identify the specific HPV types as done by PCR-based HPV 
genotyping. 
My  data confirm the previous findings (131,132) that high-risk HPV is strongly 
associated with forms of hgOED with widespread mitosoid and apoptotic cells (Group 1). 
Though not statistically significant, an intermediate level of high-risk HPV was detected in 
Group 2 lesions (57.1%) as compared to Group 1 (81.3%) and Group 3 (20%). HPV16 was 
the most predominant HPV type present in 12/16 (75%) of Group1, 7/14 (50%) of Group 2 
and 2/10 (20%) of Group 3. The focal changes in Group 2 cases could be due to early 
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proliferation of high-risk HPV that could expand throughout the epithelium over time to 
eventually become widespread as in Group 1 lesions. Correlation of these specific histologic 
changes in the presence of high-risk HPV with gene and protein expression profiles could 
help reveal how high-risk HPV infection influences the histologic progression of dysplasia and 
risk for malignant transformation.  
In this study, I showed a significant association between high-risk HPV and p16
INK4a
 
expression in Group 1 lesions. Expression of p16
INK4a
 was 100% sensitive for detecting high-
risk HPV in Group 1 lesions with a positive predictive value of 86.7%. So, p16
INK4a
 
overexpression is a reasonable surrogate marker for high-risk HPV infection in hgOED where 
widespread mitosoid cells and apoptotic cells are noted. However, 2 cases were p16
INK4a
 
positive but negative for high-risk HPV, resulting in only 33.3% specificity (95% CI: 0.84%, 
90.6%). Therefore, p16
INK4a
 expression may not be specific for high-risk HPV in hgOED cases 
that show these unique histologic changes and direct testing for HPV by PCR or in situ 
hybridization (ISH) may be warranted in these instances. My data also show that when these 
unique histologic features are focal or absent (Group 2 and Group 3 respectively), p16
INK4a
 is 
not predictive of the presence of high-risk HPV in hgOED. 
On combining Group 1 and Group 2 lesions, the sensitivity of these histologic 
features for detecting high-risk HPV was improved; point estimates for sensitivity increased 
from 54.2% to 91.7%. However, this was at a cost to specificity—point estimates for 
specificity decreased from 81.3% to 50.0%. Practically speaking, when a pathologist 
evaluates a case of hgOED and sees either diffusely distributed or focally dispersed mitosoid 
and apoptotic cells, there is a high likelihood that high-risk HPV is present and warrants direct 
testing for HPV. Whether focal changes seen in Group 2 lesions are a precursor to more 
widespread changes observed in Group 1 lesions requires further study.  
While a causative role of high-risk HPV is clearly implicated in OPC, its role in OSCC 
is still largely unknown (74) and even less is understood about its role in the development of 
pre-malignancy and subsequent malignant transformation. An initial challenge to studying 
HPV-associated disease progression is to identify high-risk HPV infection in the premalignant 
state. For OPC, tumorigenesis often occurs deep within the crypts without a surface 
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premalignant precursor (47) whereas OSCC often develops from a clinically apparent lesion 
(84) with microscopic evidence of dysplasia. Also, there is no reason to clinically evaluate the 
tonsillar crypts unless there are symptoms (e.g. neck mass, sore throat), which do not occur 
until cancer has already developed. In contrast, routine oral examination (as performed in the 
dental care) allows detection of early oral premalignant lesions thus providing the unique 
opportunity to study how HPV infection may initiate dysplastic changes or propel them 
forward to malignancy. While the mechanisms of HPV-driven neoplasia in the oropharynx 
compared to the oral cavity likely differ, the study of these oral cavity lesions may be the best 
in vivo opportunity to study the evolution of head and neck HPV-associated neoplasia.    
 
3. Carcinoma of the head and neck  
Introduction 
Head and neck cancers are malignant tumors that develop in the upper aerodigestive 
epithelium. A subset of head and neck cancers (HNCs), mostly oropharyngeal cancer, has 
been found to be strongly associated with HPV infection, particularly high-risk HPV types 16 
and 18. Other risk factors for HNC are tobacco and alcohol use (61). Although the prevalence 
of smoking is decreasing in the United States, there has been a recent increase in the 
incidence of HPV-positive oropharyngeal cancers (62). About 72% of oropharyngeal cancers 
are caused by HPV in the United States (62). It is estimated that around 2,400 and 9,400 new 
cases of HPV-associated oropharyngeal cancers are diagnosed in women and men, 
respectively, each year in the US. HPV-associated oropharyngeal cancers now outnumber 
the cases of these cancers attributable solely to smoking or alcohol use (133). 
Immunohistochemical analysis (IHC) for p16
INK4a
 expression is frequently used to 
determine HPV status in the clinic, but many reports have shown that p16
INK4a
 is not always a 
good surrogate for HPV infection (18,46,48). This study assessed the presence of HPV by 
using the PCR-based method to detect HPV DNA and compared the HPV-positive status with 
cancer anatomic site and p16
INK4a
 expression.  
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Experimental Procedures 
Tissue Samples: This study was approved by the IRB at the University of Louisville. Patients 
who attended the Head and Neck multidisciplinary clinic for evaluation of their cancer were 
asked to provide written consent. HNC specimens were classified into one of five categories 
according to anatomical subsites: a. Oral cavity (includes lip, anterior tongue, gum, floor of 
mouth, hard palate); b. Oropharynx (includes the base of tongue, lingual tonsil, soft palate, 
uvula, tonsil, and oropharynx); c. Hypopharynx (includes pyriform sinus, hypopharynx); d. 
Larynx (includes glottis, supraglottis, subglottis); and e. Other unspecified cases (includes 
sites which were not within one of the categories listed above and those of unknown primary 
cancer). This categorization is based on The International Classification of Diseases (134), 
and the method used by Hashibe et. al (135). The clinical stage of each cancer was 
determined using the TNM staging system, 7th edition (136). Demographic and disease 
characteristics of patients were collected from the deidentified database and researchers 
were blinded to the HPV status of the patients before serological analysis. 
Genomic DNA extraction and HPV detection: DNA was extracted from fresh frozen or 
formalin-fixed, paraffin-embedded (FFPE) specimens using DNAeasy Blood & Tissue kit 
(Qiagen, USA) as per manufacturer’s instructions with RNAase (20µl of 20 mg/ml) treatment. 
FFPE samples were deparaffinized using xylene and washed before DNA extraction. HPV 
detection and genotyping were performed, as described previously. β-globin amplification was 
done used for an internal control.   
p16
INK4a 
immunohistochemistry: Immunostaining was performed using standard protocols in 
the UofL pathological laboratory. IHC for p16
INK4a
 was considered positive if there was strong 
and diffuse staining present in >70% of the malignant cells. The results of the p16
INK4a
 IHC for 
malignant specimens were provided by the Cancer Database and Specimen Repository 
(CDSR) at the James Graham Brown Cancer Center, University of Louisville. There were 
cases in which p16
INK4a
 IHC was not performed as part of a patient’s standard diagnostic 
workup and hence were unavailable at the time of analysis. 
Statistical analysis: Distributions of discrete lesion characteristics were summarized by 
frequency and percentage. Fisher’s exact tests or Students t-tests were conducted to 
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evaluate differences between variables using SigmaPlot Version 12.5 (Systat Software, Inc., 
San Jose California, USA). 
Results 
Demographic Information of HNC Patients 
Summary on the distribution of 54 HNC specimens is shown in Table 7. Age ranged 
from 35-87 years and 81.5% of patients were males with two exceptions. HPV-positive HNC 
patients were about 6 years younger than patients whose tumors were HPV-negative 
(p<0.05). No significant difference in cancer stages was found between HPV-positive and 
HPV-negative HNC. 
HPV-positive HNC patients 
HPV DNA was detected in 18 out of 54 HNC specimens (Table 7). When the MY and 
GP amplicons (Figure 18) were sequenced, 16 were genotyped as HPV16 and other two 
were HPV18 and HPV33. Results were further verified using HPV type-specific primers. Of 
note, there were many samples, which produced a band around the size of MY amplicon, but 
were not detected to have HPV DNA after sequencing.  
Correlation of HPV positivity with HNC anatomic sites and p16
INK4a
 status 
HPV-positive cases were significantly associated with oropharyngeal cancer (Table 
7), p<0.001. In this study, only 16.7% of total HPV-positive patients had oral cavity cancers. 
Positive HPV status was also significantly correlated with positive p16
INK4a
 IHC staining 
(p<0.001). 
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Figure 18: HPV DNA detection in HNC samples by PCR using MY09/11 and GP5+/GP6+ 
consensus primers. β-globin was used as the loading control. 
 
Table 7: Demographics of HPV positive and HPV negative HNC patients 
Category 
HPV DNA positive 
(N=18) 
HPV DNA negative    
(N=36) 
p-value 
  
n % n % 
 
Gender 
     
 
Male 16 88.9 28 77.7 NS 
 
Female 2 11.1 8 22.2 
 
Age (years) 55.11± 8.4 61.1 ± 10.8 0.022* 
Anatomic site 
     
 
Oropharynx 11 61.1 3 8.3 <0.001* 
 
Oral cavity 3 16.7 11 30.6 
 
 
Others (Hypopharynx, larynx) 4 22.2 22 61.1 
 
Stage 
     
 
I 0 0.0 1 2.8 NS 
 
II 1 5.6 12 33.3 
 
 
III 4 22.2 13 36.1 
 
 
IVA 9 50.0 4 11.1 
 
 
IVB 0 0.0 0 0.0 
 
 
IVC 0 0.0 0 0.0 
 
 
Unknown
†
 4 22.2 6 16.7 
 
p16
INK4a
 status 
     
 
Positive 13 72.2 3 8.3 <0.001* 
 
Negative 0 0 10 27.8 
 
 
Unknown
†
 5 35.7 23 63.9 
 
*Significant values, NS: non-significant 
†
Unknown
 
values omitted during analysis 
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Discussion 
In this study, an initial characterization of the malignant specimens was done and the 
obtained data was used for their further analysis in subsequent chapters. Malignant tissue 
samples from different histological sites of the head and neck (oropharynx, oral cavity, 
hypopharynx, and larynx) were examined. The median age of HPV-positive HNC patients was 
significantly younger than HPV-negative patients. A similar trend is seen in HPV-positive OPC 
and OSCC patients in younger patients compared to those with HPV-negative cancers 
(62,137). When cases were stratified according to location, the data showed that 
oropharyngeal sites (tonsils, posterior tongue, and oropharynx) were the most common sites 
affected in patients who were HPV-positive. My results were consistent with the increasing 
incidence of HPV infection in oropharyngeal cancers (60%-100%) (62,133,138,139). HPV-
negative cancers were mainly from non-oropharyngeal cancers of the head and neck region. 
Further, the data showing only 16.7% (3/18) of HPV-positive OSCC samples supports the 
findings of previous studies that HPV prevalence is lower in OSCC (13-47%) (58,140,141). As 
expected, HPV type 16 was the predominant type found in our specimens, which was also 
reported in the majority of other studies (69,82,138,142). Other high-risk types- HPV18 and 
HPV33 were also observed. While HPV16 is the most common type detected in OPC, HPV33 
and HPV18 have shown to be rare but significant factors in OPC (32,143,144).  
Results indicated that HPV-positive cancers are significantly associated with positive 
p16
INK4a
 expression, confirming the finding of previous reports, particularly in OPCs (48). 
Studies also suggest that factors/mechanisms other than HPV infection likely stimulate 
p16
INK4a
 expression, mainly in OSCC (46,74,76). 72.2% of the HPV-positive cancers showed 
positive p16
INK4a
 staining, though most could not be evaluated for p16
INK4a
 status. The majority 
of HPV-negative OSCC was p16
INK4a
 negative. Out of 3 HPV-positive OSCC, two showed 
positive p16
INK4a
 staining (the other could not be determined). These data did not reveal any 
obvious results towards positive or negative p16
INK4a
 status in OPC and OSCC because of 
small sample size and limited available data.  
In summary, my study is in agreement with previous results showing a clear 
association of high-risk HPV with HNCs, particularly oropharyngeal cancers. In addition to 
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HPV genotyping and p16
INK4a
 staining, characterization of mitosoid cells would be useful. In 
earlier sections of this chapter, I have shown that mitosoid cells are strong biomarkers of HPV 
infection in benign MEH and distinct subset of pre-malignant oral tumors. It was not possible 
to characterize mitosoid cells in malignant specimens due to unavailability of histological 
slides. Further studies characterizing mitosoid cells in cancerous tissues of the head and neck 
would be useful to determine whether these histological features are consistently present 
during premalignant to malignant transformation. In addition to histologic biomarkers, 
identification of HPV-associated serum biomarker would be non-invasive and early method to 
diagnose HPV etiology in HNCs (discussed in Chapter III). Also, detailed molecular studies 
are needed to determine mechanism how HPV influences malignant transformation in HNCs 
(discussed in Chapters IV and V). 
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CHAPTER III 
POTENTIAL SERUM BIOMARKER FOR DETECTION OF HPV-ASSOCIATED  
HEAD AND NECK MALIGNANCY 
Chapter Overview  
HPV-related head and neck cancer incidence is increasing rapidly worldwide 
including the United States, but there are no standard non-invasive ways to detect HPV in 
these cancers. Although p16
INK4a
 overexpression in tumor tissues is widely accepted as a 
surrogate marker for HPV positivity, studies reported that non-HPV cancers also express 
p16
INK4a
. In chapter II, I have shown that mitosoid cells could serve as a strong histologic 
biomarker of HPV infection in the head and neck tumors. Detection of both p16
INK4a 
expression and mitosoid cells require cancer tissues specimens. Therefore, there is a need to 
identify serum biomarker of HPV infection that could carry the potential of earlier and non-
invasive methods of viral detection. Therefore, in this chapter, I determined whether titers for 
antibody to the HPV E7 protein could also be used as a suitable biomarker for head and neck 
malignancies associated with HPV. To this end, HPV E7 antibody titer was analyzed together 
with p16
INK4a
 staining and HPV genotyping in tumor tissues to access their potential uses as 
biomarkers for the presence of HPV. My data represent the first report that the combination of 
E7 serology and p16
INK4a
 staining represents a strong diagnostic marker for underlying HPV 
etiology in HNCs (145). 
Introduction 
Evidence of an etiologic role for HPV in head and neck squamous cell carcinoma has 
been accumulating, with high-risk HPV16 (and to a lesser extent HPV18) detected in 
carcinomas in this region. The p16
INK4a
 protein is overexpressed in HPV-positive tumors as a 
result of the HPV oncoprotein E7 inactivating the tumor suppressor pRb protein. This 
inactivation leads to increased expression of downstream genes like p16
 INK4a
 normally 
[This study was published in 2015 (145) and copyright permission was obtained from Elsevier to reuse 
in this dissertation] 
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repressed by pRb. HPV DNA detection (by in situ hybridization or PCR) and p16
INK4a
 
immunohistochemistry are currently used to determine HPV status. Both of these tests 
require cancer tissues samples. Novel diagnostic techniques using serum samples could 
carry the potential of earlier and non-invasive methods of detection. 
Studies have been done to evaluate serologic markers of HPV infection in HNC. HPV 
serology studies have focused on detecting HPV16 antibodies and have focused mostly on 
the L1 protein (146-149), with few studies involving E6 and E7 oncoproteins (149-152) or 
E1/E2 proteins (152). Antibodies to HPV16 E6 and/or E7 are suggested to be more specific 
for HNC than L1 antibodies (149,150). The presence of HPV L1 and E2 antibodies may 
indicate benign infection whereas E6 and E7 antibodies are more specific for premalignant 
and malignant lesions (i.e. transcriptionally active HPV infection). Antibodies against E6 and 
E7 proteins are largely HPV type specific. HPV18 DNA has been also detected in HNCs but 
only a few studies have examined the seroprevalence of HPV18 in HNCs (153,154). Some 
studies have suggested a correlation between HPV16 E6/E7 seropositivity and clinical 
outcome of HNC patients (155-157). 
My study examined the presence of HPV16 and 18 specific antibodies to E7 
oncoprotein in sera of HNC patients and compared the seropositive status with anatomic site 
of cancers, p16
INK4a
 IHC positivity, HPV tumor DNA, smoking status and treatment outcome. 
Currently, there are no standard commercially available serologic tests that detect HPV-
antibodies against any HPV proteins. Although HPV serological studies have been reported; 
most of them have focused on HPV16 antibodies (not HPV18) and fewer have conducted 
serology both before and after treatment of HNC patients. 
Experimental Procedures 
Serum samples: This study was approved by the IRB at the University of Louisville. Blood 
was collected from pathologically confirmed HNC patients during the period from 08/27/2009 
to 07/30/2014. Blood samples were kept at room temperature for 30 minutes to clot and then 
were centrifuged at 3,000 rpm for 10 min to obtain serum. Serum aliquots were obtained from 
the Cancer Database and Specimen Repository (CDSR) at the James Graham Brown Cancer 
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Center (JGBCC). I analyzed 92 de-identified serum samples (including 17 follow-up sera) 
from 75 patients. HNC was classified into anatomical subsets, as described previously in 
chapter II. Sera from two cervical cancer patients who were seropositive for HPV16 or HPV18 
were used as positive Group 3. 
E7 proteins of HPV16 and 18: Previously, E7 oncoproteins of HPV16 and 18, fused with 
MBP (maltose-binding protein), were expressed in E.coli and purified on amylose column 
(158). These fusion proteins were employed as antigens for ELISA in this study. 
Serological Analysis by ELISA: Total IgG antibody against E7 oncoproteins of HPV16 and 
HPV18 were examined by direct ELISA using recombinant E7 proteins as antigens. Briefly, 
500ng protein/ well in 100μl of 50mM bicarbonate buffer (pH 9.6) was coated onto Immulon
TM
 
ELISA microplates (Thermo Scientific, USA) using an overnight incubation at 4°C. After three 
washings with 200μl of PBS, wells were blocked with 100μl of 5% PBS-A (PBS containing 5% 
bovine serum albumin) and incubated for 1 h at 37°C. Wells were then washed three times 
with 200μl of PBS. Sera diluted to 1/100 in 1% PBS-A was added for 1 h at 37°C followed by 
the alkaline-phosphatase-(AP-) conjugated goat anti-IgG of human at 1/1,000 dilution in 1% 
PBS-A for 1 h at 37°C. After the addition of 100μl of the AP-chromogenic substrate (Sigma-
104 p-nitrophenyl phosphate substrate; Sigma, St Louis, MO), the absorbance was measured 
at 405 nm using Gen5 Microplate Reader and Imager Software in Synergy™ HT Multi-Mode 
Microplate Reader (BioTek Instruments, Inc., VT, USA). 
All serum samples were analyzed at the same time to avoid experimental variations. 
ELISA for all samples was performed at least three times. Human sera, which had been 
previously tested as positive for HPV16 or HPV18 E7 oncoproteins, were used as positive 
controls for each experiment. Wells without antigen or serum was used as negative control 
and wells containing the only substrate were used as background control. 
HPV DNA detection in HNC tissues: FFPE tumor samples with corresponding serum 
specimens were available HPV DNA detection and genotyping in 11 of the HNC cases. DNA 
was extracted and HPV genotyping was performed, as described previously in chapter II. 
HPV DNA status of the tumor tissues was then correlated with HPV E7 seropositivity. 
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p16
INK4a
 immunohistochemistry (IHC): Immunostaining for p16
INK4a
 results were obtained 
from a deidentified database of the Cancer Database and Specimen Repository (CDSR) at 
the James Graham Brown Cancer Center. IHC for p16
INK4a
 expression was considered 
positive if there was strong and diffuse staining present in >70% of the malignant cells. 
p16
INK4a
 result was then correlated with HPV E7 seropositivity. 
Statistical Analysis: The seropositive and seronegative groups were determined by two 
different methods regarding the distribution of absorbance values. In the first method, 
seropositivity was defined as samples whose absorbance values were 2 standard deviations 
(SD) from the mean value. We noticed that there was no difference in demographics for HPV 
seropositivity for both 2 and 3 SD of the mean. In the second method, absorbance values 
were observed based on quintile plots and two different slopes on the plots were determined 
using the non-linear procedure (158). Thresholds of the seropositive group were determined 
by the cross points of two slopes on the plots, and the samples whose absorbance values 
were greater than or equal to the threshold values. Both methods used to define seropositivity 
were in agreement. The ELISA values greater than the cut-off (1.04 and 0.905 for HPV16 E7 
and HPV18 E7, respectively) were considered seropositive. Once the seropositive group was 
determined, the associations were examined between the seropositive group and all available 
variables using Chi-square test for discrete variables and independent t-test for continuous 
variables at p=0.05. All data analyses were conducted by SAS 9.3 and Microsoft Office Excel. 
Results 
Demographic Information of HNC Patients 
Summary on the distribution of 75 HNC and 25 seropositive patients is shown in 
Table 8. All groups (total, seropositive and seronegative) were the average age of 57 years. 
None of the seropositive cases were less than 40 years. 
HPV E7 Seropositivity of HNC Patients 
Antibodies against E7 oncoproteins of HPV16 and 18 were examined by ELISA in 92 
serum samples, including 17 follow-up samples (Figure 19). Of the 75 patients, 14 and 8 
patients were seropositive for the oncogenic E7 proteins of HPV16 and HPV18, respectively. 
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Three patients were cross-reactive for E7s of both HPV types. Four follow-up sera were 
seropositive (2 for HPV16 E7, 1 for HPV18 E7 and 1 was cross-reactive for both HPV types) 
(Figure 19).  
Correlation of E7 Seropositivity with HNC anatomic sites and p16
INK4a
 status 
I evaluated the association between serology and HNC anatomic sites. Seropositive 
cases were strongly correlated with oropharyngeal cancer (Table 8). Positive HPV serology 
was also significantly associated with positive p16
INK4a
 IHC (Table 8). I further compared HPV 
serology with p16
INK4a
 IHC in oropharyngeal cancer as compared to other anatomic sites of 
the head and neck (Table 9). Only patients whose p16
INK4a
 IHC results were known were 
included, excluding unspecified cases. The association between E7 serology and p16
INK4a
 
IHC was significant in oropharyngeal carcinoma as well as in other HNC sites (Table 9). 
Although the sensitivity of E7 serology as a diagnostic marker in HPV-driven HNC (as defined 
by positive p16
INK4a
 IHC) was only 62.5%, E7 serology showed a high specificity and positive 
predictive value (94.7% and 95.2% respectively) (Table 10). Isolating only oropharyngeal 
cancers, where the role of HPV is much more clearly defined, the positive predictive value 
was 100%. 
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Table 8: Demographics of 75 HNC and 25 HPV E7 seropositive patients 
Category 
Total HNC 
patients (N=75) 
Seropositive 
(N=25) 
Seronegative 
(N=50) 
p-value 
Gender       0.186 
 Male 67 (89.33%) 24 (96%) 43  
  Female 8 (10.67%) 1 (4%) 7   
Age 57 ± 10 57.56 ± 7.75 56.60 ± 11.12 0.7002 
 < 40 yrs 4 0 4  
 40 - 59 yrs 43 16 27  
  ≥ 60 yrs 28 9 19   
Anatomical sites       0.0006* 
 Oropharynx 39 (52%) 20 (80%) 19  
  
Others (Oral cavity, 
Hypopharynx, Larynx) 
36 (48%) 5 (20%) 31   
Stage       0.674 
 II 4 1 3  
 III 15 7 8  
 IVA 48 15 33  
 IVB 2 1 1  
 IVC 3 0 3  
  Undetermined 3 1 2   
p16
INK4a
 status       <0.001* 
 Positive 32 (42.1%) 20 (80%)  12  
 Negative 19 (25.33%) 1 (4%) 18  
  Unspecified
†
  24 (31.57%) 4
‡
 (16%) 20  
Smoking status       0.3556 
 
Past or current 
smokers (>10 pack-
years) 
55(73.33%) 20 (80%) 35 
 
  Never-smokers 20 (26.67%) 5 (20%) 15  
Treatment response       0.45 
 Complete response 33 13 20  
 Partial response 10 4 6  
 Progression 11 2 9  
 Not assessed 21 6 15  
*Significant values 
†
Unspecified p16
INK4a
 status was not considered during statistical analysis 
‡
p16
INK4a
 IHC results were unavailable for 4 seropositive cases.  
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Table 9: E7 serology and p16
INK4a status in oropharyngeal and other HNCs 
Site 
E7 serology 
(HPV16, HPV18 or both) 
p16
INK4a
 status p-value* 
Positive Negative  
Oropharynx Seropositive (N=17) 17 0 0.0030 
(N=34) Seronegative (N=17) 10 7  
 Total 27 7  
Others Seropositive (N=4) 3 1 0.0221 
(N=17) Seronegative (N=13) 2 11  
 Total 5 12  
*Unspecified p16
INK4a
 status was not considered during statistical analysis 
 
Figure 19: Scatter plot of HPV16 and HPV18 E7 antibody titers of 92 serum samples 
from 75 HNC patients. Cut-off lines were drawn at 1.04 for HPV16 E7 and 0.905 for 
HPV18 E7. The values that were higher than the cut-off were considered seropositive. 
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Table 10: Diagnostic measures based on E7 serology and p16
INK4a
 status 
Site 
Sensitivity 
(%) 
Specificity 
(%) 
PPV* 
(%) 
NPV* 
(%) 
Total (n=51)  62.5 (20/32) 94.7 (18/19) 95.2 60 
Oropharynx (n=34) 63 100 100 41.2 
Others (n=17) 60 91.7 75 84.6 
*  PPV and NPV denote positive predictive value and negative predictive value respectively 
 
 
 
 
 
Figure 20: HNC patients (N=11) showing negative HPV16 and HPV18 E7 antibody titers both 
before and after treatment. 
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Figure 21: HNC patients who showed positive antibody titers before treatment revealed a 
significant decrease in titer values after treatment, except in one case (HPV004). Five of 
patients who showed decrease in antibody titer had complete/partial response to treatment 
 
Correlation of E7 Seropositivity with treatment response 
Seventeen follow-up serum samples were available for analysis. Sera (N=11) that 
were seronegative before treatment, also revealed negative serology after treatment (Figure 
20). I evaluated antibody status of the remaining 6 follow-up samples and compared with 
respective seropositive pretreatment samples (Figure 21). Follow-up samples were collected 
at a median of 96 days post-treatment (range 87-170 days). Treatment response at this time 
point was supplied by the biorepository database and was determined clinically and in some 
cases, radiographically, when imaging was available. Post-treatment serum antibody titer 
against HPV16 and 18 E7 decreased significantly compared to those at pretreatment (p 
<0.01) in 5 patients, who had a complete or partial response to treatment. One case 
(HPV004) whose titer was decreased, but not significantly, also showed a complete response 
to treatment. Three patients (HPV011, HPV032, and HPV038) became seronegative during 
follow-up (Figure 21). 
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Correlation of E7 Seropositivity with HPV DNA 
Eleven HNC tissues were available for HPV detection and genotyping (Figure 22). 
When the MY and GP amplicons of these seven samples were sequenced, 6 were genotyped 
as HPV16 and 1 sample as HPV33. A sample (HN027) showing HPV33 was confirmed by 
another PCR using HPV type 33- specific primers against oncogene E7. One sample 
(HN021), which produced a band around the size of MY amplicon, was not detected to have 
HPV DNA after sequencing. Samples (HN013, HN019, and HN025), which did not produce 
bands consistent with MY or GP, were negative for HPV DNA. Altogether, HPV DNA was 
detected in 7 samples out of 11 HNC tissues. Positive HPV DNA in cancer tissue was mainly 
from the oropharynx. 
I correlated HPV DNA status with the HPV serology of the patients whose tissues 
were available for DNA extraction and HPV genotyping. The association of HPV16 E7 
serology was strong among the samples tested positive for HPV16 DNA (N=6), except in one 
case. This exceptional case (HN014) was seronegative in repeated assays even though it 
was HPV16-DNA positive. I verified that detected HPV DNA was not a result of sample 
contamination. There were two cases (HN013 and HN021) in which HPV-DNA was not 
detected in their tissue, but sera were positive for HPV-16 E7. The reason behind this might 
be due to multiple HPV infections in a single patient, that makes MY/GP- PCR method 
inefficient and subsequent typing by sequencing is fraught with difficulties in revealing multiple 
types. The sample (HN027), which was positive for HPV33 DNA, was HPV18 E7 seropositive, 
which might be due to the cross-reactivity between epitopes of HPV33 E7 and 18 E7 proteins. 
A sample (HN025) was negative both for HPV DNA and E7 serology. In overall, the sera of 
86% of HPV DNA-positive patients (6 of 7) gave positive ELISA results. 
Correlation of E7 Seropositivity with smoking status 
I assessed the association of seropositivity with smoking status. I defined “smokers” 
as the past and current smokers who smoked 10 or more pack-years. 73% of the total HNC 
patients were smokers, indicating the high smoking prevalence in our population, regardless 
of HPV positivity. Also, seropositivity did not significantly correlate with smoking status (p 
>0.05), Table 8. Only 20% (5 out of 25) seropositive cases were never smokers. 
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Figure 22: HPV–DNA detection in HNC tissue samples using MY and GP consensus 
primers. β-globin was used as the internal control.  
Discussion 
This study evaluated serological biomarkers for clinical assessment of the role of 
HPV in HNC. Although studies have been done to detect HPV L1 (VLPs) (146-149) and E1/ 
E2 antibodies (152), these antibodies mostly indicate early benign HPV infection or 
vaccination. Since cancer usually develops after years of persistent HPV infection; detection 
of antibodies for E6/E7 oncoproteins may be helpful in the serological diagnosis of malignant 
lesions.  
Serial monitoring of HPV serology may also be useful in predicting a patient’s 
response to treatment. The decline of anti-HPV16 E6 and/or E7 antibodies after treatment 
has been shown in cervical cancers (159-161) and with a few studies in HNC (156,157). From 
our laboratory, Drs. Jenson and Ghim had followed cervical cancer patients with E7 
serological tests and found profound IgG response against E7, which was associated with 
tumor stability or dormancy (162). In a small subset of patients, I observed a significant 
decline in HPV E7 antibodies after treatment, except for one patient. I also observed that sera 
that were seronegative before treatment remained so after treatment of patients. In addition, 
some studies have suggested that HPV16 E6/E7 seropositivity is prognostic of a favorable 
clinical outcome of HNC patients (156,163). HPV status as defined by positive E6/E7 serology 
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and positive tumor HPV status (HPV DNA and p16
INK4a
) is suggested to correlate even more 
strongly with favorable prognosis than tumor HPV status (HPV DNA and p16
INK4a
 IHC) alone 
(163).  
When seropositive cases were examined, I observed a statistically significant 
correlation with oropharyngeal cancer, but not with other anatomic sites of HNC. My results 
were consistent with the increasing incidence of HPV infection in oropharyngeal cancers. I 
demonstrated that HPV serology correlates well with routine methods of testing of HPV status 
(HPV DNA detection and p16
INK4a
 IHC) as 86% (6 of 7) of HPV DNA positive HNC patients 
also displayed positive serology. Further, E7 antibody titer in patients’ sera was strongly 
correlated with p16
INK4a
 positivity in HNC tissue samples. Also, among HNC samples that 
tested positive for HPV16 DNA, the association of HPV16 E7 serology was strong.  
In the present study, HNC patients were of the average age of 57 years, regardless of 
HPV positivity. This population of patients demonstrated a high prevalence of tobacco use, 
with 74% of patients with p16
INK4a
 -positive HNC reporting >10 pack-years. Previous studies 
have suggested that this intermediate risk group has inferior survival compared to non-
smokers with HPV-induced HNC. HPV E7 seropositivity did not correlate with smoking status 
in our study population, possibly secondary to the strikingly high smoking prevalence. Indeed, 
some cases of HNC may be caused by a combination of tobacco and HPV (164). 
In this study, I also found that E7 antibody levels declined with response to treatment 
of a patient, though post-treatment serum was available in a limited subset of patients. This 
study was done with only a single follow-up sample per patient. Therefore, further studies in a 
larger sample size, including longitudinal follow-up of patients could help to identify if serial 
monitoring of E7 serology may be useful in predicting a patient’s respond to treatment. 
In summary, HPV-specific E7 antibody levels in the sera of patients with 
oropharyngeal cancer are complementary to the well-established HPV histological detection 
methods. Given the high positive predictive value of E7 serology for p16
INK4a
 positivity, 
particularly in cancers of the oropharynx, HPV serology may be particularly useful in cases 
when insufficient tissue is available to carry out p16
INK4a
 immunostaining for detection of HPV-
associated disease. Further comparisons between potential tissue and serum biomarkers i.e. 
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expression of p16
INK4a
, presence of mitosoid cells and positive E7 serology, would be useful 
to identify the best HPV-associated biomarker in head and neck tumors. 
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CHAPTER IV 
HPV DNA INTEGRATION AND VIRAL GENE METHYLATION DURING HEAD AND NECK 
CANCER PROGRESSION 
Chapter Overview 
In order to better understand the progression of HPV infection in premalignant lesions 
to head and neck cancers, I aimed to characterize HPV-associated genetic and epigenetic 
alterations involved in head and neck carcinogenesis. Studies in cervical cancer indicate that 
HPV-linked malignant conversion is associated with the specific molecular events i.e. HPV 
integration and HPV methylation. In contrast, little is known regarding malignant progression 
in HPV-linked head and neck cancers. Therefore, frequencies of HPV DNA integration and 
methylation were profiled in the premalignant and malignant head and neck tumors and 
underlying mechanisms associated with head and neck carcinogenesis were studied. 
Introduction 
Head and neck cancer (HNC) comprises squamous cell carcinoma (SCC) of the oral 
cavity (oral squamous cell carcinoma, OSCC), oropharynx (oropharyngeal squamous cell 
carcinoma, OPC), hypopharynx and larynx. In addition to excessive tobacco and alcohol 
consumption, the human papillomavirus (HPV) infection has been established as an 
etiological factor for HNCs, particularly OPC. Patients with HPV-associated cancers display 
better treatment response and survival than patients whose tumors are HPV-negative, 
independent of treatment strategy (63,64). While HPV is strongly associated with OPC, the 
relationship of HPV to OSCC and its premalignant precursor (high-grade oral epithelial 
dysplasia, hgOED) are not clearly defined. Our group (127) and few others (131,132) have
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recently reported that HPV is strongly associated with a certain histologic subset of hgOED. In 
this chapter, I aimed to further characterize these premalignant lesions and their relationship 
with malignant lesions to better understand the underlying molecular mechanisms in HPV-
associated head and neck carcinogenesis. 
 The major viral oncogenes E6 and E7 are generally thought to be responsible for 
HPV-associated malignancy, as shown in Figure 2. Their expression is mainly regulated by 
viral protein E2, which is a transcription factor that binds to the early promoter p97 at specific 
E2-binding sites (E2BSs) located within the long control region (LCR) of HPV and can repress 
the expression of HPV E6 and E7 oncogenes (20,21), Figure 3. Overexpression of E6 and 
E7 can be caused either by disruption of E2 gene via HPV genome integration or by inhibition 
of E2 protein binding to the LCR via HPV methylation (85). Therefore, viral integration and 
methylation are considered as two main regulatory mechanisms for malignant transformation 
(23,24,91,92), Figure 7 and Figure 8. 
Integration of HPV into the genome of an infected host cell has been extensively 
characterized in cervical cancers that are the widely acknowledged as HPV-associated 
cancers (96,97). In HNC, studies are mostly limited to cancer cell lines with few studies in 
patient specimens (83,100-105) and data on premalignant lesions are limited. While viral 
integration is thought to play an important role in cervical cancer (92), the relevance of viral 
integration is controversial in head and neck carcinogenesis (100). My first objective in this 
chapter is to address the role of viral integration in the development of cancers of the head 
and neck by determining the integration status in histologically distinct premalignant and 
malignant lesions. 
Methylation of the HPV genome, which contains 15 CpG sites in the long control 
region (LCR), has been suggested as a biomarker for cervical cancer progression (23,24). 
Hypermethylation within HPV-LCR has been reported in cervical cancers or high- grade 
cervical dysplasia compared with low-grade CIN (23,24). In cervical cancer, it is shown that 
methylation of HPV inhibits binding of the transcriptional repressor (E2), resulting in 
overexpression of viral oncoproteins and leading to malignant transformation. However, very 
few studies have evaluated HPV methylation status in HNC specimens and their results are 
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inconsistent (111,112). To date, there is no information about the methylation pattern in 
premalignant hgOED lesions. My second objective in this chapter is to address the role of 
HPV DNA methylation in malignant transformation in head and neck tumors. 
Toward these ends, I analyzed the physical integration of HPV DNA into the host 
chromosomes and presence of potential DNA methylation sites in the HPV epigenome in 
patients with premalignant and malignant tumors of the head and neck. Profiling of these 
genetic and epigenetic events may help to better understand the complex mechanisms of 
HPV-mediated head and neck carcinogenesis.  
Experimental Procedures 
Tissue specimens and cell lines: This study was approved by the IRB at the University of 
Louisville. Premalignant specimens from 40 patients were obtained from Biorepository of 
University of Louisville Oral Pathology Laboratory (as mentioned in Chapter II). HNC 
specimens from 50 patients were collected from Cancer Database and Specimen Repository 
at the James Graham Brown Cancer Center (as mentioned in Chapter II subheading 3). HNC 
cell lines were established at the University of Michigan and carry the heading, University of 
Michigan Squamous Cell Carcinoma (UMSCC). The HPV-negative cell line (UMSCC-1) and 
HPV-positive cell lines (UMSCC-47 and UMSCC-104) were purchased from EMD Millipore 
Corporation (Temecula, CA, USA), and cultured using standard protocols. Cervical cancer 
cell lines, CaSki and SiHa, were cultured as suggested by American Type Culture Collection 
(ATCC, Manassas, VA, USA).  
DNA extraction and HPV detection: DNA was extracted from fresh frozen or FFPE 
specimens using DNAeasy Blood & Tissue kit (Qiagen, USA) as per manufacturer’s 
instructions with RNAase (20 µl of 20mg/ml) treatment. FFPE samples were deparaffinized 
and washed before DNA extraction. HPV detection and genotyping were performed, as 
previously described (126). β-globin was used as an internal control. Sixteen of the 50 HNC 
specimens were HPV16 positive (Table 7 for demographics). In premalignant lesions, HPV16 
DNAs were present in 12/16 of Group 1, 7/14 of Group 2 and 2/10 of the Group 3. HPV type 
16 is known to be the most common carcinogenic HPV type in cervical cancer development. 
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Similarly, HPV16 was the predominant form of HPV in specimens and cell lines derived from 
head and neck tumors. I used HPV16-positive premalignant and malignant samples for 
further analysis. 
HPV integration and viral load by quantitative PCR: I employed a previously described 
real-time quantitative PCR assay to evaluate viral load and integration in cell lines and HNC 
specimens (165). The primers and probes were designed for specific amplification of the E2 
hinge regions which are known to be disrupted most frequently during the process of viral 
integration (165). E6 primers and probes were also designed accordingly. β-globin was used 
as an internal control. In a total volume of 20 µl, the final primer, probe and DNA template 
concentrations were 0.3 µM, 0.1 µM, and 20 ng respectively. TaqMan™ Universal Master Mix 
II, with UNG (Uracil-N-glycosylase), was used according to the manufacturer’s instructions 
(Thermo Fisher Scientific, USA). HPV16 plasmid cloned in a pBR322 vector (300 pg to 0.3 
pg) was used to plot a standard curve. The relative viral load was estimated by calculating the 
ratio of a copy of E6 found in the specimen to copy of E6 present in SiHa cell because SiHa 
cells are known to contain a well-defined viral copy number (165). HPV integration status was 
evaluated using E2/E6 ratio. The ratio of E2 to E6 equal or greater than 1 indicates the 
presence of HPV DNA in the episomal state with no integrated forms of viral DNA. An E2/E6 
ratio of 0 indicates HPV DNA in an integrated state with no episomal forms of viral DNA. An 
E2/E6 of 0.5 shows the presence of equal copies of integrated and episomal forms of HPV 
DNA. Samples were categorized as predominantly integrated if the E2/E6 ratio was less than 
0.5 and predominantly episomal if the ratio was greater than 0.5. Cervical cancer cell lines 
(CaSki and SiHa) were used as positive controls for studying HPV genome integration in HNC 
cell lines and different head and neck tumor lesions. Water controls were included in each 
run. All experiments were performed in duplicates at least three times. 
Determination of E2 Gene Integrity: The integrity of the E2 gene was determined by 
amplification of the full-length E2 ORF (nucleotide 2755 to 3852 of NC_001526.2; primers 
16E2a and E2b listed in Table 11). Disruption of this region was defined as an absence of the 
full-length E2 amplicon on agarose gel electrophoresis and positive signals of parallel β-actin 
amplification. Positive signals for amplification of the ~1 kb full-length E2 amplicon from CaSki 
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DNA were used as a control because CaSki cells are known to carry an intact E2 gene. Also, 
amplification of first half of E2 (primers 16E2a and 16E2c) and last half of E2 region (primers 
16E2d and 16E2b) was performed for further confirmation of E2 integrity. 
Bisulfite-sequencing: Purified genomic DNA was bisulfite converted using an EpiTect ® 
Plus Bisulfite Kit (Qiagen, CA, USA) according to the manufacturer’s protocol. In this 
treatment, unmethylated cytosine residues are converted to uracil whereas 5-methylcytosine 
is unaffected. Target DNA is then amplified by PCR in which uracil residues are converted to 
thymine. The DNA methylation status of HPV DNA was then evaluated by the direct 
sequencing of PCR products. Because HPV type 16 have different variants (categorized 
based single nucleotide polymorphisms present in LCR and/or E6), an Asian-American 
variant of HPV type 16 (Genbank accession number: AF402678.1) was used as reference 
HPV16 sequence for primer design and further analysis. The bisulfite-treated DNA was 
amplified by PCR using different sets of primers designed to target the 15 CpG sites in LCR 
region of HPV (Figure 8, Table 11). Primers were designed within the consensus sequences 
among different variants of HPV16 (Genbank accession numbers: AF402678.1, AF125673.1, 
AY686584.1, NC_001526.2, and KF954093.1). Different secondary primer sets were adopted 
in cases where PCR amplification was negative using primary primers. As an internal control 
for the presence of bisulfite-modified DNA, primers specific to a modified region of the β-actin 
(ACTB) gene containing no CpG sites was used. PCR reaction mixtures consisted of 10X HiFi 
PCR buffer, 50mM MgSO4, 10 mM dNTPs, 20 µM of each primer and 1 U of HiFi Taq 
polymerase (Thermo Fisher Scientific, USA) in a total volume of 20 µl. PCR conditions were 
95°C (2 min); 45 cycles of 45 sec at 95°C, 45 sec at 52°C and 45 sec at 68°C, followed by 10 
min at 68°C. PCR products were run on 3% agarose gel and extracted using QIAquick Gel 
Extraction Kit (Qiagen, USA) and sent for sequencing to the DNA Core Facility at the 
University of Louisville. Amplified products were directly sequenced using the same primers. 
Sequencing data was analyzed using NCBI BLAST database and SeqMan Pro program 
(Lasergene 12, DNAstar Inc., Wisconsin). 
RNA extraction and qRT-PCR analysis: Total RNA was isolated from cultured UMSCC-1, 
47 and 104 cells by using PureLink® RNA Mini Kit (Thermo Fisher Scientific, USA), with 
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DNase I treatment, according to manufacturer's instructions. Single-stranded complementary 
DNA (cDNA) was synthesized from 1 μg of total RNA using SuperScript® VILO cDNA 
Synthesis Kit (Thermo Fisher Scientific, USA) according to the manufacturer's instructions. 
Quantitative real-time reverse transcription–polymerase chain reaction (qRT-PCR) was 
performed in separate 20-μL reaction volumes to evaluate the expression of HPV16 E6, E7, 
and E2 genes, and cellular genes p16 (CDKN2a/INK4a), EGFR and β-actin. To investigate 
the expression of E2 gene, primers were designed near the 5’ end and upstream of the 
frequent E2 breakpoint to monitor the relative expression of truncated E2 mRNA. qRT-PCR 
was performed in triplicate using 100 ng of cDNA as template, the gene-specific forward and 
reverse primers (0.3 μM each) (Table 11), and the Power SYBR® Green Supermix (Thermo 
Fisher Scientific, USA) in an Applied Biosystems VIIa
TM
 7 Real-Time PCR detection system 
(Thermo Fisher Scientific, USA). The amplification program for all primer sets was 95°C for 3 
minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. Real-time 
PCR amplification data were analyzed and threshold cycle (Ct) numbers were automatically 
determined by VIIa
TM
 7 software v1.2.4 (Thermo Fisher Scientific, USA). The relative 
expression of each mRNA was calculated by the ΔCt method (166,167). Endogenous β-actin 
mRNA levels were used for normalization of RNA expression. Due to the small amounts of 
RNA recovered from clinical biopsies, qRT-PCR was only performed on cell lines and not on 
clinical biopsy samples. 
Statistical analysis: Comparisons were performed using Student’s t-test or Fisher’s exact 
test or Mann-Whitney Rank Sum Test. SigmaPlot Version 12.5 (Systat Software, Inc., San 
Jose California, USA) and Microsoft Excel 2013 (Microsoft Corporation, Redmond WA) were 
used for data computation and statistical analysis. Statistical significance was established at 
p-value ≤0.05 (*p<0.05; ** p<0.01; ***p<0.001).  
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Table 11: List of primers employed to detect HPV DNA, HPV integration, E2 gene integrity, 
bisulfite sequencing and qRT-PCR. 
Target Primer Sequence (5’-3’) 
HPV detection  
L1 MY09
*
 (For) CGTCCMARRGGAWACTGATC 
 MY11
*
 (Rev) GCMCAGGGWCATAAYAATGG 
L1 GP5+ (For) TTTGTTACTGTGGTAGATACTAC 
 GP6+ (Rev) GAA AAATAA ACTGTAAATCATATTC 
β-globin GH20 (For) GAAGAGCCAAGGACAGGTAC 
 PC04 (Rev) CAACTTCATCCACGTTCACC 
HPV integration by qPCR  
E2 16E2F AACGAAGTATCCTCTCCTGAAATTATTAG 
 16E2R CCAAGGCGACGGCTTTG 
 16E2probe (FAM)-CACCCCGCCGCGACCCATA-(TAMRA) 
E6 16E6F GAGAACTGCAATGTTTCAGGACC 
 16E6R TGTATAGTTGTTTGCAGCTCTGTGC 
 16E6probe 
(FAM)-CAGGAGCGACCCAGAAAGTTACCACAGTT-
(TAMRA) 
E2 gene Integrity  
E2 (full length) 
16E2a (For) ATGGAGACTCTTTGCCAACGTT 
16E2b (Rev) TCATATAGACATAAATCCAGTAGAC 
E2 (first half) 
16E2a (For) ATGGAGACTCTTTGCCAACGTT 
16E2c (Rev) TTATTCTTTGATACAGCCAGTGTTG 
E2 (last half) 
16E2d (For) CCTCACTGCATTTAACAGCTCA 
16E2b (Rev) TCATATAGACATAAATCCAGTAGAC 
Bisulfite sequencing   
5’-LCR, enhancer  
(2F+3R) For GTGTATGTGTTTTTAAATGTTTGTGT 
(2F+3R) Rev CACAATATACATAATAATTCAATAATTAC 
enhancer  (4F+4R) For GTAATTATTGAATTATTATGTATATTGTG 
 (4F+4R) Rev CACACACCCATATACAATTTTACAA 
promoter  (5F+5R)For TTGTAAAATTGTATATGGGTGTGTG 
 (5F+5R) Rev ACAACTCTATACATAACTATAATAACT 
5’-LCR and  BSP-6 (For) TAAATTATATTTGTTATATTTTGTTTTTGT 
enhancer BSP-6 (Rev) TAATTAACCTTAAAAATTTAAACCTTATAC 
β-actin mACTB (For) TGGTGATGGAGGAGGTTTAGTAAGT 
 mACTB (Rev) AACCAATAAAACCTACTCCTCCCTTAA 
Gene expression by qRT-PCR  
 E6 For CAGCAATACAACAAACCG 
  Rev GCAACAAGACATACATCG 
 E7 For CAGAGGAGGAGGATGAAATAG 
  Rev AGGTCTTCCAAAGTACGAATG 
 E2 For TGATAGTACAGACCTACGTGACCATATAGA 
  Rev CCCATTTCTCTGGCCTTGTAAT 
 p16
INK4a
 For CATAGATGCCGCGGAAGGT 
  Rev CCCGAGGTTTCTCAGAGCCT 
 EGFR For GGAGAACTGCCAGAAACTGACC 
  Rev GCCTGCAGCACACTGGTTG 
 β-actin For CCATCGTCCACCGCAAAT 
  Rev GCTGTCACCTTCACCGTTCC 
 IPO8 For CAGTGCATTCCACTCTTCGT 
  Rev ACGAAGCTCACTAGTTTTGACC 
 
 65 
 
Results 
Frequency of viral DNA integration in HNC cell lines 
HPV16 DNA integration into the host genome is known to be strongly associated with 
HPV-induced cancer progression, and different integration patterns were reported in two 
cervical cancer cell lines (168). In this study, using an absolute quantification method with 
qPCR confirmed 2 copies of HPV16 DNA from SiHa cell line as previously reported (169). 
SiHa cells were then used as a reference for estimating the relative viral copy number in other 
cell lines and human tissue specimens (165). I found 325 copies of HPV16 DNA in CaSki, 
although different HPV DNA copy numbers (60–600) were previously reported in this cell line 
(169). 
Integration of HPV16 DNA in the HNC cell lines and tumor tissues was examined 
using a method that was designed to provide a ratio of E6 to E2 gene copy number (165). 
The disruption of the E2 gene upon viral integration is known to be associated with HPV-
induced cancer malignancy and was, therefore, the major focus of this study. The E2/E6 ratio 
was 0.0 in SiHa, indicating that both copies of HPV16 DNA were integrated into chromosomal 
DNA on this cell line as reported previously (169). CaSki cells showed the E2/E6 ratio of 0.12, 
indicating that the majority of HPV DNA in this cell line is integrated. These results were 
further confirmed by amplifying E2 ORF with nested PCR primers (Table 11). No full length of 
E2 was found in SiHa while small 3’- or 5’- E2 fragments were amplified (Figure 23C). In 
CaSki, both full length and small fragments of E2 ORF were amplified confirming the 
presence of mixed forms of intact and disrupted E2 DNAs (Figure 23). 
UMSCC-47 and 104 cell lines, originated from tumors of the anterior tongue and floor 
of the mouth, respectively, were classified as oral cavity cancers according to the anatomy-
based classification of HNCs (170,171). HPV16 DNAs were detected from both cell lines 
while no DNA was found from the cell line UMSCC-1, which also originated from an oral 
cavity tumor. Relative to SiHa, the number of viral copies in HPV16-positive HNC cell lines 
(UMSCC-47 and UMSCC-104) was 2 (Figure 26). However, no full length of E2 was 
amplified in both cell lines, suggesting both contained only integrated HPV16 DNA (Figure 
23). HPV DNA integration was confirmed by evaluating E2/E6 ratio from these cell lines. 
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E2/E6 ratio values obtained from UMSCC-47 and UMSCC-104 (0.0 and 0.045 respectively) 
suggested that in both cell lines contained integrated HPV as the predominant species 
(Figure 26). 
Characterization of HNC cell lines with integrated HPV DNA 
Because the disruption of the E2 gene upon HPV DNA integration causes robust and 
chronic expression of the viral E6 and E7 oncogenes in cervical cancer, the expression of E2, 
E6, and E7 genes was profiled in HNC cell lines. Quantitative RT-PCR assays showed that 
E6/E7 mRNA levels varied considerably between the two HPV-positive HNC cell lines studied 
(Figure 24). E7 expression was significantly higher in UMSCC-104 compared to UMSCC-47 
(p<0.001); however the latter showed higher E6 expression than the former (p<0.05). 
Expression of E2 was analyzed using the primers designed to anneal upstream of the 
frequent E2 breakpoint and both cell lines showed similar levels of E2 expression. 
Additionally, the expression of p16
INK4a
 and EGFR has been associated with HNCs (172,173), 
so their expression was also examined in HNC cell lines. The expression of p16
INK4a
 was 
similar in HPV-positive HNC cell lines and significantly higher than that in the HPV-negative 
UMSCC-1 cell line. EGFR expression was relatively higher in UMSCC-104 than UMSCC-1, 
but was not significantly different between UMSCC-47 and UMSCC-1 (Figure 24). 
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Figure 23: Determination of E2 gene integrity (A) by using HPV16 E2 primers (16E2 a, b, c, 
and d, Table 11) which detect intact and disrupted E2 gene. (B) Agarose gel image showing 
the full length of E2 in CaSki and disrupted E2 sequences in SiHa, UMSCC-47, and UMSCC-
104. (C) Schematic representation of integrated HPV DNA in CaSki, SiHa, UMSCC-47 and 
UMSCC-104 cell lines. 
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Figure 24: Relative expression of E6, E7, E2, p16 and EGFR in UMSCC-47 and UMSCC-104 
head and neck cell lines (Significance level at *p<0.05 and **p<0.01) 
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Differential HPV16 DNA integration rates in head and neck tumors collected at the 
different stages of malignant progression 
In chapter II, I classified three different groups of premalignant oral samples based on 
their histological features. Briefly, Group 1 contained diffuse mitosoid/ apoptotic cells while in 
Group 2 and Group 3, histological features were focal or lacking. Group 1 was found to be 
strongly associated with the presence of HPV and higher levels of p16
INK4a
 expression when 
compared with specimens in Group 2 and Group 3. Here, I evaluated HPV copy number and 
integration status to determine if there was a relationship between these parameters in the 
differently staged groups. HPV copy number was detected at variable levels in premalignant 
lesions and was significantly higher in Group 1 lesions compared to Group 2 (p <0.001) and 
Group 3 (p= 0.04, Mann-Whitney test, Figure 25). Relative to SiHa, the HPV copy number in 
Group 1 lesions ranged from 1-47 with one exception of 0.1 copies. In contrast, all 
premalignant samples in Group 2 and Group 3 groups showed relative viral loads less than 
0.1 (Figure 25). When I analyzed the integration state of HPV genome in HPV16 positive 
premalignant lesions, I observed a significant difference in the physical state of the viral DNA 
among the study groups (p=0.006, Table 12). The specimens in Group 1 contained a 
significantly higher level of integrated HPV DNA (90.9%) compared to Group 2 (28.6%) and 
Group 3 (0%). In contrast to Group 1, where integrated DNA was the predominant species, 
both episomal and integrated forms of HPV DNA were found in samples in Group 2. 
HPV DNA copy number and integration status were also analyzed in 16 HNC 
specimens (malignant forms) and compared with those of premalignant tumors. Relative to 
SiHa, variable viral loads between 0.1 and 205 copies/cell (two cases had less than 0.1) were 
found in malignant specimens (Figure 25). 75% of these HNC specimens had integrated HPV 
as the predominant species, whereas only 6.25% of these HNC specimens had episomal 
DNA as the predominant species (Table 12). The patterns of HPV genome integration were 
similar between malignant and premalignant lesions of Group 1. Similarly, there was also no 
significant difference in viral load between Group 1 premalignant lesions and malignant 
specimens (p= 0.79).  
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Figure 25: Box plot showing viral load in malignant (N=16) and different groups of 
premalignant [Group 1 (N=11), Group 2 (N=7) and Group 3 (N=2)] tumors, expressed in a 
number of times the level in SiHa cells. The bottom and top of the box show the first and third 
quartiles respectively, the solid line inside the box is the second quartile (i.e. the median), and 
the dashed line shows the mean value. Whiskers in the box plot represent the highest and 
lowest values excluding outliers as shown by dots. Long whisker in the case of the malignant 
specimen shows high variability in HPV copy number.  In the case of Group 2 and Group 3 
tumors, the values for mean, median and quartiles were almost same, so only solid lines are 
seen in the plot. (Significance level *p<0.05, **p<0.01, NS- non-significant, Mann-Whitney 
Rank Sum Test) 
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Figure 26: Assessment of HPV16 DNA integration by analyzing E2/E6 ratio in (A) 
premalignant (Group 1, Group 2 and Group 3) tumors and (B) cancer cell lines (cervix-CaSki 
and SiHa; and head and neck, UMSCC-47 and 104), and malignant head and neck tumor 
specimens.  
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Table 12: HPV DNA integration in HPV16 positive premalignant hgOED and HNCs 
HPV DNA integration status 
Premalignant hgOED 
HNC 
(malignant) 
Group 1 Group 2 Group 3 
Overall 
p-value 
Solely or predominantly integrated 10 (90.9%) 2 (28.6%) 0 (0.0%) 
0.006 
12 (75%) 
Episomal or predominantly 
episomal 
1 (9.1%) 3 (42.9%) 1 (50%) 
1 (6.25%) 
Both episomal and integrated 0 (0.0%) 2 (28.6%) 1 (50%) 3 (18.75%) 
 
 
Table 13: Methylation pattern of HPV16 cervical and HNC cell lines and HNC specimens* 
Sample*  | 
CpG sites    
% 
Methyla
tion 
  
E2BS1 Enhancer E2BS2 SP1 E2BS3 E2BS4 
7428 7434 7455 7461 7535 7553 7676 7682 7694 7862 31 37 43 52 58 
SiHa 0 U U U U U U U U U U U U U U U 
CaSki 93.33 M M M M M M M M M U M M M M M 
UMSCC-47
†
 
76.92 M mutated M M M M U U M U mutated M M M M 
UMSCC-104 0 U U U U U U U U U U U U U U U 
HN08-T 93.33 M M M M M M M M M U M M M M M 
HPV037 60.0 M M M M U U U U U U M M M M M 
HN022 26.67 U U U U U M U U U U M U U M M 
U denotes unmethylated; M denotes methylated. 
*The remaining 13 HNC and 20 premalignant hgOED specimens were unmethylated at 
all 15 CpG sites. 
†
UMSCC-47 only has 13 CpG sites due to two point mutations at nucleotides 7434 CG>CA 
and 31 CG>TG.  
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HPV LCR methylation in head and neck malignant progression 
Methylation of the HPV genome has emerged as a biomarker for cancer progression 
in cervical cancer (23,24). To determine the role of HPV methylation in head and neck 
carcinogenesis, I first localized CpG sites within the HPV16 LCR.  This region contains a 
promoter for transcription of viral early genes that includes E2 binding sites (E2BS) 1 to 4 and 
an SP-1 binding site (Figure 8 and Table 13). There were 15, 15, 13 and 15 CpG sites in 
SiHa, CaSki, UMSCC-47 and 104 LCRs, respectively. UMSCC-47 had less CpG numbers 
than other cell lines tested because of its two point mutations [nucleotide (nt.) 7434 CG>CA 
and nt. 31 CG>TG], as reported previously (174). A variety of methylation patterns on the 
promoter within the LCR were found in four HPV cancer cell line derived from HPV16 
infections. CaSki and UMSCC-47 cells showed hypermethylation (93.33% and 76.92% of 
available CpGs, respectively). The CpG at nt.7862 within E2BS-2 was unmethylated in both 
cell lines. UMSCC-47 had additional unmethylated CpGs at nucleotides 7676 and 7682. In 
contrast, UMSCC-104 and SiHa cell lines showed unmethylated CpG at all 15 sites within 
LCR. Consequently, two different HPV cancer cell lines (CaSki and UMSCC-47) showed 
hypermethylation and the other two (SiHa and UMSCC-104) showed hypomethylation 
patterns. 
The methylation patterns on viral LCR were then profiled in premalignant and 
malignant lesions of the head and neck in specimens where DNA integration rates were 
analyzed (Table 13). The methylation patterns of CpG were not different among premalignant 
specimens between the histologically distinct groups. Indeed, all CpG sites within the LCR 
were unmethylated in all premalignant specimens. Moreover, all HNC specimens were 
predominantly unmethylated, except three malignant samples which contained methylated 
CpG (93.33%, 60%, and 26.67% methylation, respectively). From these results, I observed 
overall hypomethylation pattern of HPV epigenome from samples of HNC patients.   
Discussion 
The molecular determinants of HPV-associated HNC development and progression 
are not well-defined. Viral integration and methylation could potentially play a role in HPV-
induced head and neck carcinogenesis as seen in HPV-associated cervical cancer. However, 
 74 
 
limited studies have addressed this highly relevant issue and are mostly done using HNC cell 
lines with few studies in patient tumor samples and even fewer in pre-malignant specimens. 
In this study, I have analyzed histologically characterized HPV-positive tumors, collected at 
different stages of malignancy, with a goal of elucidating mechanisms of HPV-associated 
head and neck malignancy. 
I used cervical and head and neck cancer cell lines to collect reference data that are 
useful for the analysis of clinical samples. HNC cell line UMSCC-47 contained integrated HPV 
with disruption of the E2 gene, similar to SiHa. Further, UMSCC-104 showed a low E2/E6 
ratio with no amplified product for the full length of E2 (Figure 23), indicating that HPV had 
integrated (Figure 26). These results were consistent with data from other researchers (168) . 
However, one study suggested the presence of only episomal HPV in UMSCC-104 (175). 
This discrepancy might be due to the use of a different set of primers that do not target full-
length E2. According to Akagi et. al, in UMSCC-104, the integration breakpoint is at the far 3’ 
end of E2 gene, which differs from the frequent breakpoint site as seen in SiHa and UMSCC-
47 (168). This unexpected location of the breakpoint likely explains why this was missed by 
Olthof et. al (175). 
Methylation is another mechanism by which expression of the HPV oncogenes can 
be reduced and contribute to malignant progression (176-179) , therefore I also studied 
promoter methylation in HPV cell lines and patient samples.  I began by studying promoter 
methylation in HPV-positive HNC cell lines (UMSCC-47 and -104) and compared with that in 
cervical cancer cell lines (CaSki and SiHa). The SiHa cell line where HPV DNA had integrated 
was hypomethylated within the LCR, whereas CaSki containing both integrated and episomal 
HPVs was hypermethylated (Table 13, Figure 23 and Figure 26). Surprisingly, the pattern of 
methylation and its correlation with integration status showed exactly the opposite in the two 
HNC cell lines: UMSCC-47 with only integrated DNA (similar to SiHa) showed 
hypermethylation pattern (resembling CaSki), and UMSCC-104 containing predominantly 
integrated HPV DNA showed hypomethylation pattern (Table 13, Figure 23 and Figure 26). 
Therefore there was no correlation between integration status and promoter methylation of 
HPV DNA between the different cancer cell lines used in this study. 
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As mentioned earlier, viral integration and methylation are considered as two different 
mechanisms to interfere with E2 function thereby increasing oncogene expression and 
potentially leading to malignant transformation.  Both HPV- positive HNC cell lines used in this 
study showed integrated HPV DNA, therefore it was not possible to correlate viral oncogene 
expression with integration status. However, the UMSCC-104 cell line which was derived from 
a recurrent tumor showed significantly higher E7 expression compared to UMSCC-47. In 
contrast, the UMSCC-47 cell line with hypermethylated HPV showed higher E6 levels than 
UMSCC-104, which contained hypomethylated HPV DNA. These data show no clear pattern 
relating promoter methylation to oncogene expression, except to possibly suggest that there 
may be differences between oncogenes in this regard.  More studies are necessary to 
determine whether changes in methylation patterns in the LCR influence the expression of the 
HPV oncogenes, E6 and E7. 
Overexpression of p16
INK4a
 has been correlated with HPV-positive cancers (172,173). 
As expected, p16
INK4a
 expression was significantly higher in both HPV- positive HNC cell lines 
compared to HPV-negative UMSCC-1 cell line. EGFR is also frequently overexpressed in 
HNC independent of HPV etiology (180,181). Overexpression of EGFR is considered a poor 
prognostic factor in HNCs (182). Accordingly, compared to UMSCC-1 (which is HPV-negative 
HNC cell line), I found significantly higher EGFR expression in UMSCC-104 cells which was 
isolated from an HPV-positive tumor that did not respond to treatment (170).  
Integration of high-risk HPV DNA into host cells in severe dysplasia or carcinoma in 
situ of the cervix has been suggested as the first epidemiological marker of malignancy (183-
186). Therefore, for the first time, I analyzed HPV integration status in HPV16-positive 
samples collected at different malignant stages of tumors from the head and neck region, 
mainly by incorporating pre-malignant lesions in the study. I found that HPV integration status 
differed significantly between histologically distinct premalignant hgOED groups. Although the 
consequences of HPV DNA integration in oral dysplastic cells remains unexplored, I found 
that Group 1 (having diffuse mitosoid/ apoptotic cells) was more likely to have integrated HPV 
DNA (90.9%) than Group 2 and Group 3 (where histological features were focal or lacking). 
Group 1 had mostly integrated HPV DNA, which may confer higher malignant transformation 
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potential of Group 1 to HPV-associated cancer than Group 2 or Group 3. Therefore, the 
presence of an abundance of mitosoid cells in any premalignant squamous lesion could 
indicate the potential development of an HPV-associated oral cancer, though further research 
is warranted to confirm this hypothesis. In the malignant specimens, I also observed 
integration of HPV DNA in a significant proportion of HPV-positive HNCs, which was as 
expected based on the results from cell lines. These observations obtained from malignant 
specimens were also consistent with the results from other studies (104,105). 
In the case of cervical cancerous and pre-cancerous lesions, higher CpG methylation 
in E2BS was seen in samples containing only episomal HPV16 compared to those with 
integrated HPV16 genomes (178). So, HPV LCR methylation was considered as an 
alternative mechanism to HPV integration for cervical malignancy. However, HPV epigenome 
of head and neck tumors was mostly hypomethylated in contrast to what was observed in 
cervical lesions (23,24). This is also in contrast with a small study consisting of 3 HPV-
positive HNCs, which showed hypermethylation in LCR regions (111). However, a study in a 
large number of malignant samples reported hypomethylation of LCR in OPSCC (112), which 
is consistent with the results obtained in this study. Moreover, my analyses showed no 
significant differences in the methylation pattern between head and neck premalignant and 
malignant specimens with or without integration. In malignant specimens containing 
predominantly episomal HPV DNA, I didn’t find any methylation for CpG sites. Additionally, 
since all 15 CpG in premalignant specimens were unmethylated, I could not find any 
difference in methylation pattern among 3 groups, although they varied in integration status. 
Consequently, my results indicated that integration status of tumor lesions of the head and 
neck did not seem to correlate with HPV methylation pattern. This warrants further extensive 
research to determine the relationship of HPV genome methylation and integration in head 
and neck carcinogenesis. 
Overall, this is the first study to show differential HPV integration pattern in 
histologically distinct premalignant samples. This study revealed that HPV DNA integration 
might play a role in the process of HPV-induced head and neck carcinogenesis but not HPV 
methylation.
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CHAPTER V 
HOST EPIGENETIC CHANGES BY HPV INFECTION 
Chapter Overview 
DNA methylation is an important epigenetic modification in human cells. Both viral 
genomic and host chromosomal DNA can undergo methylation. In chapter IV, I found that 
promoter methylation of HPV DNA (HPV epigenome) gave no consistent patterns in head and 
neck cancer. In this chapter, I focused on characterization of host epigenetic changes to 
better understand cancer progression driven by HPV infection in the head and neck. For this 
study, an array of tumor suppressor genes was selected based on the data available from 
PubMed that seem to be implicated in HPV carcinogenesis. Results of my study showed that 
EREG is a candidate target gene for epigenetic regulation by HPV in HNC cells. 
Introduction 
Epigenetic modification, such as DNA methylation, histone modification, chromatin 
remodeling and microRNA, are essential for normal cellular differentiation, development and 
gene expression (187). Therefore, abnormal epigenetic modifications may contribute various 
pathological states. In particular, gene silencing through aberrant promoter methylation is 
considered as an important cause of tumorigenesis (118,188). Unmethylated cytosines in 
CpG island within the promoter region allows gene expression while methylated CpG causes 
silencing of genes. Methylated CpG binds with methyl-CpG-binding proteins and in turn, 
recruit histone deacetylases, resulting in transcriptional inactivation and loss of gene 
expression, as described in Figure 9 (113,189). Methylation of DNA is catalyzed by a group 
of enzymes called DNA methyltransferases (DNMTs), Figure 9A. DNMT1 is mainly 
responsible for maintenance methylation in which the methylation pattern is transmitted 
during cell division (190). The DNMT3 group of methyltransferases, particularly DNMT 3a and
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DNMT3b performs de novo methylation in which previously unmethylated cytosines are 
modified (113). There is growing evidence that the DNA methylation is a target for epigenetic 
changes induced by HPV E7 and E6 oncogenes (119,191). It has been shown that HPV16 
infection is associated with an up-regulation of DNMT1 and DNMT3a (119). Therefore, 
different studies related to epigenetic alterations have been largely investigated in cervical 
cancers, where hypermethylation of viral and host genes were frequently detected in 
advanced cancers (86-90,192). Accordingly, epigenetic alteration (particularly, promoter 
hypermethylation of the tumor suppressor genes) are known to play a major role in the 
development of HNCs (121,122,125,193,194). Although studies have shown epigenetic 
modulation in HNCs (121,122,195), it is unknown the extent to which these changes 
contribute to HPV-mediated carcinogenesis and progression. A better understanding of the 
epigenetic differences between HPV-positive and HPV-negative HNCs will help to identify 
molecular signatures involved in HPV-mediated HNC carcinogenesis. 
In order analyze the methylation status of tumor suppressor genes (TSGs) and 
identify epigenetic changes specific for HPV-positive HNCs, I surveyed publicly available 
resources- NCBI Epigenomics and PubMed literature. Thereby, I selected 38 candidate TSGs 
thought to be hypermethylated and repressed on cervical cancers and HNC (125,193-210). 
There were only a few reports on the relationship between HPV infection and methylation of 
host genes in HNCs (104,195,211-215) and results varied among studies. Herein, I 
hypothesized that presence of HPV infection leads to methylation of host genes and thereby 
reduces expression of distinct unique tumor suppressor genes in HNCs. 
Experimental Procedures 
Cell culture: Head and neck cancer cell lines; UMSCC-1 (HPV-negative) and UMSCC-47 
(HPV-positive); were purchased from EMD Millipore Corporation (Temecula, CA, USA) and 
cultured as per manufacturer’s instructions. UMSCC-1 and -47 originated from the floor of the 
mouth and anterior tongue, respectively, such that they are classified as oral cavity cancers 
(subsets of HNCs).  
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DNA isolation: DNA was isolated from cultured UMSCC-1 and 47 cells using DNAeasy® 
Blood & Tissue kit (Qiagen, USA) as per manufacturer’s guidelines. The same method was 
applied to isolate DNA from 5-aza-2′-deoxycytidine treated cells. 
RNA isolation and cDNA synthesis: Total RNA was extracted from all samples by using 
PureLink® RNA Mini Kit (Thermo Fisher Scientific Inc, USA), with DNase I treatment, 
according to manufacturer's instructions. To detect mRNA expression, single-stranded 
complementary DNA (cDNA) was synthesized from 1 µg total RNA by using SuperScript® 
VILO cDNA Synthesis Kit (Thermo Fisher Scientific Inc, USA) according to the manufacturer's 
guidelines.  
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) Analysis: Quantitative 
RT-PCR was conducted on a ViiA7 Real-Time PCR system (Applied Biosystems, Thermo 
Fisher Scientific Inc, USA). Expressions of DNMTs were quantified using Power SYBR Green 
PCR Master Mix (Thermo Fisher Scientific Inc, USA) and normalized against expression of a 
β-actin housekeeping gene. Each sample was measured two times at least and fold changes 
in mRNA expression levels were calculated using the comparative threshold (Ct) cycle 
method. Expressions of DNMTs were also measured using pre-designed TaqMan primers 
and probes in TaqMan array plate. Results were consistent from both Sybergreen assay and 
TaqMan array assay plate. 
Quantification of global DNA methylation: DNA was isolated as described previously in 
earlier chapter II. Global methylation levels were assayed using Methylamp™ Global DNA 
Methylation Quantification Ultra Kit (Epigentek) following the manufacture’s protocol. In this 
assay, DNA is immobilized to the well which is specifically coated with DNA binding 
substance. The methylated fraction of DNA is recognized by 5-methylcytosine antibody and 
quantified through an ELISA-like reaction.  
Selection of endogenous control for Taqman gene expression studies: TaqMan® 
Human Endogenous Control array (Applied Biosystems, Thermo Fisher Scientific Inc, USA) 
was used to identify appropriate endogenous controls that are invariably expressed in 
different samples being compared (i.e. 5-aza-dc treated and untreated UMSCC-1 and 
UMSCC-47 cells). This array card contains a panel of 16 endogenous control gene 
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candidates (probe/primer sets preloaded into the array card), Table 14. cDNA from each 
sample were synthesized from 1 µg total RNA and equal concentration (200 ng in each well) 
were loaded in triplicates into the endogenous control array card according to manufacturer’s 
specifications, centrifuged and run on a ViiA7 Real-Time PCR system (Applied Biosystems, 
Thermo Fisher Scientific Inc, USA). Accordingly, three genes- namely 18S rRNA, GAPDH, 
and IPO8 were selected (since their standard deviations were less than 0.5 Ct) and added in 
TaqMan custom array plate.  
Customized TaqMan® Array Plate: Assorted from various previous studies, 38 tumor 
suppressor gene (TSG) candidates that showed to be hypermethylated with decreased 
expression in cervical and HNCs were selected and added in custom array plate (Table 15). 
In addition, the plate also contains three DNMTs (DNMT1, DNMT3a, and DNMT3b); four 
HPV-affected genes (TP53, RB1, p16
INK4a
, EGFR) and three internal control genes (18S, 
GAPDH, IPO8; which was selected from TaqMan Endogenous Control Arrays). Relative 
changes in gene expression in UMSCC-47 versus UMSCC-1 and relative changes on 5-aza-
dc treatment as compared to untreated (DMSO treated) control cells was analyzed using 
normalization with IPO8.  
5-aza-2′-deoxycytidine (5-aza-dc) treatment: The de-methylation reagent 5-aza-dc 
treatment assay was used to analyze the functional effect of gene methylation on its 
expression in HNCs. 5-aza-dc (Sigma Aldrich Inc., St. Louis, MO) was dissolved in DMSO to 
make a stock solution of 20 mM and stored in aliquots at −80°C until use. From the stock 
solution, it was diluted directly in the culture medium to obtain desired final concentrations. 
Cells were treated with 5-aza-dc at different concentrations (0.5–30 μM) for 96 h. The culture 
medium containing freshly prepared 5-aza-dc was replaced every 24 h. Control cells were 
treated in parallel with DMSO only. Cell viability and global methylation were tested to 
determine optimal 5-aza-dc concentration for each cell type. Cells were harvested, and DNA 
and RNA were isolated. 
Cell viability: Cell viability before and after 5-aza-dc treatment was assessed by crystal violet 
staining method. Briefly, cells were seeded in each well of a 24-well plate and were allowed to 
grow for 24 h or 70 % confluence before treatment. Cells grown in monolayer were treated 
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with various doses of 5-aza-dc for 96 h.  After treatment, cells were washed with PBS, fixed 
with ice-cold methanol and stained with 0.5% crystal violet (prepared in 50% methanol) for 15 
mins and then washed with PBS and air-dried for 10 mins. Cells were then destained with 
10% acetic acid for 5 mins in the rocker. Absorbance was measured at 595nm using Gen5 
Microplate Reader and Imager Software (BioTek Instruments, Inc., VT, USA). For the 
evaluation of cell viability, the average absorbance of the control (5-aza-dc untreated) wells 
was regarded as 100%, and the percentage of cell growth in each well was calculated (% of 
control). 
Promoter Methylation Detection: DNA samples were subjected to bisulfite treatment using 
an EpiTect ® Plus Bisulfite Kit (Qiagen, CA, USA) following the manufacturer’s protocol. In 
this treatment, methylated cytosine remains unaffected whereas unmethylated cytosine 
residues are converted to uracil, which gets converted to thymine during PCR amplification. 
Methylation-specific PCR (MS-PCR) was performed to identify promoter methylation of 
EREG, GRB7, SMG1, RUNX3, and CHFR in HNC cell lines. Ensemble database was used to 
find and retrieve promoter sequences of these genes. Nucleotide sequences from ~1 kbp 5'-
flanking sequence to ~500 bp downstream of the transcription initiation site (TSS) of the gene 
was entered into MethPrimer program (http://www.urogene.org/methprimer/) (216). Primers 
specific for methylated sequences and unmethylated sequences of the gene were designed 
using MethPrimer program (Table 16). To control for the presence of bisulfite-modified DNA, 
primers specific to a modified region of the β-actin (ACTB) gene containing no CpG sites were 
used (mACTB Forward primer: TGGTGATGGAGGAGGTTTAGTAAGT and Reverse primer: 
AACCAATAAAACCTACTCCTCCCTTAA). The amplified products were resolved on 3% 
agarose gel and visualized under Bio-Rad ChemiDoc™ imaging system using ChemiDoc™ 
XRS software. Results of promoter methylation of SMG1, RUNX3 and CHFR are included in 
an appendix so as not to distract from the focus of the study.  
Statistical analysis: Data was analyzed by Students t-test or Analysis of Variance (ANOVA). 
One-way ANOVA or Student’s t-test was employed to test the effect of treatment on 
expression of each gene on each cell line individually. Two-way ANOVA was done to test the 
effect of treatment across the two cell types for each gene (i.e. the interaction between 
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“Treatment” and “Cell type”). Bonferroni p-value correction was designed to test the 
interaction effect across seven genes and to correct the Type 1 error rate (i.e. false positive 
result) for multiple comparisons. The analysis was performed using SigmaPlot Version 12.5 
(Systat Software, Inc., San Jose, CA, USA), GraphPad Prism Version 7 (GraphPad Software, 
Inc., La Jolla, CA, USA) and Microsoft Excel 2013 (MS Corp, Redmond WA). P values ≤ 0.05 
were considered statistically significant (*p<0.05, **p<0.01 and ** p<0.001). Error bars 
represented standard deviations of the mean fold change.  
Table 14: Endogenous control genes contained on Applied Biosystems (ABI) Human 
Endogenous Control Array 
Gene name 
Gene symbol with ABI 
product reference number 
Eukaryotic 18S rRNA 18S-Hs99999901_s1 
Actin, beta ACTB-Hs99999903_m1 
Beta-2-microglobulin B2M-Hs99999907_m1 
Glyceraldehyde-3-phosphate dehydrogenase GAPDH-Hs99999905_m1 
Glucuronidase, beta GUSB-Hs99999908_m1 
Hydroxymethylbilane synthase HMBS-Hs00609297_m1 
Hypoxanthine phosphoribosyltransferase 1 HPRT1-Hs99999909_m1 
Importin 8 IPO8-Hs00183533_m1 
Phosphoglycerate kinase 1 PGK1-Hs99999906_m1 
Polymerase (RNA) II polypeptide A, 220kDa POLR2A-Hs00172187_m1 
Peptidylprolyl isomerase A (cyclophilin A) PPIA-Hs99999904_m1 
Ribosomal protein, large, P0 RPLP0-Hs99999902_m1 
TATA box binding protein TBP-Hs99999910_m1 
Transferrin receptor (p90, CD71) TFRC-Hs99999911_m1 
Ubiquitin C UBC-Hs00824723_m1 
Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta polypeptide YWHAZ-Hs00237047_m1 
 
 
 83 
 
Table 15: Genes present in the custom TaqMan Array Plate including three endogenous 
controls (18S, GAPDH and IPO8) 
 
Table 16: Methylation-specific PCR primers 
Genes Primers for methylated sequence Primers for unmethylated sequence 
Amplicon size (bp); 
(Methylated, M; 
Unmethylated, U) 
EREG Met-Forward UnMet-Forward 154 (M) and 153  (U) 
 
GTTTTTTAGTTATTGTCGCGAGTTC TTTTTAGTTATTGTTGTGAGTTTGT 
 
 
Met-Reverse UnMet-Reverse 
 
 
TTATCTCCTCTTTAAAACGACCG TTATCTCCTCTTTAAAACAACCAAA 
 
GRB7 Met-Forward UnMet-Forward 197 (M) and 196  (U) 
 
TTTTTTATTATTTGTAGAGAAGCGG  TTTTTTATTATTTGTAGAGAAGTGG 
 
 
Met-Reverse UnMet-Reverse 
 
 
AACACAACCTAAAACCCTAATACGA  ACACAACCTAAAACCCTAATACAAC 
 
CSF3 Met-Forward UnMet-Forward 154 (M) and 153  (U) 
 
GATCGTGATTATTTTGGTTAATACG ATTGTGATTATTTTGGTTAATATGG 
 
 
Met-Reverse UnMet-Reverse 
 
 
 CTCACTACAAACTCTACCTCTCGAA CTCACTACAAACTCTACCTCTCAAA 
 
SMG1 Met-Forward UnMet-Forward 177 (M) and 178  (U) 
 
GCGTACGTGAATTTAAGGGTAC GGTGTATGTGAATTTAAGGGTATGT 
 
 
Met-Reverse UnMet-Reverse 
 
 
AACAAAAAATCTCCACTACTACGAC AACAAAAAATCTCCACTACTACAAC 
 
RUNX3 Met-Forward UnMet-Forward 180 (M) and 178  (U) 
 
ATTTTTTGAAGGGTTGAAAATTTTC TTTTGAAGGGTTGAAAATTTTTG 
 
 
Met-Reverse UnMet-Reverse 
 
 
 CAAAACGATCAATAAAAAAACGTA CCAAAACAATCAATAAAAAAACATA 
 
CHFR Met-Forward UnMet-Forward 165 (M) and 166  (U) 
 
TTTTGTGATAATATATTTTTTTCGT TTTTTGTGATAATATATTTTTTTTGT 
 
 
Met-Reverse UnMet-Reverse 
 
 
ATAATCTTAATCTCCTAACCTCGTA ATAATCTTAATCTCCTAACCTCATA 
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Results 
Increased DNMT1a and DNMT3a expression in UMSCC-47 cells 
As an initial characterization of epigenetic modifications associated with HPV-positive 
HNC cells, DNA methyltransferase activity, and the global DNA methylation were quantified in 
UMSCC-47 (HPV-positive) and UMSCC-1 (HPV-negative) cells. Significantly higher 
expressions of DNMT1a and DNMT3a were found in HPV-positive UMSCC-47 cells as 
compared to HPV-negative UMSCC-1 cells (Figure 27A). This result supports the finding that 
shows up-regulation of  DNMT1 and DNMT3a induced by HPV16 infection (119). However, 
DNMT3b expression was decreased in the UMSCC-47 cell line. As expected, global DNA 
methylation in UMSCC-47 cells was significantly higher compared to UMSCC-1 cells (Figure 
27B). These results were consistent with a study done by Lechner et al. which showed 
increased mRNA expression of both DNMT1 and DNMT3a in HPV-positive HNC cell lines 
(213). Consistent results were also found in E6- and E7-transfected HNC cell lines (213). 
Gene expression profiling of tumor suppressor genes in HPV-positive and negative 
HNC cells  
In this study, I selected 38 tumor suppressor genes, which were reported previously 
to be altered in either cervical cancer or HNC; although it should be noted that HPV-specific 
alteration in the expression of host genes has been poorly characterized and results varied 
from one study to another. Some of these genes that were previously shown to be 
hypermethylated and/or inactivated in HNCs are -- GRB7, CDH11, SFRP4 (212); CDH8, 
CDH13, PCDH10 (213); PAX1 (125); SFRP4 (197); SMG-1 (214); MT1G (198); PHF21B 
(199); RUNX3 (200); MGMT, RASSF1A (194); RASSF1 (201,202); CADM1/IGSF4 (203); 
DAPK1 (202,215); S100A2 (206); CDH1, EDNRB, RARB, APC, DCC, NDRG2 (193); TUSC3 
(207,212); TCF21 (211); GALC (209); EREG (195); FITH (195,210). There were genes that 
were previously found to be hypermethylated and inactivated specifically in HPV-positive 
HNCs (or were more hypermethylated in HPV-positive HNCs than HPV-negative HNCs); such 
as CCNA1 (211,212) RUNX2, SPON2, PREX1, IRS1 (195), TIMP3, CHFR (215); GATA4, 
IRX4 (104,208). 
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 The expression levels of these 38 tumor suppressors were analyzed in a custom 
array plate that I designed. No significant changes in the expression of CCNA1, SPON2, 
PREX1, IRS1, TIMP3, GATA and IRX4 were found between the HPV-positive (UMSCC-47) 
and HPV-negative (UMSCC-1) cell lines. Nevertheless, six genes (GRB7, RUNX3, RUNX2, 
CHFR, RARB, and EREG) showed significantly reduced expression in the HPV-positive HNC 
cell line compared with the HPV-negative HNC cell line (Figure 28). In addition, one gene, 
SMG-1 was marginally reduced in HPV-positive cell line as compared to HPV-negative cell 
lines (p=0.08). 
 
 
Figure 27: Relative expression of DNMT (A) and global methylation (B) in head and neck 
cancer cell lines. HPV-positive cell line (UMSCC-47) showed significantly higher DNMT1 and 
DNMT3a expressions and greater percentage global methylation than HPV-negative cell line 
(UMSCC-1). (Significance level at *p<0.05, **p<0.01 and NS non-significant) 
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Figure 28: Gene expression profile of six tumor suppressor genes that showed reduced 
expression in HPV-positive cell line (UMSCC-47) as compared to that of HPV-negative cell 
line (UMSCC-1). (Significance level at *p<0.05, **p<0.01, **p<0.001 and NS non-significant) 
 
Determination of optimal de-methylation condition using 5-aza-dc treatment 
Seven tumor suppressor genes showing decreased expression in HPV-positive HNC 
cell line were selected to test whether their decreased expression corresponds with promoter 
methylation using the de-methylation agent (5-aza-dc). Initially, I determined optimal 
conditions for de-methylation using 5-aza-dc by testing cell viability and global methylation.  
When cells are treated with 5-aza-dc (a nucleoside analog of cytidine), it gets incorporated 
into DNA during replication forming azacytosine-guanine dinucleotide. DNA methyltransferase 
(DNMT) recognizes this dinucleotide as a natural substrate for methylation and subsequently 
gets covalently bound (i.e. trapped) to DNA, thereby inactivating its enzymatic function (217). 
Since 5-aza-dc does not actively de-methylate the DNA, but rather inhibits the methylation of 
new DNA during cell division, cells were treated with 5-aza-dc for a relatively long period of 
time (4 days with re-treatment every day due to poor stability of the drug). Further, since 
different cell lines vary in terms of toxicity to this drug, as well as their response in de-
methylation, I treated cell lines with different concentrations (0.5–30 μM) of 5-aza-dc.  I found 
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that treatment with 5 μM 5-aza-dc for 96 hours showed optimal de-methylation potency based 
on global methylation (67% and 75% reduction in global methylation in UMSCC-1 and 47 
respectively) with ~60 and 70% cell viability (Figure 29 and Figure 30).  
 
Figure 29: Cell viability of HPV-positive (UMSCC-47) and HPV-negative (UMSCC-1) cell 
lines with increasing dosage of 5-aza-dc treatment for 96 hours. 
 
 
Figure 30: Changes in global methylation (%) in HPV-negative (UMSCC-1) cell line (A) and 
HPV-positive (UMSCC-47) cell line (B) after treatment with increasing dosage of 5-aza-dc for 
96 hours. 
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Changes in expression of candidate tumor suppressor genes in de-methylation 
condition after 5-aza-dc treatment 
To identify candidate genes whose expression is significantly increased upon de-
methylation, HNC cell lines were treated with 5 µM 5-aza-dc for 96 hours and expression of 
the seven target genes was analyzed. As described in experimental procedures, the effect of 
treatment was statistically analyzed for each gene on each cell type individually as well as 
across the two cell types (i.e. Bonferroni corrected interaction), Figure 31. Out of 7 genes, 5 
were less likely to be regulated specifically in HPV-positive HNCs. For example, SMG1 was 
up-regulated upon de-methylation treatment only in HPV-negative UMSCC-1 cell line 
(p=0.02), but not in HPV-positive UMSCC-47 cell line (p=0.795).  Although the significant 
change in expression of CHFR, RUNX3, and RARB was found on 5-aza-dc treatment, these 
alterations were observed in both cell lines. The expression of the fifth gene, RUNX2 was 
unchanged in both cell lines on 5-aza-dc treatment.  
With a goal to identify a gene that is epigenetically regulated specifically in the HPV-
positive environment, I found two genes, GRB7 and EREG that showed significant change on 
de-methylation as putative targets of HPV-mediated promoter methylation. De-methylation 
treatment significantly increased the expression of GRB7 and EREG in HPV-positive 
UMSCC-47 cell line (p<0.05 and p<0.001 respectively) with no evidence of an effect in the 
HPV-negative UMSCC-1 cell line (p=0.33 and p=0.21 respectively), Figure 31. When the 
effect of 5-aza-dc treatment was analyzed across the two cell types (i.e. overall effect), I 
found no significant effect on GRB7 and EREG expression across cell types (Bonferroni 
corrected interaction p=0.26 and p=1.0, respectively). This result further confirms that 5-aza-
dc treatment has an effect on GRB7 and EREG expression in cell-type specific manner but 
not in overall interaction across the cell lines. 
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Figure 31: Changes in expression of tumor suppressor genes on de-methylation treatment (5 
µM 5-aza-dc for 96 hours) in HPV-negative (UMSCC-1) and HPV-positive (UMSCC-47) cell 
lines. Statistical bars represents the changes on gene expressions on each cell line 
individually as well as Bonferroni corrected interaction of treatment across the two cell types 
(Significance level at *p<0.05, **p<0.01, **p<0.001 and NS non-significant) 
EREG promoter was methylated in the HPV-positive HNC cell line and was 
hypomethylated after 5-aza-dc treatment 
To further determine whether the silencing of EREG expression was due to promoter 
methylation, I examined the methylation status of the EREG promoter region in HPV-positive 
UMSCC-1 and HPV-negative UMSCC-47 cell lines using methylation-specific PCR (MS-
PCR), which covered the CpG island in the promoter region of EREG (Figure 32A). MS-PCR 
assay revealed distinct differences in CpG methylation of the EREG promoter between 
UMSCC-1 and UMSCC-47 cell lines. A methylated band (lanes indicated by M) was identified 
in UMSCC-47 whereas an unmethylated band (lanes indicated by U) was observed in 
UMSCC-1 (Figure 32B). To further confirm methylation-mediated transcriptional silencing of 
EREG, cell lines were treated with a de-methylation agent (5-aza-dc). After 5 μM 5-aza-dc 
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treatment, the unmethylated band (U) was observed in UMSCC-47 cells, while no change 
was found in UMSCC-1 cells (Figure 32C). This suggests that the restoration of EREG 
mRNA expression following 5-aza-dc treatment in UMSCC-47 was likely caused by de-
methylation of the hypermethylated CpG sites in the EREG promoter. 
Methylation of GRB7 promoter in both HPV-positive and HPV-negative cell lines 
Methylation-specific PCR analyses showed the presence of both methylated and 
unmethylated GRB7 promoters in both cell lines, indicating partial methylation of GRB7 in 
these cell types. Even on de-methylation treatment, there was no change in methylated and 
unmethylated bands on the agarose gel (Figure 33B). The promoter of GRB7 contains CpG 
sites (Figure 33A) but does not seem to contain CpG island as predicted by MethPrimer 
software (Criteria used for CpG island prediction was Island size > 100 and GC% > 50.0). 
Therefore, I further checked for the presence of an upstream promoter, which can possibly 
affect the expression of GRB7. A study reported that methylation of CSF3 promoter 
significantly correlates with GRB7 expression; both GRB7 and CSF3 are on chromosome 17q 
and are commonly amplified together (218). Methylation-specific PCR of CSF3 promoter also 
revealed similar results as observed from the GRB7 promoter. Both methylated and 
unmethylated bands (lanes M and U respectively) of CSF3 promoter were seen in UMSCC-1 
and UMSCC-47 cell lines (Figure 33D and 33C). This indicates that epigenetic regulation of 
GRB7 may not be specific to the HPV-positive environment. This result reduces enthusiasm 
for GRB7 as a candidate gene for epigenetic regulation in HPV-associated HNCs.  
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Figure 32: Methylation status of EREG promoter (A) EREG promoter showing CpG island. 
The locations where methylated and unmethylated methylation-specific PCR (MS-PCR) 
primers anneal are indicated by the rectangular box; MF1-MR1 (methylated- forward and 
reverse primers) and UF1-UR1 (unmethylated- forward and reverse primers). TSS indicates 
transcription start site. (B)  MS-PCR of EREG in bisulfite-modified DNA from HPV-negative 
(UMSCC-1) and HPV-positive (UMSCC-47) cell lines. (C) MS-PCR of EREG after 5-aza-dc (5 
µM for 96 hours) treatment. MS-PCR of β-actin serves as an internal control for bisulfite-
modified DNA. No template DNA serves as negative control. 
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Figure 33: Methylation status of GRB7 and CSF3 promoters. A) GRB7 promoter showing 
CpG sites and the locations of methylated and unmethylated methylation-specific PCR (MS-
PCR) primers. MS-PCR of GRB7 (B) and CSF3 (C and D) in bisulfite-modified DNA from 
HPV-negative (UMSCC-1) and HPV-positive (UMSCC-47) cell lines with or without 5-aza-dc 
(5 µM for 96 hours) treatment. No template DNA serves as negative control. (Note: CSF3 
promoter methylation is known to regulate GRB7 expression) 
Discussion 
Epigenetic changes are considered as important mechanisms in HNC progression, 
but how these changes differ between HPV-positive and HPV-negative cancers are less 
defined. I conducted a study that helps to identify an epigenetic mechanism that is specific to 
HPV-positive HNCs. For this, I screened 38 tumor suppressor genes to identify a putative 
candidate regulated by promoter methylation.  
From gene expression profile of 38 tumor suppressors in the custom array, I selected 
7 genes (GRB7, RUNX3, RUNX2, CHFR, RARB, EREG, and SMG-1) as the targets for 
further studies, which showed reduced expressions in HPV-positive cell line than HPV-
negative cell line (Figure 28). To determine whether the reduced expression of these genes 
is due to promoter methylation, I treated cell lines with a de-methylation agent, 5-aza-2′-
deoxycytidine (5-aza-dc).  It is shown that 5-aza-dc is able to re-express genes that are 
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silenced by DNA methylation; although, this reactivation can vary from gene to gene and 
different tissue/cell types (217). On 5-aza-dc treatment, I found different expression profiles of 
tumor suppressor genes in two HNC cell lines. Out of 7 genes, only EREG and GRB7 genes 
expression was significantly increased upon de-methylation treatment specifically in HPV-
positive UMSCC-47 cell line. Although GRB7 expression was increased on 5-aza-dc 
treatment only in UMSCC-47, without any significant change in expression in UMSCC-1, 
GRB7 promoter was found to be methylated in both cell lines. This indicates that epigenetic 
regulation of GRB7 may not be specific to the HPV-positive environment. Further analyses 
quantifying the methylation status between UMSCC-1 and UMSCC-47 cell lines may help to 
better understand the relationship between gene methylation and transcriptional regulation in 
specific cell type.  
In the case of EREG, I found a high correlation between gene expression and 
promoter methylation. Methylated EREG promoter was detected in UMSCC-47 (Figure 32B) 
where EREG was down-regulated (Figure 28). When these cells were treated with 5-aza-dc, 
EREG expression was restored (Figure 31) and the unmethylated band was seen (Figure 
32C). In contrast, higher expression of EREG was found in the UMSCC-1 cell line (Figure 
28), which corresponded with its unmethylated promoter (Figure 32B). Also, 5-aza-dc 
treatment showed no significant change in EREG expression in the UMSCC-1 cell line. 
Consequently, these results suggest that EREG is regulated via promoter methylation 
specifically in HPV-positive UMSCC-47 cell line. Subsequently, EREG was identified as a 
putative candidate gene for being a driver of the carcinogenic process specific to HPV-
positive HNCs. Consistent with my results, a genome-wide methylation study done using two 
HPV-negative HNC cell lines (UMSCC-4 and UMSCC-74A) and an HPV-positive HNC cell 
line (UMSCC-47) have shown enrichment in EREG gene for hypermethylation and decreased 
expression in a UMSCC-47 (195). However, authors did not discuss the functional 
characterization of EREG in their study.  
EREG gene encodes for Epiregulin protein, which is a member of the epidermal 
growth factor (EGF) family of proteins. Epiregulin was originally purified from the conditioned 
medium of the mouse fibroblast-derived tumor cell line and identified as a tumor growth 
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inhibitor, which induced morphological changes in HeLa cells (219). Epiregulin functions as 
one of the ligands for the ErbB family receptors, namely EGF receptor (EGFR or ErbB1) and 
ErbB4 (220). Studies suggested that epiregulin has dual biological activity (219,221,222). On 
one hand, it stimulates proliferation of fibroblasts, hepatocytes, smooth muscle cells, and 
keratinocytes (223-225) and EREG is overexpressed in many human cancers (226-228). On 
the other hand, EREG inhibits the growth of several epithelial tumor cells (219,221,229) and 
not all cancer cells have high levels of EREG expression (230). While the oncogenic function 
of epiregulin is known to involve the activation of PI3K/AKT and MAP kinase cell signaling 
pathways (228), little is known regarding the mechanism by which epiregulin functions as a 
tumor suppressor in epithelial cancers. It is suggested that epiregulin inhibits the binding of 
EGF (a potent mitogenic ligand of EGFR) to EGFR on epithelial tumor cells, which might be 
the reason for growth inhibition of these cells (219).  
Little is known about the role of EREG in the development of HNCs. A study showed 
that epiregulin expression is higher in oral squamous cell carcinoma (OSCC) specimens than 
in normal gingiva and oral dysplasia (231), thereby indicating that epiregulin expression may 
be associated with cancer progression. Although authors did not determine HPV status of 
these OSCC specimens, I would expect mostly HPV-negative because my study and others 
(58,137) have shown that HPV prevalence is extremely low in OSCC. Another study done in 
two HPV-negative HNC cell lines showed that  increased transcription of epiregulin was 
associated with the metastatic phenotype (232). Based on these findings, there is a high 
possibility that increased EREG expression is related to HPV-negative HNCs, but not to HPV-
positive cancers. My study and Sartor et. al (195) showed the promoter methylation and 
transcriptional inactivation of EREG in HPV-positive HNC cell line, but not in HPV-negative 
HNC cell lines. This opens up a possibility that EREG may act as a tumor suppressor in HPV-
positive HNC and as an oncogene in HPV-negative HNC. Further studies on HPV-positive 
and HPV-negative HNC cell lines and tissue specimens are required to confirm this 
hypothesis. Additionally, further studies have to be conducted to elucidate the role of EREG in 
HNC development. 
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Studying the role of EREG in head and neck carcinogenesis would be beneficial for 
the better application of treatment based on HPV status of a patient. Since HPV-positive HNC 
patients have better therapy response than HPV-negative HNC patients, clinical trials are 
undergoing to de-intensify the current treatment standards to reduce associated toxicities 
(173,233). So, de-intensification of chemotherapy has been implemented by replacing with 
cetuximab, a monoclonal antibody that inhibits EGFR. This is because EGFR is frequently 
overexpressed in HNCs independent of HPV etiology (180,181). Interestingly, some studies 
showed that the effect of cetuximab can be enhanced in cells with high levels of EGFR 
ligands such as EREG (221,230). In colorectal cancer, patients with high EREG expression 
benefit more from cetuximab therapy compared with low EREG expression (234). A study 
done in HNC cell lines also showed that expression of epiregulin (along with other EGFR 
ligands) is correlated with responsiveness to cetuximab (235). Because my study and Sartor 
et. al (195) showed that HPV presence in HNC cell lines causes decreased EREG 
expression, there is a possibility that HPV presence may decrease the efficacy of cetuximab 
therapy in HPV-positive HNCs. The further in-depth study is required to address this highly 
relevant issue and to determine whether 5-aza-dc induction of EREG expression increases 
sensitivity to cetuximab in HPV-positive HNCs. 
There is a growing interest to use 5-aza-dc (also called decitabine) as a therapeutic 
agent for cancers in which epigenetic silencing of critical regulatory genes has occurred 
(217,236). Consequently, decitabine has been used in clinical trials for hematological and 
solid malignancies (237,238). The U.S. Food and Drug Administration (FDA) has approved 
decitabine for the treatment of myelodysplastic syndrome, a pre-leukemic bone marrow 
disorder (239). One group has investigated the efficacy of decitabine in combination with 
cisplatin in HNCs (240). However, studies are not yet done to explore the possibility of 
combinational therapy of a de-methylation agent decitabine and an EGFR-inhibitor cetuximab, 
which may be an effective therapeutic strategy for treating HNCs; particularly HPV-positive 
ones. 
A major limitation of this study is that results were drawn based on two selected 
model cell lines representing HPV presence (UMSCC-47) and HPV absence (UMSCC-1) in 
HNCs. So, further studies are necessary using more HPV-positive/negative cell lines and 
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human HNC specimens to confirm whether EREG epigenetic regulation is specific to HPV-
positive HNCs. Moreover, since HPV E7 is known to increase DNMT1 and DNMT3a activity 
(119), additional studies should be done by silencing E7 in HPV-positive cells or 
overexpressing E7 in HPV-negative cells to determine whether epigenetic inactivation of 
EREG is due to HPV E7 oncoprotein (see Appendix). Another limitation of this study is that 
the effect in gene expression using 5-aza-dc in combination with histone deacetylases 
(HDAC) inhibitor was not determined. Studies have indicated that 5-aza-dc in combination 
HDAC inhibitors can produce a synergetic reactivation of some genes (241,242), so future 
studies should be aimed using HDAC inhibitor alone or in combination with 5-aza-dc which 
would provide a better picture of the genes regulated by promoter methylation in HNCs. 
Overall, in this chapter, I attempted to better characterize the methylation differences 
between HPV-positive and HPV-negative head and neck cancers. My finding concurs with the 
observation of Sartor et. al (195) that promoter hypermethylation may possibly contribute to 
down-regulation of EREG gene in the HPV-positive HNCs. This study should be continued to 
determine whether epigenetic inactivation of EREG plays a role in HPV-associated head and 
neck tumorigenesis. 
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CHAPTER VI 
CONCLUDING REMARKS 
My dissertation identifies the potential biomarkers and genetic and epigenetic 
mechanisms associated with HPV in head and neck tumors, as illustrated in Figure 35.   
HPV-positive HNCs are characterized as a distinct entity from HNCs that are linked to 
tobacco and alcohol use, and lack HPV-related etiology. Of note, HPV-positive HNC patients 
are found to have more favorable treatment response and better survival than patients whose 
tumors are HPV-negative. As HPV detection has huge diagnostic and prognostic significance, 
there should be a suitable biomarker which precisely diagnoses HPV infection and a 
personalized treatment regimen based on HPV status. For these reasons, the knowledge of 
genetic and epigenetic profiles in HPV-positive HNCs is very important. This will help to 
distinguish the underlying molecular basis between HPV-associated and –unassociated 
carcinogenesis that may lead to the development of novel therapeutic strategies. 
As the progression of HPV infection in premalignant lesions to HNCs is unknown, in-
depth clinical, histologic and molecular characterization of HPV-associated head and neck 
tumors is needed. In chapter II, pathologically distinct tumors of the head and neck (benign, 
premalignant and malignant) were characterized both histologically and molecularly. I found 
that benign head and neck tumors i.e. multiple epithelial hyperplasias (MEH) are caused by 
low-risk HPV types (126), whereas premalignant and malignant head and neck tumors are 
caused by high-risk HPV types, predominantly HPV type 16 (127). Other benign lesions 
called oral squamous papillomas were mostly HPV negative. Additionally, I found that 
“mitosoid cells”, which were previously thought to represent an HPV-associated cytopathic 
effect in benign MEH, can also be found in HPV-positive premalignant head and neck tumors 
(127). My results strongly support that “mitosoid cells” in head and neck tumors are histologic 
biomarkers for HPV infection.  
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The identification of serum biomarkers of HPV infection is equally important, which 
could lead to the development of early and non-invasive methods of HPV detection. In 
chapter III, I assessed serum HPV E7 antibody titer as a potential serological biomarker. I 
have shown for the first time that the combination of HPV E7 seropositivity and p16
INK4a
 
expression is a strong diagnostic biomarker for HPV-associated head and neck malignancy 
(145). HPV E7 serology may be particularly useful in cases when a tissue specimen is not 
sufficient for histological tests (e.g. immunostaining of p16
INK4a
 or detecting mitosoid cells). 
Further, serial monitoring of decline in HPV serology may be useful in predicting a patient’s 
response to treatment. 
In chapter IV, I extrapolated knowledge of HPV-induced oncogenicity in cervical 
cancer to understand molecular determinants of HPV-associated HNCs. I analyzed whether 
HPV DNA - integration and -methylation might play important roles in HPV-linked head and 
neck carcinogenesis as seen in HPV-associated cervical cancers. I found that integration of 
HPV DNA into the host genome appears to be essential for neoplastic transformation of 
premalignant lesions; however, HPV DNA methylation might not play a role in the process of 
HPV-induced head and neck carcinogenesis. I also suggest that Group 1 premalignant 
lesions which contain diffuse mitosoid cells might have higher malignant transforming 
potential, though further long-term follow-up studies are required to appropriately address any 
trends towards malignant transformation. 
Study of HPV epigenetics indicated that viral DNA methylation might not be involved 
in head and neck carcinogenesis (Chapter IV). Therefore, in chapter V, I studied epigenetic 
changes (i.e. promoter methylation and transcriptional inactivation) of host genes specific to 
HPV- associated head and neck malignancy. For this, 38 tumor suppressor genes were 
selected based on literature and screened to identify a putative candidate. I found that HPV-
positive HNC cell lines showed promoter hypermethylation and transcriptional inactivation of a 
candidate tumor suppressor gene EREG. It suggests that epigenetic regulation of EREG may 
be specific to HPV-positive HNCs and may play a role in the development of HPV-associated 
HNCs. This result needs to be put in a broader context using human cancer specimens and 
understanding the role of EREG in head and neck carcinogenesis. The EREG gene encodes 
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a ligand of the epidermal growth factor receptor (EGFR). Further studies on EREG gene 
could provide insights into possible treatment strategies using EGFR inhibitors (i.e. 
cetuximab, the Food and Drug Administration (FDA)-approved drug for HNC patients). Future 
studies are also needed to explore the possibility of using combinational therapy of two FDA-
approved drugs - cetuximab and decitabine (5-aza-dc) for treating HNCs, particularly HPV-
positive cancers. 
Overall, in this dissertation, I found variation in HPV presence among pathologically 
distinct head and neck tumors. I also identified potential biomarkers of underlying HPV 
etiology in head and neck malignancy. This study also provides better insights into the 
putative genetic and epigenetic mechanisms by which HPV triggers head and neck 
carcinogenesis, though further studies are required to explore this highly relevant issue.   
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Figure 34: A schematic representation of a summary of the dissertation.  
Different types of head and neck tumors were associated with the distinct type of HPV. 
Benign tumors, particularly multiple epithelial hyperplasias (MEH) were caused by low-risk 
HPV types. Pre-malignant (mainly Group1 lesions) and malignant (particularly oropharyngeal 
cancers, OPC) were caused by high-risk HPV types. Potential serum and tissue biomarkers 
for underlying HPV etiology were identified (shown in quotation marks). Mitosoid cells 
represented not only an HPV-associated cytopathic effect in benign MEH but also a subset of 
premalignant tumors. p16
INK4a
 may serve as a surrogate marker only in Group 1 lesions 
compared to other premalignant lesions. E7 serology complements p16 expression as a 
strong biomarker for HPV-associated malignancy. Integration of HPV DNA and epigenetic 
inactivation of host gene EREG may play a role in HPV-associated malignancy. But, viral 
DNA methylation may not be required for transformation of premalignant lesions to malignant. 
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APPENDICES 
Introduction 
During the course of my dissertation work, some supporting experiments were not 
completed and some of the studies did not produce significant results. Therefore, I had to 
change research aims and/or experimental focus. These results are not included in 
dissertation chapters and therefore are shown in the appendix. 
 
I. Determine the presence of Fanconi anemia genes mutation(s) in HPV-positive 
head and neck cancer specimens 
Introduction 
My original thesis proposal was to study whether a defect in Fanconi Anemia (FA) - 
DNA repair system is associated with HPV-induced HNCs and whether this defect is linked 
with improved prognosis in HPV-positive HNCs. This was based on the studies which have 
shown a defect in FA-DNA repair pathway is implicated in hypersensitivity to DNA cross-
linking agents (243) and HPV-induced HNC exhibit improved sensitivity to chemo/radio 
therapies (244). While there is evidence for a DNA repair defect in HNCs, it is not well 
documented whether this is specific to the HPV-positive environment. Sixteen proteins 
encoded from 16 Fanconi anemia (FANC) genes are involved in a DNA-repair pathway 
known as the Fanconi Anemia-DNA repair pathway (245) (Figure S1). Based on these 
findings, I hypothesized that HPV-positive HNCs contain mutations in Fanconi genes that are 
not present in HPV-negative HNCs and this defect in Fanconi anemia-DNA repair pathway is 
implicated in improved prognosis in HPV-positive HNCs. 
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Figure S1: Fanconi anemia (FA)-DNA repair pathway showing into three groups of FA 
proteins: 1) Core complex proteins (FANCA, B, C, E, F, G, L and M); which in response to 
DNA damage is required for mono-ubiquitination of  2) ID complex (FANCI and FANCD2); 
and 3) DNA repair foci proteins [FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2, FANCO/ 
RAD51C, FANCP/SLX4 and FANCQ/XPF4/ERCC4] participate directly in DNA interstrand 
crosslink repair. Accessory proteins such as MHF1/2 and FAAP24 (not shown here) help 
FANCM to recruit core complex to the sites of DNA damage. The monoubiquitinated FANCD2 
is the center of the pathway and a measure of functional FA pathway. BRCA1 is currently not 
considered to be a true FA protein though it is an essential part of the FA-DNA repair 
pathway.  
Experimental Procedures 
I had a plan to test all coding exons of 16 FANC genes (total 303 exons) by PCR-based 
amplification using primers spanning intron-exon junctions. I had started with the amplification 
and sequencing of 9 exons of FANCO/RAD51C; 14 exons of FANCL; 23 exons of FANCM; 
14 exons of FANCG and 43 exons of FANCD2. Primers, PCR conditions and the target PCR 
product for each exon of FANC genes were tested first by using HeLa cell DNA. By optimizing 
PCR conditions, I amplified the respective exons in the HNC samples. Then, target PCR 
products were excised from an agarose gel, purified, and sequenced.  
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When a gene is known to produce multiple transcripts, the primers for shared exons and 
primers unique for the spliced exon were designed. Multiple primer pairs were employed if the 
coding exons were larger than 450bp. Primers were designed using Primer 3 software or IDT 
PrimerQuest tool to cover at least 15bp at each 5’and 3’ sides of the exons. I ordered primers 
(either forward or reverse) tagged with M13 primer (5’-GTAAAACGACGGCCAGT-3’) so that 
all amplified products can be sequenced using a single M13 primer. 
Data analysis 
Sequencing data was analyzed for variant detection using Mutation Surveyor software 
(SoftGenetics LLC., PA, USA). All sequences were compared to the related NCBI reference 
sequences. The chromatograms of all the computationally determined variants were checked 
manually for confirming the existence of those variants. SeqMan Pro program (Lasergene 12, 
DNAstar Inc., Wisconsin) was used to align and compare the sequences from all the samples 
analyzed. The identified variants were searched in NCBI dbSNP for Human to find their 
related rs#, and those, which was not found, was considered as novel variants. Human 
Splicing Finder website (http://www.umd.be/HSF/) was used to determine whether the 
detected intronic and exonic mutations lead to splicing defects.  
All insertion and deletions in the gene coding region, nonsense variants, and variants 
located at the splice site consensus sequences were considered as potentially deleterious. 
Missense variants first were searched in UniProt Database for determining their functional 
effects. If their functional effect was not known, bioinformatics tools were utilized to predict 
their effect. For predicting the functional effect of the missense variants, PolyPhen and SIFT 
tools were used. Missense variants predicted to be deleterious by Polyphen or SIFT 
algorithms and having a minimum allele frequency (MAF) >0.5% was considered as 
potentially deleterious variants. The MAF > 0.5% was used to exclude singleton mutations 
(private mutations seen in a single individual) which do not provide enough power for 
analysis. The predicted potentially deleterious variants were planned to genotype in more 
cases and controls. 
Following mutational analysis, each putative mutation was independently re-amplified in 
tumor DNA (to eliminate artifacts). I compared the sequencing results of each patient’s tumor 
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to their matched tissue samples in order to eliminate background germline variations and to 
focus on somatic alterations unique to the tumor genome. The comparison was done with 
HPV-negative samples to establish a link between FANC mutation and HPV infection.  
Results and Discussion 
I analyzed two HPV-positive HNC samples with their matched normal tissues, and two 
HPV− samples (altogether 6 samples). In 6 samples, I had sequenced 9 exons of 
FANCO/RAD51C; 14 exons of FANCL; 23 exons of FANCM; 14 exons of FANCG and 43 
exons of FANCD2. I was unable to get useful sequencing results from FANCD2 Exons 18, 19, 
20, 22 and 26 amplified products. Although the primers were designed to target exons, some 
intergenic and intron regions adjacent to exons were also amplified and sequenced. Variants 
unique to HPV-positive HNC cases are shown in Table S1 and Table S2.  
The majority of mutations that were observed were heterozygous synonymous. Mutations 
that were heterozygous non-synonymous were mostly present in both tumor and normal 
matched tissues, showing germline variations instead of somatic alterations unique to the 
tumor genome. These mutations include FANCD2 c.2219C>CT (or p.P714PL); RAD51C 
c.439C>CA (or p.Q133QK); FANCM ----c.437A>AC (or p.T118TP) c.5268C>CG (or 
p.A1728AG) and c.5273C>CG (or p.Q1730QE); FANCG --- c.816G>GC (or p.E108ED), 
c.923G>GC (or p.G144GA) and c.2197G>GC (or p.A569AP).  
Heterozygous non-synonymous mutation of FANCG c.819G>GC (or p.Q109QH) and 
heterozygous deletion of FANCM c.2379het_delT were found in HPV+ tumors but not in 
matched normal. However, these mutations were not observed in additional HPV-positive 
cases and FANCG c.819G>GC was also present in additional HPV-negative cases; 
suggesting these alterations were not exclusively specific for the HPV-positive environment.  
Most of the intronic variants were heterozygous and were also present in matched 
normal. Heterozygous deletion of RAD51C c.947-74het_delG was found in one HPV-positive 
tumor but there wasn’t predicted potential splice site, making this mutation non-significant. 
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Table S1: Exonic variants identified in 5 FANC genes in DNA of only HPV-positive HNC 
cases 
No. Gene Exon 
Nucleotide 
Change* 
Amino Acid 
Change 
Mutation type Total Samples 
1 FANCD2 14 c.1200A>AG p.V374VV 
Heterozygous 
synonymous 
2 (tumor+ matched 
normal) 
2 FANCD2 17 c.1587C>CT p.N503NN 
Heterozygous 
synonymous 
2 (tumor+ matched 
normal) 
3 FANCD2 23 c.2219C>CT p.P714PL 
Heterozygous non-
synonymous 
2 (tumor+ matched 
normal) 
4 FANCD2 42 c.4176T>TG p.L1366LL 
Heterozygous 
synonymous 
2 (tumor+ matched 
normal) 
5 RAD51C 2 c.439C>CA p.Q133QK 
Heterozygous non-
synonymous 
2 (tumor+ matched 
normal) 
6 FANCL 6 37214T>TG p.G145GG 
Heterozygous 
synonymous 
4 (tumors+ matched 
normal) 
7 FANCM 1 c.437A>AC, p.T118TP 
Heterozygous non-
synonymous 
4 (tumors+ matched 
normal) 
8 FANCM 1 c.484T>TC p.P133PP 
Heterozygous 
synonymous 
2 (tumor+ matched 
normal) 
9 FANCM 13 c.2379het_delT 
 
Heterozygous deletion 
1 (tumor) 
10 FANCM 20 c.5268C>CG p.A1728AG 
Heterozygous non-
synonymous 
4 (tumors+ matched 
normal) 
11 FANCM 20 c.5273C>CG p.Q1730QE 
Heterozygous non-
synonymous 
4 (tumors+ matched 
normal) 
12 FANCM 21 c.5470T>TG p.C1795CW 
Heterozygous non-
synonymous 
2 (tumor+ matched 
normal) 
13 FANCM 21 c.5550T>TG p.V1822VG 
Heterozygous non-
synonymous 
4 (tumors+ matched 
normal) 
14 FANCM 21 c.5554T>TG p.G1823GG 
Heterozygous 
synonymous 
3 (2 tumor+ 1 matched 
normal) 
15 FANCM 23 c.6749A>AC 
 
Heterozygous 
3 (2 tumors+ 1 matched 
normal) 
16 FANCM 23 c.6880A>AC 
 
Heterozygous 
4 (tumors+ matched 
normal) 
17 FANCM 23 c.6883T>TC 
 
Heterozygous 
3 (2 tumors+ 1 matched 
normal) 
18 FANCG 4 c.816G>GC p.E108ED 
Heterozygous non-
synonymous 
2 (tumor+ matched 
normal) 
19 FANCG 4 c.819G>GC p.Q109QH 
Heterozygous non-
synonymous 
2 tumors 
20 FANCG 4 c.923G>GC p.G144GA 
Heterozygous non-
synonymous 
2 (tumor+ matched 
normal) 
21 FANCG 4 c.927G>GC p.L145LL 
Heterozygous 
synonymous 
2 (tumor+ matched 
normal) 
22 FANCG 13 c.2197G>GC p.A569AP 
Heterozygous non-
synonymous 
2 (tumor+ matched 
normal) 
*A mutation in the mRNA region is prefixed with a “c” and a mutation in the protein sequence is prefixed 
with a “p”.  
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Table S2: Intronic variants identified in 5 FANC genes in only HPV-positive HNC cases 
No. Gene Intron 
adjacent 
to exon 
Nucleotide 
Change* 
Mutation 
type 
Total Samples Prediction using 
Human Splicing 
Finder 
1 FANCD2 5 c.455+155T>TG Heterozygous 2 (tumor+ matched 
normal) 
Potential donor splice 
site 
2 FANCD2 7 c.517-16A>AG Heterozygous 2 (tumor+ matched 
normal) 
None 
3 FANCD2 13 c.1068-38C>CG Heterozygous 2 (tumor+ matched 
normal) 
Potential acceptor 
splice site 
4 FANCD2 16 c.1357-76A>G Homozygous 1 (tumor) Potential donor splice 
site 
5 FANCD2 17 1492-149A>AG Heterozygous 2 (tumor+ matched 
normal) 
None 
6. FANCD2 30 c.2938-4A>AC Heterozygous 3 (2 tumors+1 
matched normal) 
Potential acceptor 
splice site 
7. FANCD2 42 c.4263+33T>TC Heterozygous 2 (tumor+ matched 
normal) 
None 
8 RAD51C 1 c.17C>CT Heterozygous 2 (tumor+ matched 
normal) 
None 
9 RAD51C 7 c.947-74het_delG Heterozygous 
deletion 
1 (tumor)  
10 FANCL 6 c.537+27T>TG Heterozygous 2 (tumor+ matched 
normal) 
Potential acceptor 
splice site 
11 FANCL 6 c.537+97A>G Homozygous 2 (tumor+ matched 
normal) 
None 
12 FANCL 9 c.758-27A>C Homozygous 2 (tumor+ matched 
normal) 
Potential acceptor 
splice site 
13 FANCM 9 c.1666+194het_delT Heterozygous 
deletion 
2 (tumor+ matched 
normal) 
Potential acceptor 
splice site 
14 FANCM 12 c.2245+97G>GA Heterozygous 4 (tumors+ matched 
normal) 
None 
15 FANCM 21 c.5801+36T>G Homozygous 4 (tumors+ matched 
normal) 
Potential donor splice 
site 
16 FANCG 2 c.667+24G>GC Heterozygous 2 (tumor+ matched 
normal) 
Potential donor splice 
site 
*A mutation in the mRNA region is prefixed with a “c”. A mutation that is called outside of an mRNA 
region is assigned as plus or minus the number of bps by which it resides away from the closest 
nucleotide of the mRNA 
 
Next gene sequencing data 
 Next gene sequencing (NGS) using Ion AmpliSeq™ Comprehensive Cancer Gene 
Panel (Ion Torrent, Thermo Fisher Scientific) was done in two samples (one HPV negative 
HNC sample and one HPV positive HNC sample). This panel contained 7 FANC genes-- 
namely FANCA, FANCC, FANCD2, FANCF, FANCG, BRIP1, and ERCC4. 
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 Table S3 shows SNPs (Single nucleotide polymorphisms) which were identified in the 
HPV-positive sample. FANCD2 c.1179T>C and ERCC4 intronic mutations were found in both 
HPV-positive and HPV-negative samples.  
 Interestingly, FANCD2 (c.1214A>G missense mutation) was seen only in an HPV-
positive HNC sample, not in an HPV-negative sample. Sanger sequencing was conducted for 
further verification. But, this mutation in that particular location was not observed in the same 
sample. So, FANCD2 (c.1214A>G missense mutation) obtained from NGS seems to be a 
false positive SNP. This is probably because Next Gene sequencer has problems in the 
regions of repeated bases in the sequence. Indeed, the location of c.1214A>G mutation was 
found in the region where there were repeats of A (the sequence was: aagaaataag). 
Table S3: SNPs identified from an HPV-positive sample 
Gene Mutation* Classification 
Genotype Type
†
 Location Coding 
Amino acid 
Change 
Variant 
effect 
FANCD2 c.1214A>G 
Suspected 
Deleterious 
A/G SNV exonic c.1214A>G p.Asn405Ser missense 
FANCD2 c.1179T>C Unknown T/C SNV exonic c.1179T>C WT synonymous 
FANCD2 c.1170C>T Unknown C/T SNV exonic c.1170C>T WT synonymous 
ERCC4 
 
Unknown A/A SNV intronic 
   
*A mutation in the mRNA region is prefixed with a “c”.  
†
single nucleotide variants (SNVs)  
 
Overall results obtained from mutational analysis of Fanconi-anemia-DNA repair genes 
suggest that mutations in FANC genes may not be specific to HPV-positive head and neck 
cancers, though further studies on larger number of specimens are required. 
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II. E7 knockdown or overexpression to determine whether viral oncoprotein E7 
mediates promoter methylation and transcriptional inactivation of a candidate 
gene EREG 
Introduction: 
The work presented in chapter V suggested a hypothesis that promoter methylation 
and inactivation of EREG is mediated by HPV presence in head and neck cancers. Since 
HPV16 E7 oncoprotein has been shown to upregulate DNMT1 and DNMT3a (119); I 
rephrased the above hypothesis as − E7 oncoprotein causes promoter methylation of EREG. 
To test this hypothesis, I attempted to perform lentiviral knockdown of E7 in HPV-positive 
UMSCC-47 cell line and lentiviral-based overexpression of E7 in HPV-negative UMSCC-1 cell 
line. 
Experimental Procedures 
Cloning and production of lentiviral plasmids for overexpression of E7: The E7 coding 
region containing EcoRI and XhoI restriction sites was obtained from PCR-amplification of 
HPV16 purified plasmid (i.e. a plasmid containing full genome of HPV16 cloned in the 
pBR322 vector). Amplification was done using primers against the full length of E7 (forward 
primer with EcoRI site: aaagGAATTCatgcatggagatacacctac and a reverse primer with XhoI 
site: aaaaCTCGAGttatggtttctgagaacagatg). Amplified product was gel purified, digested with 
EcoRI and XhoI and then ligated with a pLUTdNB lentiviral vector which was also digested 
with the same restriction enzymes. This pLUTdNB vector is pTRIPZ base modified 
doxycycline-inducible expression vector. pLUTdNB plasmid ligated with E7 cDNA was then 
transformed into XL10-Gold Ultracompetent cells (Agilent Technologies, CA, USA) using β-
mercaptoethanol to increase transformation efficiency, according to the manufacture’s 
protocol.  After transformation, the plasmid was isolated and then sequenced to confirm the 
cloning of full-length of HPV16 E7 cDNA into a pLUTdNB lentiviral expression vector.  
Production of E7 overexpressing lentiviral particles: Lentivirus packaging protocol was 
followed as described by Applied Biological Materials Inc. (Richmond Canada) with some 
modifications. HEK 293T cells were co-transfected with the lentiviral constructs pVSV-G 
(envelope vector) and psPAX2 (packaging vector) (Addgene) along with a pLUTdNB plasmid 
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expressing full length of E7 (expression vector). Empty vector was used as a control and 
transfected into HEK 293T cells. Transfections were carried out using TurboFect Transfection 
Reagents in Opti-MEM® Reduced-Serum Medium (Thermo Fisher Scientific). Later, the 
culture medium was centrifuged at 3,000 rpm for 15 mins at 4°C. The filtered supernatant was 
used for lentiviral infection. 
HPV16 E7 shRNA lentiviral particles: HPV 16 E7 shRNA lentiviral particles and control 
shRNA lentiviral particles were purchased from Santa Cruz Biotechnology, Inc, USA. HPV 16 
E7 shRNA lentiviral particles contain a pool of concentrated, transduction-ready viral particles 
containing 2 target- specific constructs that encode 19-25 nucleotide shRNA designed to 
knock down gene expression. Control shRNA Lentiviral Particles encodes for a scrambled 
shRNA sequence suitable as a negative control for shRNA lentiviral transduction experiment.  
Lentiviral particles transduction: A protocol for lentivirus particles transduction was 
followed as described by Santa Cruz Biotechnology, Inc. Before lentiviral transduction, the 
working concentration of puromycin was determined for the selection of transduced UMSCC-
1 (HPV-negative) or UMSCC-47 (HPV-positive) cell lines. For this, in a separate experiment, 
UMSCC-1, and UMSCC-47 cells were treated with varying concentrations of puromycin 
dihydrochloride (Santa Cruz Biotechnology, Inc) from 1 µg/ml to10 µg/ml. Then, an optimal 
concentration of puromycin (2 µg/ml) was selected as the lowest concentration that kills 100% 
of non-transfected cells in 2-3 days.  
For lentiviral infection, cells were seeded in a 12-well plate 24 hours prior to viral 
infection. Next day, media was replaced with Polybrene (Santa Cruz Biotechnology, Inc) 
containing media to enhance binding of pseudo-viral capsid to the cell membrane. Then, cells 
were infected with lentiviral particles (E7 over-expressing particles in UMSCC-1; and E7 
shRNA lentiviral particles in UMSCC-104 cell lines). After cells underwent lentiviral 
transduction, stably transfected clones were selected using 2 μg/ml puromycin. After antibiotic 
selection, cells were expanded for stable E7 cDNA or E7 shRNA expression in UMSCC-1 and 
UMSCC-47 respectively. Cells stably expressing control shRNA or control empty vector was 
also isolated via puromycin selection. 
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E7 mRNA expression: Total RNA was isolated and cDNA was synthesized following the 
same protocol as described in chapter IV using primers against E7 by SYBR Green assay.  
Western Blot Analysis: Cells were lysed and total protein was extracted using RIPA buffer 
(Cell Signaling Technology) and protease inhibitors as per the protocol. Total protein 
concentration was determined using the Bio-Rad Bradford protein assay reagent (Bio-Rad 
Laboratories, USA) with bovine serum albumin (BSA; Pierce, USA) as a standard.  Extracted 
protein samples were mixed with sodium dodecyl sulfate (SDS) loading buffer (20% glycerol, 
4% SDS, 100 mM Tris, pH 6.8, 0.002% bromophenol blue), and heated at 95°C for 5 min. 
These proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gels 
(NUPAGE 10% Bis-TRIS, Invitrogen, USA) and transferred to polyvinylidene difluoride 
(PVDF) membrane (Immobilon-P transfer membrane, EMD Millipore, USA), which were 
blocked with 5% nonfat dry milk in Tris-buffered saline containing 0.05% Tween 20 (TBST) for 
1 h at room temperature. The membrane was then incubated with mouse monoclonal anti-E7 
antibody (Abcam / Santa Cruz Biotechnology, USA) or rabbit polyclonal anti-β-actin (Genetex) 
antibodies overnight at 4 °C. After washing with TBST for 3 times, membranes were 
incubated with 1:5000 diluted secondary antibodies [horseradish peroxidase (HRP)- 
conjugated goat anti-mouse IgG or HRP-conjugated mouse anti-rabbit IgG (Thermo Scientific 
Pierce, USA)] for 1 h at room temperature. Proteins were detected by chemiluminescence 
(SuperSignal West Dura Extended Duration Substrate; Thermo Scientific Pierce, USA) and 
bands were visualized on X-ray film (CLXPosure Film, Thermo Scientific Pierce, USA) using 
an SRX-101A processor (Konica Minolta Medical Imaging USA, Inc).  
 
Results and Discussion 
Cloning of E7 into lentiviral expression vector 
HPV16 E7 cDNA was amplified and cloned into a pLUTdNB lentiviral expression 
vector (Figure S2). After cloning, isolated plasmid was digested using EcoRI and XhoI, which 
gave ~300bp product in an agarose gel, which corresponded to the full length of HPV16 E7 
(Figure S2-D). For verification, the sequence of cloned vector was compared with other 
sequence variants of HPV16 (such as AF402678.1, AF125673.1, AY686584.1, NC_001526.2, 
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and KF954093.1) using SeqMan Pro program (Lasergene 12, DNAstar Inc., Wisconsin) and 
NCBI BLASTN database. The obtained full-length nucleotide sequence was then translated 
into an amino acid sequence using EditSeq (DNASTAR) software and compared with other 
sequences using NCBI BLASTP database. 100% sequence identity was obtained between 
the cloned sequence with protein sequences of HPV16 E7 (accession no. AAO85409.1), 
suggesting the successful cloning of HPV16 E7 cDNA into lentiviral expression vector 
pLUTdNB. 
 
Figure S2: Cloning of E7 into a pLUTdNB lentiviral expression vector. A) Gel image showing 
EcoRI and XhoI digested E7 DNA, which was initially PCR-amplified from HPV16 plasmid. 
This DNA band was purified from the gel and used to ligate with digested pLUTdNB. B) Gel 
image showing EcoRI and XhoI digested pLUTdNB vector, which was purified from the gel. 
Restriction digested E7 and pLUTdNB DNAs were ligated and cloned into E. coli. C) Gel 
image showing cloned E7-pLUTdNB plasmid DNAs (Lanes #1 and #3) isolated from 
transformed E. coli. (Lane #2 showed the absence of cloned plasmid) D) Cloned plasmids 
were digested with EcoRI and XhoI that produced the fragments of ~300 bp (shown by the 
arrow), which corresponded to the full-length of E7. 
 
Lentiviral knockdown of E7 in HPV-positive HNC cell line  
After lentiviral transduction, puromycin selection was done to obtain UMSCC-47 cells 
stably expressing E7 shRNA. Puromycin-resistant cells were obtained, indicating successful 
lentiviral transduction. However, as shown in Figure S3, knockdown of E7 did not 
significantly reduce E7 mRNA in UMSCC-47 cells as compared to cells stably expressing 
scrambled control shRNA. To confirm above results, E7 protein levels was tested by 
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immunoblotting, but could not be detected. Even a positive control (i.e. purified E7 protein) 
was not detectable in the immunoblot. This may be due to the low quality of commercial E7 
antibodies. However, the immunoblot was positive for house-keeping protein (β- actin). So, 
further experiments have to be done to obtain effective knockdown of E7 in HPV-positive 
UMSCC-47 cell line. 
 
Figure S3: E7 expression in UMSCC-47 cells after the lentiviral shRNA-mediated 
knockdown, showing unsuccessful knockdown of E7 compared to scrambled control shRNA.  
Lentiviral transduction of E7 cDNA in HPV-negative HNC cell line 
 E7 overexpressing lentiviral particles were produced and then transduced in HPV-
negative UMSCC-1 cell line. However, transduced cells started dying after treatment with 2 
μg/ml puromycin (similar to non-transduced cells), indicating unsuccessful lentiviral 
transduction. This may be due to the poor quality of lentiviral particles or due to other 
reasons. So, experiments should be repeated troubleshooting the relevant issues.  
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III. Epigenetic changes in host tumor suppressor genes SMG1, RUNX3, and CHFR in 
HNCs 
In chapter V, I selected 7 genes (GRB7, RUNX3, RUNX2, CHFR, RARB, EREG, and 
SMG-1) from 38 tumor suppressors as the targets for further studies and then focused on the 
promoter methylation status of GRB7 and EREG, since they were the potential candidate 
genes regulated in HPV-positive HNC cell lines. I have not included the promoter methylation 
status of other genes as not to distract from the focus of the project, therefore have discussed 
in this part of the appendix. 
Correlation of DNA methylation status of SMG1, RUNX3 and CHFR promoters with their 
expression 
The methylation status of promoters of SMG1, RUNX3 and CHFR and the effect of 
de-methylation treatment were analyzed using MS-PCR method. Both HPV-positive 
(UMSCC-47) and HPV-negative (UMSCC-1) HNC cell lines contained methylated as well as a 
unmethylated SMG1 promoter (Figure S4 A-B). RUNX3 and CHFR methylation status was 
detected in both cell lines (Figure S4C-F). Even on de-methylation treatment, there was no 
change in bands of all three genes- SMG1, RUNX3, and CHFR (Figure S4). These results 
suggest that epigenetic regulations of SMG1, RUNX3 and CHFR may not be specific to HPV-
positive HNCs. 
Expressions of SMG1, RUNX3, and CHFR genes were higher in UMSCC-1 than 
UMSCC-47 (Figure 28), but promoter methylation status was found similar in both cell types 
(Figure S4). This result indicated that in the case of these 3 genes, the correlation between 
increased promoter methylation and decreased expression tended to be low. There was also 
no change in methylation status of the promoter of these genes even after de-methylation 
treatment (Figure S4), although 5-aza-dc caused increased SMG1 expression in UMSCC-1, 
and increased expression of RUNX3 and CHFR in both cell types (Figure 31).These results 
additionally indicate that methylation-mediated gene silencing of SMG1, RUNX3, and CHFR 
may not be cell-type specific.  
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Figure S4: Methylation status of SMG1, RUNX3, and CHFR promoters. Promoter regions of 
SMG1 (A), RUNX3 (C) and CHFR (E), showing CpG island and the locations of methylation-
specific PCR (MS-PCR) primers. Agarose gel images showing MS-PCR of SMG1 (B), 
RUNX3 (D) and CHFR (F) in bisulfite-modified DNA from HPV-negative (UMSCC-1) and 
HPV-positive (UMSCC-47) cell lines with or without 5-aza-dc (5 µM for 96 hours) treatment. 
No template DNA serves as negative control. 
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LIST OF ABBREVIATIONS AND SYMBOLS 
5-aza-dc  5-aza-2′-deoxycytidine 
CIN   Cervical intraepithelial neoplasia 
CpG   5'- Cytosine-phosphate-Guanine-3' 
DNA   Deoxyribonucleic acid 
DNMT   DNA methyltransferase 
E2BS   E2 binding sites 
E2F-TF   E2 factor family of transcription factors   
EGFR   Epidermal growth factor receptor 
EREG   Epiregulin 
FFPE   Formalin-fixed, paraffin-embedded 
hgOED   High-grade oral epithelial dysplasia 
HN   Head and Neck 
HNC   Head and Neck carcinoma/ cancers 
HNSCC  Head and Neck squamous cell carcinoma 
HPV   Human papillomavirus 
H&E   Hematoxylin and eosin staining 
IHC   Immunohistochemistry 
ISH    in situ hybridization 
LCR   Long control region 
MEH   Multiple epithelial hyperplasia 
MS-PCR  Methylation-specific PCR 
OCSCC  Oral Cavity Squamous Cell Carcinoma 
OPSCC or OPC Oropharyngeal Squamous Cell Carcinoma 
OPC   Oropharyngeal cancer 
ORF   Open Reading Frame 
PCR   Polymerase Chain Reaction 
PV   Papillomavirus 
qRT-PCR  Quantitative Reverse Transcription-PCR 
Rb    Retinoblastoma 
SCC   Squamous Cell Carcinoma 
SNPs    Single nucleotide polymorphisms 
TBP   TATA binding protein 
TSG(s)   Tumor suppressor gene(s) 
URR    Upstream Regulatory Region 
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